QuickLinks-- Click here to rapidly navigate through this document

TABLE OF CONTENTS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.   )

Filed by the Registrant ☒
Filed by a Party other than the Registrant  ☐
Check the appropriate box:
 ☐
​
Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

o​

Preliminary Proxy Statement

o
 ☐

​
​
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

ý
☒

​
​
Definitive Proxy Statement

o
 ☐

​
​
Definitive Additional Materials

o
 ☐

​
​
Soliciting Material under §240.14a-12


Amicus Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
☒
​​
Amicus Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

ý

No fee required.

o
 ☐

​
​
Fee paid previously with preliminary materials.
 ☐
​​
Fee computed on table belowin exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:
(2)Aggregate number of securities to which transaction applies:
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4)Proposed maximum aggregate value of transaction:
(5)Total fee paid:

o

Fee paid previously with preliminary materials.

o

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.



(1)

Amount Previously Paid:
(2)Form, Schedule or Registration Statement No.:
(3)Filing Party:
(4)Date Filed:

TABLE OF CONTENTS

LOGO


April 29, 2019

26, 2022

Dear Stockholder:

We are pleased to invite you to attend our 20192022 Annual Meeting of Stockholders to be held at the offices of Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 on Thursday, June 27, 2019,9, 2022, at 9:00 a.m. Eastern Daylight Time.

The Annual Meeting of Stockholders will be held in virtual-only format via webcast.

Enclosed are the following:

    •
Our Notice of Annual Meeting of Stockholders and Proxy Statement for 2019;

•
2022;
Our 20182021 Annual Report to Stockholders (including our Annual Report on Form 10-K for fiscal year 2018)2021); and

•
A proxy card with a return envelope to record your vote.

The accompanying notice of the 20192022 Annual Meeting and Proxy Statement describe the business we will conduct at the meeting and provide information about Amicus Therapeutics, Inc. that you should consider when you vote your shares.

Your vote is important. When you have finished reading the Proxy Statement, please promptly vote your shares by marking, signing, dating and returning the proxy card in the enclosed envelope or vote via telephone or Internet according to the instructions in the Proxy Statement. If you attend the Annual Meeting, you may vote your shares in person even though you have previously voted by proxy if you follow the instructions in the Proxy Statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend in person.

the webcast.

Sincerely,

GRAPHIC


John F. Crowley
Chairman and Chief Executive Officer

TABLE OF CONTENTS

Table of Contents
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
​​
​​
PROPOSAL 1: ELECTION OF DIRECTORS
​​
6
​​
Nominees for Election at the Annual Meeting
​​
7
Committee Memberships
​​
12
​​
CORPORATE GOVERNANCE
​​
13
​​
Corporate Governance Guidelines
​​
13
Environmental, Social & Governance (ESG)
​​
14
Committees of the Board and Meetings
​​
17
​​
COMPENSATION DISCUSSION AND ANALYSIS
​​
23
​​
Executive Summary
​​
23
Stock Ownership Guidelines
​​
24
Elements of Compensation
​​
29
The Corporate Multiplier
​​
30
2021 Company Scorecard
​​
31
​​
COMPENSATION AND LEADERSHIP DEVELOPMENT COMMITTEE REPORT
​​
38
​​
COMPENSATION AND EQUITY TABLES
​​
39
​​
Officer Summary Compensation Table
​​
39
Grants of Plan-Based Awards
​​
40
Outstanding Equity Awards at Fiscal Year End
​​
41
Options Exercised and Stock Vested
​​
43
Potential Payments upon Termination or Change in Control
​​
47
CEO Pay Ratio
​​
49
Director Summary Compensation Table
​​
50
​​
SHARE OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
​​
53
​​
PROPOSAL 2: APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN
​​
57
​​
Overview, Background and Reason for the Proposal
​​
57
Summary of the 2007 Plan
​​
59
Change in Control
​​
62
Clawback Policy
​​
65
​​
PROPOSAL 3: INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
​​
66
​​
REPORT OF AUDIT AND COMPLIANCE COMMITTEE
​​
68
​​
PROPOSAL 4: ADVISORY VOTE ON EXECUTIVE COMPENSATION
​​
69

TABLE OF CONTENTS

LOGO


April 29, 2019

26, 2022


NOTICE OF 20192022 ANNUAL MEETING OF STOCKHOLDERS

To our Stockholders:

The 20192022 Annual Meeting of Stockholders of Amicus Therapeutics, Inc. will be held at the offices of Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 on Thursday, June 27, 20199, 2022 at 9:00 a.m. Eastern Daylight Time. The meeting will be held in a virtual-only format online via webcast. You will be able to attend the 2022 Annual Meeting as well as vote and submit your questions during the live webcast of the meeting by visiting www.virtualshareholdermeeting.com/FOLD2022.The purpose of this meeting is to vote on the following:

    1.
    Elect four Class III directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2022 Annual Meeting or until their respective successors have been elected;

    2.
    Approve the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool;

    3.
    Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019;

    4.
    Approve, on an advisory basis, the Company's executive compensation; and

    5.
    Consider and act upon any other business that is properly presented at the meeting.

1.
Elect five Class III directors as nominated by the Board of Directors each to serve a three-year term expiring at the 2025 Annual Meeting or until their respective successors have been elected;
2.
Approve the Amended and Restated 2007 Equity Incentive Plan to add 6,000,000 shares to the equity pool;
3.
Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
4.
Approve, on an advisory basis, the Company’s executive compensation; and
5.
Consider and act upon any other business that is properly presented at the meeting.
These items of business are more fully described in the Proxy Statement accompanying this Notice.

The record date for the 20192022 Annual Meeting is April 29, 2019.14, 2022. Only stockholders of record at the close of business on that date are entitled to notice of and to vote at the meeting or any adjournment thereof.

BY ORDER OF THE BOARD OF DIRECTORS:



BY ORDER OF THE BOARD OF DIRECTORS:



GRAPHIC

Ellen Rosenberg
Chief Legal Officer and Corporate Secretary

Cranbury, New Jersey

Ellen Rosenberg
Chief Legal Officer and Corporate Secretary
Philadelphia, Pennsylvania
April 29, 2019

        You are cordially invited to attend26, 2022

The 2022 Annual Meeting will be held virtually over the meeting in person.Internet. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy card or vote by telephone or the Internet as instructed in the accompanying materials as promptly as possible in order to ensure your representation at the meeting. You can revoke a proxy at any time prior to its exercise by following the instructions in the Proxy Statement. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must provide a valid proxy issued in your name from that record holder.

TABLE OF CONTENTS

AMICUS THERAPEUTICS, INC.
3675 Market Street, Philadelphia, Pennsylvania 19104
1 Cedar Brook Drive, Cranbury, New Jersey 08512
(609) 662-2000

(215) 921-7600
PROXY STATEMENT FOR THE AMICUS THERAPEUTICS, INC.
2019
2022 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON
JUNE 27, 2019

9, 2022

GENERAL INFORMATION ABOUT THE ANNUAL MEETING

Why Did You Send Me this Proxy Statement?

We sent you this Proxy Statement and the enclosed proxy card because the Board of Directors (the "Board"“Board”) of Amicus Therapeutics, Inc. (sometimes referred to as "we," "us," "our," "Amicus"“we,” “us,” “our,” “Amicus” or the "Company"“Company”) is soliciting your proxy to vote at the 20192022 Annual Meeting of Stockholders (the "Annual Meeting"“Annual Meeting”) and any adjournments of the meeting to be held at the offices of Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512in a virtual-only format online via webcast on Thursday, June 27, 20199, 2022 at 9:00 a.m. Eastern Daylight Time. This Proxy Statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the meeting and the information you need to know to vote at the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. You do not need to attend the Annual Meeting to vote your shares. Instead you may simply complete, date, sign and return the enclosed proxy card, or follow the instructions on the enclosed proxy card to submit your proxy by telephone or on the Internet.

We intend to mail this Proxy Statement, our 20182021 Annual Report to Stockholders (including our Annual Report on Form 10-K for fiscal year 2018)2021), the attached Notice of Annual Meeting and the enclosed proxy card to all stockholders entitled to vote at the Annual Meeting on or about April 29, 2019.


26, 2022.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
FOR THE ANNUAL MEETING TO BE HELD ON JUNE 27, 2019.

9, 2022.

THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 20192022 ANNUAL MEETING
OF
STOCKHOLDERS AND OUR 20182021 ANNUAL REPORT TO STOCKHOLDERS ARE AVAILABLE AT:
www.sec.gov, through the Investor Relations section of our web site atwww.amicusrx.com or
at
http://www.proxyvote.com

Who Can Vote?

Only stockholders of record at the close of business on April 29, 201914, 2022 are entitled to vote at the Annual Meeting. On this record date, there were 230,450,221280,152,758 shares of our common stock ("(“Common Stock"Stock”) outstanding and entitled to vote. Each share of Common Stock is entitled to one vote. The Common Stock is our only outstanding class of voting stock.

Stockholder of Record: Shares Registered in Your Name

If, on April 29, 2019,14, 2022, your shares were registered directly in your name with our transfer agent, American Stock Transfer & Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card or follow the instructions on the proxy card or Notice of Internet Availability to submit your vote by telephone or Internet to ensure your vote is counted.


    Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If, on April 29, 2019,14, 2022, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in "street name"“street name” and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your account. A number of brokers and banks enable beneficial owners to give voting instructions via telephone or the Internet. Please refer to the voting instructions provided by your bank or broker.

You are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you provide a valid proxy fromplease contact your broker, bank or other custodian.nominee for a 16-digit control number that will be required to gain access to the meeting. You will be able to vote your shares electronically during the Annual Meeting by following the instructions available on the meeting website.
1

TABLE OF CONTENTS

What am I voting on?

There are four matters scheduled for a vote:

    •
Elect fourfive Class III directors;

•
Approve the Amended and Restated 2007 Equity Incentive Plan to add 7,000,0006,000,000 shares to the equity pool;

•
Ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019;2022; and

•
Approval,
Approve, on an advisory basis, of the Company'sCompany’s executive compensation.

How Do I Vote?

Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the Annual Meeting.

        Stockholder Make sure to have your proxy voting card, voting instruction form or Notice of Record:    If your shares are registered directlyInternet Availability in your name, you may vote:

    •
    By mail.  Complete and mail the enclosed proxy card in the enclosed postage prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our Board.

    •
    In person at the meeting.  If you attend the meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting.

    •
    By telephone.  You may vote over the telephone by calling toll-free 1-800-690-6903hand and follow the recorded instructions. Please haveinstructions to submit your vote in one of five ways:
​​
VOTE IN ADVANCE OF THE MEETING*
​​
​​
VOTE AT THE VIRTUAL MEETING
​​
​​
By
Internet
​​
By
Telephone
​​
By
Mail
​​
By
QR Code
​​
​​
At the Meeting
​​
​​
Visit 24/7
www.proxyvote.com

Follow on-screen
instructions
​​
Dial toll-free
24/7

1-800-690-
6903
(registered
holders)

1-800-454-
8683
(beneficial
holders)

Follow
recorded
instructions
​​
Cast your
ballot, sign
your proxy
card and
mail in the
postage-
paid return envelope
​​
Scan this QR
code to vote
with your
smartphone or
device



​​
​​
To cast a virtual ballot:

Follow the on-screen instructions available after
logging into the meeting at:
www.virtualshareholdermeeting.com/FOLD2022
on June 9, 2022

Enter your 16-digit control number
​​
*  Refer to the 16-digit control number included on your proxy card, available when you call.voting instruction form or Notice of Internet Availability of Proxy Materials to vote. Your vote must be received by 11:59 p.m. Eastern Daylight Time on June 26, 20198, 2022 to be counted.

•
Internet.  You may vote via the Internet by going to www.proxyvote.com and follow the on-screen instructions. Please have your proxy card available when you access the web page. Your vote must be received by 11:59 p.m. Eastern Daylight Time on June 26, 2019 to be counted.

Beneficial Owner:Owners: If your shares are held in "street name"“street name” (held in the name of a bank, broker or other nominee), you must providefollow the instructions provided by your bank, broker or other nominee with instructions on how to vote your shares and can do so as follows:

    •
    By mail.  You will receive instructions from your broker or other nominee explaining how to vote your shares.

    •
    In person at the meeting.  Contact the broker or other nominee who holds your shares to obtain a broker'sthese proxy card and bring it with you to the meeting. You will not be able to vote at the meeting unless you have a proxy card from your broker.materials.

How Many Votes do I have?

Each share of Common Stock that you own as of April 29, 2019,14, 2022, entitles you to one vote on each matter to be voted on at the Annual Meeting.

Will My Shares be Voted if I Do Not Return My Proxy Card?

If your shares are registered in your name, they will not be voted if you do not return your proxy card by mail or vote at the meeting as described above under "How“How Do I Vote?"” If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above under "How“How Do I Vote?,"” the bank, broker or other nominee has the authority to vote your unvoted shares only for Proposal 3. The broker, bank or other nominee will not be permitted to vote on the other Proposals without your voting instructions. We encourage you to provide voting instructions. This ensures your shares will be voted at the meeting in the manner you desire. If your broker cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker chooses not to vote on a matter for which it does have discretionary voting authority, this is referred to as a "broker non-vote"“broker non-vote”.
2

TABLE OF CONTENTS

May I Revoke My Proxy?

If you give a proxy, you may revoke it at any time before the Annual Meeting. You may revoke your proxy in any one of the following ways:

    •
signing a new proxy card and submitting it as instructed above;

•
notifying the Company'sCompany’s Secretary in writing before the Annual Meeting that you have revoked your proxy; or

•
attending the meeting in person and voting in personat the meeting if you are a stockholder of record. Attending the meeting in person will not in and of itself revoke a previously submitted proxy unless you specifically request it.

What if I Receive More Than One Proxy Card?

You may receive more than one proxy card or voting instruction form if you hold shares of our Common Stock in more than one account, which may be in registered form or held in street name. Please vote in the manner described under "How“How Do I Vote?"” for each account to ensure that all of your shares are voted.

How Does the Board of Directors Recommend That I Vote on the Proposals?

        The Board recommends that you vote as follows:

"FOR" the election of the nominees for director;

        "FOR" the approval of the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool;

"FOR" ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019; and

"FOR" the approval of the compensation of our named executive officers.

​
PROPOSAL 1
​
​
ELECTION OF DIRECTORS
​​
 
​​
 
​​
 
​
​
​
 
BOARD’S
RECOMMENDATION:
“FOR” EACH NOMINEE
​​
​We are asking stockholders to elect five directors for a three-year term. The table below sets for the information with respect to our five nominees standing for election. All of the nominees are currently serving as directors. Additional information about the candidates and their respective qualifications can be found on the “Nominees for Election at the Annual Meeting” of this Proxy Statement.
 
​
​
Name
​​
Age
​​
Director Since
​
​
John F. Crowley
​​
55
​​
2010
​
​
Michael A. Kelly
​​
65
​​
2020
​
​
Margaret G. McGlynn
​​
62
​​
2009
​
​
Michael G. Raab
​​
57
​​
2004
​
​
Glenn P. Sblendorio
​​
66
​​
2006
​
​
PROPOSAL 2
​
​
APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN
​
​
​ 

BOARD’S
RECOMMENDATION:
“FOR”
​​
We are asking stockholders to approve the Amended and Restated 2007 Equity Incentive Plan to add 6,000,000 shares to the equity pool.
​
​
PROPOSAL 3
​
​
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
​
​
​ 

BOARD’S
RECOMMENDATION:
“FOR”
​​
We are asking stockholders for ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.
​
​
PROPOSAL 4
​
​
ADVISORY VOTE ON EXECUTIVE COMPENSATOIN
​
​
​ 

BOARD’S
RECOMMENDATION:
“FOR”
​​
We are asking stockholders for the approval of the compensation of our named executive officers.
​
3

TABLE OF CONTENTS

If any other matter is properly presented, the proxy card provides that your shares will be voted by the proxy holder listed on the proxy card in accordance with his/her best judgment. At the time this Proxy Statement was printed, we knew of no matters that needed to be acted on at the Annual Meeting other than those discussed in this Proxy Statement.

What Vote is Required to Approve Each Proposal and How are Votes Counted?

Proposal 1: Elect Directors

​​
The nominees for director who receive the most votes cast (also known as a "plurality"“plurality” of the votes) will be elected. You may vote FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Abstentions, or votes that are withheld, will not be counted as voting on the matter for purposes of electing directors. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote customers'customers’ unvoted shares held by the firms in street name for the election of directors. These broker non-votes will have no effect on the results of this vote.

​​
Proposal 2: ApproveApproval of the
Amended and Restated 2007
Equity Incentive Plan

​

​

The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to approve the Amended and Restated 2007 Equity Incentive Plan. Abstentions will have the effect of a vote against this proposal. Brokerage firms do not have the authority to vote customers'customers’ unvoted shares held by the firms in street name on this proposal and therefore are not entitled to vote on the matter. These broker non-votes will have no effect on the results of this vote.

​​
Proposal 3: Ratify Appointment
of Independent Registered Public
Accounting Firm

​

​

The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to ratify the selection of our independent registered public accounting firm. Abstentions will have the effect of a vote against this proposal. Brokerage firms have authority to vote customers'customers’ unvoted shares held by the firms in street name on this proposal. We are not required to obtain the approval of our stockholders to appoint our independent registered public accounting firm. However, our Board believes it is advisable to give stockholders the opportunity to ratify this appointment. If our stockholders do not ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019,2022, the Audit and Compliance Committee of our Board will reconsider its selection.


​​
Proposal 4: Approval, on an Advisory Basis, of Executive Compensation

​

​

The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to adopt this resolution. Abstentions will have the effect of a vote against this proposal. Brokerage firms do not have the authority to vote customers'customers’ unvoted shares held by the firms in street name on this proposal and therefore are not entitled to vote on the matter. These broker non-votes will have no effect on the results of this vote. This advisory vote on executive compensation is not binding on our Board. However, the Board will take into account the result of the vote when determining future executive compensation arrangements.

​​

How are votes counted?

Votes Counted?

Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count "For"“For”, "Withhold"“Withhold” (with respect to the election of directors) and "Against"“Against” (with respect to proposals other than the election of directors) votes, abstentions and broker non-votes. Shares represented by abstentions and broker non-votes will be counted in determining whether there is a quorum for the Annual Meeting. Abstentions will have no effect on Proposal 1 but will have the effect of a vote against Proposal 2, 3 and 4. Broker non-votes will not be counted towards the vote total for any proposal.

Who Will Pay the Costs of Soliciting these Proxies and How Are They Being Solicited?

        We

Amicus will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses.
4

TABLE OF CONTENTS

What Constitutes a Quorum for the Meeting?

The presence, in person or by proxy, of the holders of a majority of the issued and outstanding shares of our Common Stock is necessary to constitute a quorum at the meeting. Votes of stockholders of record who are present at the meeting in person or by proxy, abstentions and broker non-votes are counted for purposes of determining whether a quorum exists.

How canCan I find outFind Out the resultsResults of the votingVoting at the Annual Meeting?

Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a Current Report on Form 8-K within four business days after the Annual Meeting.

When are stockholder proposals dueStockholder Proposals Due for next year'sNext Year’s Annual Meeting?

If you wish to submit a proposal to be considered for inclusion in next year'syear’s proxy materials or nominate a director, your proposal must be in proper form according to Securities and Exchange Commission ("SEC"(“SEC”) Regulation 14A, Rule 14a-8 and received by the Secretary of the Company no later than December 31, 2019.27, 2022. Proposals received after that date will not be included in the proxy materials we send out in connection with the 20202023 Annual Meeting of Stockholders. If a proposal is received before that date, the proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in accordance with our Restated By-laws, stockholder notice of any such proposal, other than a stockholder proposal intended to be included in our proxy statement and submitted pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, must be received by us not


earlier than December 1, 2019November 27, 2022 and not later than December 31, 2019;27, 2022; provided, however, that in the event that the date of the 20202023 Annual Meeting of Stockholders is more than 30 days before or more than 60 days after the anniversary date of the 20202022 Annual Meeting of Stockholders, notice by the stockholder to be timely must be delivered not earlier than the close of business on the 90th day prior to the 20202023 Annual Meeting of Stockholders and not later than the close of business on the later of the 60th day prior to the 20202023 Annual Meeting of Stockholders or the 10th day following the day on which we make a public announcement of the 20202023 Annual Meeting of Stockholders. All stockholder proposals should be marked for the attention of the Chief Legal Officer and Corporate Secretary, c/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.

3675 Market Street, Philadelphia, Pennsylvania 19104.

In addition, to comply with the universal proxy rules (once effective), stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Securities Exchange Act of 1934 no later than April 10, 2023.
Attending the Annual Meeting

The Annual Meeting will be held at the offices of Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512in a virtual only format online via webcast on Thursday, June 27, 20199, 2022 at 9:00 a.m. Eastern Daylight Time. When you arrive at Amicus, signs will direct you to the appropriate meeting rooms. You are not required to attend the Annual Meeting in order to vote.
5

TABLE OF CONTENTS



PROPOSAL NO. 1—ELECTION OF DIRECTORS

Recommendation:

The Board recommends the vote "FOR"“FOR” the election of each ofJohn F. Crowley, Michael G. Raab, Glenn P. Sblendorio, Margaret G. McGlynn and Michael G. Raab and Glenn P. SblendorioA. Kelly as a director, and proxies solicited by the Board will be voted in favor thereof unless a stockholder has indicated otherwise on the proxy.

The Board has voted to nominate John F. Crowley, Michael G. Raab, Glenn P Sblendorio, Margaret G. McGlynn and Michael G. Raab and Glenn P. SblendorioA. Kelly for election at the Annual Meeting for a term of three years to serve as Class III directors until the 20222025 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified. The Class I directors—Lynn D. Bleil, Bradley L. Campbell and Robert Essner and Dr. Ted W. Love—and the Class II director—directors—Craig A. Wheeler—Wheeler, Burke W. Whitman and Eiry W. Roberts, M.D.—will serve until the Annual Meetings of Stockholders to be held in 20202023 and 2021,2024, respectively, and until their respective successors have been elected and qualified.

Unless authority to vote for any of these nominees is withheld, the shares represented by the signed and dated proxy cards will be votedFOR the election as directors of Mr. Crowley, Ms. McGlynn, Mr. Raab, Mr. Sblendorio, Mr. Kelly and Mr. Sblendorio.Ms. McGlynn. In the event that any nominee becomes unable or unwilling to serve, the shares represented by the enclosed proxy will be voted at the discretion of the individuals designated as proxies on the proxy cards. We have no reason to believe that any nominee will be unable or unwilling to serve as a director.

A plurality of the shares voted at the Annual Meeting is required to elect each nominee as a director.

Our Board of Directors

Our Restated Certificate of Incorporation and Restated By-laws provide that our business is to be managed by or under the direction of our Board. Our Board is divided into three classes and one class is elected at each Annual Meeting of Stockholders to serve for a three-year term. Our Board consists of nineeleven members. Our Board is divided amongst three classes as follows:

    •
The Class I directors are Ms. Bleil, Mr.Messrs. Campbell Mr.and Essner and Dr. LoveMs. Bleil, and their term will expire at the 20202023 Annual Meeting of Stockholders;

•
The Class II director is Mr.directors are Messrs. Wheeler and hisWhitman and Dr. Roberts, and their term will expire at the 20212024 Annual Meeting of Stockholders; and

•
The Class III directors are Messrs. Crowley, Raab, Sblendorio and SblendorioKelly and Ms. McGlynn, and their term will expire at the 20192022 Annual Meeting of Stockholders.

Our Restated Certificate of Incorporation and Restated By-laws provide that the authorized number of directors may be changed only by resolution of the Board. Our Board has authorized that the maximum size of the Board be set at tentwelve members.

On February 27, 2019,23, 2022, our Board, upon the recommendation of the Nominating and Corporate Governance Committee, voted to nominate Mr.Messrs. Crowley, Raab, Sblendorio and Kelly and Ms. McGlynn Mr. Raab and Mr. Sblendorio for re-election as Class III directors at the 20192022 Annual Meeting for a term of three years to serve until the 20222025 Annual Meeting of Stockholders until their respective successors have been duly elected and qualified.

The Board has determined that each of the director nominees possesses the requisite skills, personal integrity, business judgment, industry experience and willingness to devote adequate time and effort necessary to serve as an effective member of the Board. A description of the background of each, along with other specific experiences, qualifications, attributes or skills that contributed to the Board'sBoard’s decision to nominate the nominees, is set forth below, followed immediately by like disclosure for our existing directors whose terms of office extend beyond the Annual Meeting.

The Board is currently composed of eleven talented directors with diverse skill sets, demographic and professional backgrounds. For the graphs below, diversity includes ethnicity, gender and veteran status but the Company also values and considers diversity of age, perspective, skill, experience, competency, culture, disability and LGBTQ status when evaluating candidates for nomination.
6

TABLE OF CONTENTS


Nominees for Election at the Annual Meeting

​
Name
​​
Age
​​
Position
​
​
John F. Crowley(1)
​​
55
​​
Director
​
​
Michael A. Kelly(2)(3)
​​
65
​​
Director
​
​
Margaret G. McGlynn(4)(5)
​​
62
​​
Director
​
​
Michael G. Raab(3)(6)(7)
​​
57
​​
Director
​
​
Glenn P. Sblendorio(8)
​​
66
​​
Director
​
 (1)
Chairman of the Board
 (2)
Member of the Science and Technology Committee
 (3)
Member of the Audit and Compliance Committee
 (4)
Chair of the Compensation and Leadership Development Committee
 (5)
Member of the Nominating and Corporate Governance Committee
 (6)
Lead Independent Director
 (7)
Chair of the Nominating and Corporate Governance Committee
 (8)
Chair of the Audit and Compliance Committee
7

TABLE OF CONTENTS

 
​​
Name
AgePosition

John F. Crowley(1)Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005, except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004, except for the period from September 2006 to March 2007 when he was in active duty service in the United States Navy (Reserve). Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation (“Genzyme”) in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Currently, Mr. Crowley serves as a member of the Board of Directors of Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Entrada Therapeutics, Inc. (NASDAQ: TRDA). Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University’s School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.

52Director

Margaret McGlynn(2)(3)

59Director

Michael G. Raab(4)(5)(6)

54Director

Glenn P. Sblendorio(7)

63Director
(1)
Chairman of the Board

(2)
Chair of Compensation Committee

(3)
Member of Nominating and Corporate Governance Committee

(4)
Lead Independent Director

(5)
Chair of Nominating and Corporate Governance Committee

(6)
Member of Audit and Compliance Committee

(7)
Chair of Audit and Compliance Committee

John F. Crowley has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005, except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004, with the exception of the period from September 2006 to March 2007 when he was in active duty service in the United States Navy (Reserve). Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation ("Genzyme") in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.

Skills and Qualifications: Mr. Crowley possesses strong leadership qualities, demonstrated through his service as an executive and director in the pharmaceutical industry, including his prior roles as Chief Executive Officer of development stage biopharmaceutical companies, and has extensive and intimate knowledge of the rare disease community and the needs of people living with rare diseases. He also provides our Board with in-depth knowledge of our company through the day-to-day leadership of our executives, all of which contributed to our conclusion that he should continue to serve as a Director and Chairman of the Company.


​​
Michael A. Kelly has served as a member of the Board since December 2020. Mr. Kelly is a former senior executive of Amgen, Inc. and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by Mr. Kelly in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc. (NASDAQ: AMGN), most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Inc. (NASDAQ: BIIB), Tanox, Inc., and Monsanto Life Sciences, a division of the Nutrasweet Kelco Company. Currently, Mr. Kelly is an independent member of the Board of Directors for Aprea Therapeutics, Inc. (NASDAQ: APRE), DMC Global, Inc. (NASDAQ: BOOM), NeoGenomics, Inc. (NASDAQ: NEO), and Hookipa Pharma, Inc. (NASDAQ: HOOK). He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations.
Skills and QualificationsMargaret G. McGlynn: Mr. Kelly brings more than two decades of leadership experience in the life sciences industry and a wealth of knowledge and background in managing and growing global healthcare and biotechnology companies to the Board. He has served as a member of our Board since October 2009. She retired from Merck after 26 yearsin various strategic finance and commercial operations positions, including, roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as CEOFounder and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn servesa global life sciences transformation and management consulting business, Chief Financial Officer and Board member of multiple biotechnology companies. Mr. Kelly also has extensive experience in developing and executing global corporate strategies for multi-product biotechnology organizations, a special skill set in organizational diversity, as well as leadership experience in humanitarian aid facing organizations focused on health outcomes and disaster relief. Mr. Kelly’s skills and experience and the substantial time he devotes to Amicus matters contributed to our conclusion that he should continue to serve as a director of the Company and as member of the Boards of Directors of Air ProductsAudit and Chemicals, Inc. (NYSE: APD)Compliance and Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX). She is also Chair of the Board of HCU Network America, a non-profit which provides advocacyScience and supports research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo.Technology committees.
8

TABLE OF CONTENTS

 
​​
Margaret G. McGlynn has served as a member of the Board since October 2009. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as Chief Executive Officer and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Boards of Directors of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) and Novavax, Inc. (NASDAQ: NVAX). Previously, she served on the Boards of Air Products and Chemicals, Inc. (NYSE: APD) and Orphan Technologies. She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and supports research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a M.B.A. in Marketing and an honorary doctorate in sciences from the State University of New York at Buffalo.
Skills and Qualifications:Ms. McGlynn has significant leadership experience in the pharmaceutical industry, including her service as a senior executive of Merck where she led commercialization across


several therapeutic areas and geographies and managed large organizations. This experience, combined with her service on biopharmaceutical company boards and a rare disease patient advocacy organization, which gives her important insights into Amicus'sAmicus’s business and a comprehensive understanding of compensation management and the relationship of compensation practices to the organization and its development, contributed to our conclusion that she should continue to serve as a director of the Company, Chair of the Compensation Committee and member of the Nominating and Corporate Governance Committee.

Michael G. Raab has served as a member of our Board of Directors since its founding and as Lead Independent Director since September 2018. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. (NASDAQ: ARDX) since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates ("NEA") from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc. Mr. Raab holds a B.A. from DePauw University.

 
​​
Michael G. Raab has served as a member of the Board of Directors since 2004 and as Lead Independent Director since September 2018. Mr. Raab has served as President and Chief Executive Officer of Ardelyx, Inc. (NASDAQ: ARDX) since March 2009. Mr. Raab previously served as a partner of New Enterprise Associates (“NEA”) from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel® at Genzyme Corporation. Mr. Raab currently serves as a member of the Board of Directors of Ardelyx, Inc. Mr. Raab serves as Chairman of Tempest Therapeutics, Inc. (NASDAQ: TPST), a San Francisco based clinical stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor pathways. He also serves on the Emerging Companies and Health Section Governing Boards of the Biotechnology Innovation Organization. Mr. Raab holds a B.A. from DePauw University.
Skills and Qualifications: Mr. Raab has significant experience in drug development and commercialization of products in the rare diseases, cardio renal and GI diseases. He also has extensive management experience in the biopharmaceutical industry serving as Chief Executive Officer of a late-stage biopharmaceutical company and from his prior time overseeing NEA investments in pharmaceuticals and biotechnology. Mr. Raab also brings a global perspective and an integrity-based approach to compliance and governance matters, and devotes substantial time to Amicus matters, all of which contributed to our conclusion that he should continue to serve as a director of the Company, the Lead Independent Director, Chair of the Nominating and Corporate Governance Committee and a member of the Audit and Compliance Committee.

Glenn P. Sblendorio has served as a member of our Board since June 2006. Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. (NASDAQ: ISEE), formerly Ophthotech Corporation (NASDAQ: OPHT) and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March, 2006 through March, 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.

 
​​
Glenn P. Sblendorio has served as a member of the Board since June 2006. Mr. Sblendorio is currently Chief Executive Officer of IVERIC bio, Inc. (NASDAQ: ISEE), formerly Ophthotech Corporation (NASDAQ: OPHT), a position that he has held since 2017 and is a member of the Board of Directors of IVERIC. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company (NASDAQ: MDCO) from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Mr. Sblendorio also serves as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (Chair, Audit). Mr. Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University.
Skills and Qualifications: Mr. Sblendorio has significant corporate leadership experience, industry knowledge and demonstrated knowledge of financial and financing matters through his prior experience in leading pharmaceutical companies. He brings substantial expertise in the management of financial and compliance risks associated with global pharmaceutical operations and financial management strategies. Mr. Sblendorio'sSblendorio’s specific expertise includes his service on other boards and he devotes significant time to Amicus matters both in scheduled meetings and with management and the auditors. He is the "audit“audit committee financial expert"expert” as defined in the SEC regulations, with particular expertise in the matters faced by the audit committee of a company with its commercial revenue guidance, geographic expansion and related expenses, all of which contributed to our conclusion that he should continue to serve as a director of the Company and Chair of the Audit and Compliance Committee.

9

TABLE OF CONTENTS

Directors Whose Terms Do Not Expire This Year

​
Name
​​
Age
​​
Position
​
​
Name
AgePosition

Lynn D. Bleil(1)Bleil(1)(2)

(3)		​​55
58
​​
Director
​

​

Bradley L. Campbell

​​43
46
​​
Director
​

​

Robert Essner(3)

Essner(4)
​​71
74
​​
Director
​

Ted.​

Eiry W. Love,Roberts, M.D.(2)(4)

(3)
​​60
58
​​
Director
​

​

Craig A. Wheeler(1)Wheeler(2)(5)

​​58
61
​​
Director
​
​
Burke W. Whitman(1)(4)
​​
66
​​
Director
​
 (1)
Member of the Nominating and Corporate Governance Committee
 (2)
Member of the Compensation and Leadership Development Committee
 (3)
Member of the Science and Technology Committee
 (4)
Member of the Audit and Compliance Committee
 (5)
Chair of the Science and Technology Committee
 
​​
Lynn D. Bleil has served as a member of the Board since September 2018. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey’s worldwide Healthcare Practice before her retirement as a Senior Partner in 2013, after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Board of Directors of Stericycle, Inc. (NASDAQ: SRCL), Sonova Holding AG (VX: SOON) and Alcon AG (NYSE: ALC). Her prior directorships included DST Systems, Inc. (NYSE: DST), and Auspex Pharmaceuticals (NASDAQ: ASPX). Ms. Bleil is also the Chair of the Intermountain Park City Hospital Governing Board, a non-profit organization. Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business.
(1)
Member of Compensation Committee

(2)
Member of Nominating and Corporate Governance Committee

(3)
Member of Audit and Compliance Committee

(4)
Chair of Science and Technology Committee

(5)
Member of Science and Technology Committee

Lynn D. Bleil has served as a member of the Board since September 2018. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey's worldwide Healthcare Practice before her retirement as a Senior Partner in 2013, after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Board of Directors of Stericycle, Inc. (NASDAQ: SRCL), Sonova Holding AG (VX: SOON) and Alcon AG (NYSE:ALC). Her prior directorships included DST Systems, Inc. (NYSE: DST), and Auspex Pharmaceuticals (NASDAQ: ASPX). Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business.

Skills and Qualifications:Qualifications: Ms. Bleil brings more than three decades of experience in the broader healthcare industry and biopharma, having advised numerous executives and Boards in the sector on strategic, organizational and operational issues. She has broad expertise in healthcare strategy, business development, go-to-market strategies, reimbursement and policy.

 
​​
Bradley L. Campbell has served as a member of the Board since June 2018 and as President and Chief Operating Officer since January 2015. He brings 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization responsible for the commercialization of Galafold®. He also oversees the Technical Operations, Market Access, Program Management, Clinical Operations and Regulatory Affairs functions. Mr. Campbell currently serves on a number of Boards including Gennao Bio, the Alliance for Regenerative Medicine (ARM), and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of ARYA Sciences Acquisition Corp III, a healthcare focused Special Purpose Acquisition Vehicle, as well as Progenics Pharmaceuticals (NASDAQ: PGNX) from 2016 until its successful acquisition by Lantheus Holdings in 2020. Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School.
Skills and Qualifications: Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme© for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates. Mr. Campbell is also a director for Progenics (NASDAQ: PGNX) and a board member of BioNJ. Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.

        Skills and Qualifications:    Mr. Campbell's significant experience within the pharmaceutical industry, much of which has been focused on rare diseases, andincluding expertise in corporate development, strategic planning, business operations, sales marketing and product management, along withmarketing. His experience, as well as his prior service on the Board of Directors of another publicly-held biopharmaceutical company, all contributedother publicly held companies in the pharmaceutical industry, provides valuable contributions to the Company's decision that he should be appointed a director of the Company as we continue our ongoing expansion as a fully integrated global commercial company.

 
​​
Robert Essner has served as a member of the Board since June 2012. Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth Pharmaceuticals, Inc., now part of Pfizer Inc., in 2008. During his 32 year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr. Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner was formerly a Director at MassMutual Financial Group. He received a Bachelor’s degree from Miami University and a Master’s degree from the University of Chicago.
10

TABLE OF CONTENTS

Skills and Qualifications: Mr. Essner retired as Chairman and Chief Executive Officer of Wyeth Pharmaceuticals, Inc., now part of Pfizer Inc., in 2008. During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr. Essner


spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr. Essner was formerly a Director at MassMutual Financial Group. He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago.

        Skills and Qualifications:    Mr. Essner'shas significant executive leadership experience in the pharmaceutical industry, including building and leading pharmaceutical businesses and launching products and managing corporate risks, includingrisks. His experience includes serving as Chairman and Chief Executive Officer of a pharmaceutical company, as well as his servicehaving served on the Board of Directors of another publicly-heldpublicly held company in the pharmaceutical industry.

 
​​
Eiry W. Roberts, M.D., has served as a member of our Board since 2021. Dr. Roberts is a former senior executive of Eli Lilly and Company and is currently the Chief Medical Officer of Neurocrine Biosciences, Inc. She has over 25 years of pharmaceutical drug development experience, ranging across all phases of development from research through commercialization, spanning multiple therapeutic areas. Prior to Neurocrine, Roberts spent 26-years at Eli Lilly, during which she advanced through various senior and executive level roles, concluding her tenure as Vice President in Research & Development. Roberts served as the Chair of the Medical Review Committee at Eli Lilly. She is a member of the Healthcare Business Women’s Association and an Adjunct Professor of Medicine at Indiana University, Department of Clinical Pharmacology. She formerly served on the Springboard Ventures Steering Committee and was a member of the Indiana Health Forum. She has non-profit Board experience, previously serving on the Board of the Indianapolis Children’s Choir and the St. Richard’s Episcopal School Board of Trustees. Dr. Roberts is an M.D. trained in pharmacology and medicine in the United Kingdom, qualifying from the University of London. Dr. Roberts continued her post-graduate clinical training in clinical pharmacology and cardiology at St. Bartholomew’s Hospital and at the Royal London Hospital.
Skills and Qualifications: Ms. Roberts has Ms. Roberts brings more than 25 years of healthcare industry contributedexperience to our conclusion that he should be re-elected to servethe Board, spanning the areas of pharmaceutical drug development, regulatory affairs, pricing, and access. She has immense experience in leading therapeutic programs through all phases of the drug development process, regulatory frameworks, and product commercialization. She has an extensive background in medicine and experience as a director of the Company and continue to serve on the Audit and Compliance Committee.

Ted W. Love,M.D., has served as a member of the Board since June 2012. Dr. Love is currently the CEO of Global Blood Therapeutics, Inc. (NASDAQ: GBT). From February 2010 to August 2012, Dr. Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals, Inc. From 2001 to 2009, Dr. Love was the President, Chief ExecutiveMedical Officer and Chairman of the Board of Directors of Nuvelo Inc. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at Theravance, Inc. Prior to that, Dr. Love spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr. Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of Genentech's Product Development Committee. In addition to Amicus, Dr. Love currently serves on the Board of Directors of Global Blood and was previously a board member of Cascadian Therapeutics. Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

        Skills and Qualifications:    Dr. Love's significant medical, scientific and drug development experience, in addition to his executive leadership experience in the pharmaceutical industry, experience as Chief Executive Officer and Chairman of a biopharmaceutical companycompany. The culmination of her skills and service on the Boards of Directors of other publicly-held biopharmaceutical companies, contributed to our conclusion that he should be re-elected to serve as a director of the Company and lead the Science and Technology Committee.

Craig A. Wheeler has served as a member of our Board since June 2016. Since September 2006, Mr. Wheeler has served as President and Chief Executive Officer of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). At Momenta, Mr. Wheeler led the company through the launch of its first complex drug products. He has overseen the company's growthexperience add important insight into the diversifiedAmicus business it is today. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led US and Europeanits development into a leading global commercial organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. He began his career at Merck & Company, Inc.'s (NYSE: MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals, Inc. where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. Mr. Wheeler received his BS and MS in chemical engineering from Cornell University and his MBA from the Wharton School of the University of Pennsylvania.organization.

 
​​
Craig A. Wheeler has served as a member of the Board since June 2016. He is the CEO of Headwaters Biotech Advisors, where he serves as an advisor to executives in the Biotech industry. Mr. Wheeler recently completed a 14 year tenure as President and Chief Executive Officer of Momenta Pharmaceuticals (NASDAQ: MNTA), where he grew the company from a startup, through multiple product launches, and ultimately to a $6.5B acquisition by J&J in the fall of 2020. In 2011, he was an E&Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr. Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led US and European commercial organizations and the pharmaceutical division’s global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group’s health care practice and worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&D strategy. He began his career at Merck & Company, Inc.’s (NYSE: MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals, Inc. where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5 billion. Mr. Wheeler received his B.S. and M.S. in chemical engineering from Cornell University and his M.B.A. from the Wharton School of the University of Pennsylvania.
Skills and Qualifications: Mr. Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his demonstrated expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies.
11

TABLE OF CONTENTS

 
​​
Burke W. Whitman has served as a member of the Board since June 2019. He also serves as a member of the Board of Directors of Omega Healthcare Investors (NYSE: OHI); Board of Directors of the Marine Corps Heritage Foundation; Board of Trustees of The Lovett School; Reserve Forces Policy Board; and as Chief Executive of Colmar Holdings, a private investment company. Previously he served as Chief Executive Officer (and initially Chief Operating Officer) of Health Management Associates (NYSE: HMA) 2005-08; Chief Financial Officer of Triad Hospitals (NYSE: TRI) 1998-2005; President of Deerfield Healthcare (private) 1994-98; Vice President of Almost Family (NASDAQ: AFAM) 1992-94; and Investment Banker with Morgan Stanley (NYSE: MS) 1988-92. Concurrently through 2018, he served as a reserve Major General and the senior reserve officer of the United States Marine Corps, capping 33 years of service which included active duty during 1985-88 and 2009-18 when he served with the Secretary of Defense, led multiple deployments, and was Commanding General of Marine Forces Reserve and the 4th Marine Division. Mr. Whitman previously served on the Board of Directors of the Federation of American Hospitals (Audit Chair), Board of Directors of the Toys for Tots Foundation (Investment Chair), Board of Visitors of Marine Corps University, and Founders Group of the National Museum of the Marine Corps. He holds an MBA from Harvard Business School, a Master of Strategic Studies from the Army War College, and a BA from Dartmouth College.
Skills and Qualifications: Mr. Wheeler's deep understandingWhitman is an experienced executive and board leader of national and global organizations in health, defense, education, finance, and real estate. His broad knowledge of the managementhealthcare sector, specific experience in strategic finance and growth, of pharmaceutical companies contributeand skill in organizational leadership and governance, provide a multifaceted perspective to our conclusion that he shouldglobal biopharma business.

Committee Memberships
​
Directors
​​
Independent
​​
Age
​​
Director
Since
​​
Audit and
Compliance
​​
Compensation
and
Leadership
Development
​​
Nominating
and
Corporate
Governance
​​
Science
and
Technology
​
​
Lynn D. Bleil
​​
✔
​​
58
​​
2018
​​
 
​​
●
​​
●
​​
●
​
​
Bradley L. Campbell
​​
​​
46
​​
2018
​​
​​
​​
​​
​
​
John F. Crowley (CH)
​​
 
​​
55
​​
2010
​​
 
​​
 
​​
 
​​
 
​
​
Robert Essner
​​
✔
​​
74
​​
2012
​​
●
​​
​​
​​
​
​
Michael A. Kelly
​​
✔
​​
65
​​
2020
​​
●
​​
 
​​
 
​​
●
​
​
Margaret G. McGlynn
​​
✔
​​
62
​​
2009
​​
​​
C
​​
●
​​
​
​
Michael G. Raab (LID)
​​
✔
​​
57
​​
2004
​​
●
​​
 
​​
C
​​
 
​
​
Eiry W. Roberts, M.D.
​​
✔
​​
58
​​
2021
​​
​​
●
​​
​​
●
​
​
Glenn P. Sblendorio
​​
✔
​​
66
​​
2006
​​
C
​​
 
​​
 
​​
 
​
​
Craig A. Wheeler
​​
✔
​​
61
​​
2016
​​
​​
●
​​
​​
C
​
​
Burke W. Whitman
​​
✔
​​
66
​​
2019
​​
●
​​
 
​​
●
​​
 
​
​
“CH”
​​
Chairman of the Board
​
​
“C”
​​
Committee Chair
​
​
“LID”
​​
Lead Independent Director
​
12

continue to serve as a director of the Company and as a member of the Science and Technology and Compensation Committees.TABLE OF CONTENTS


AMICUS CORPORATE GOVERNANCE

General

This section describes key corporate governance policies and practices that we believe ensure that Amicus is managed for the long termlong-term benefit of all our stakeholders. We continuously review these policies and practices and compare them to those of our peer group and those suggested by various authorities in corporate governance to ensure we adopt best industry practices. Policies and practices that we have adopted include criteria for selecting director nominees, board leadership structure, and responsibilities of the Board of Directors and its committees, among others. Complete copies of our Corporate Governance Guidelines, Board Committee charters, and Code of Conduct are available on the "Investors—“Investors—Corporate Governance"Governance” section of our website, www.amicusrx.com.www.amicusrx.com. You may also request a copy of these documents in writing to:

Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, N.J. 08512,3675 Market Street, Philadelphia, PA 19104, Attn: Ellen Rosenberg, Corporate Secretary.

Corporate Governance Guidelines

Our Board of Directors has adopted corporate governance guidelines to assist our directors in the exercise of their duties and responsibilities and to serve the best interests of Amicus and its stakeholders. These guidelines provide, among other things, that:

    •
The responsibility of the Board is to oversee the business and operations of Amicus;

•
The majority of the Board must be independent directors;

•
The directors have full access to management and to outside independent consultants as needed;

•
The Board conducts an annual self-evaluation; and

•
The Board establishes appropriate limitations for service as directors on other company boards.

Director Independence

Our Board has reviewed the materiality of any relationship that each of our directors has with Amicus, either directly or indirectly, as well as other factors that may impact the independence determination for each of our directors. Based on this review, our Board has determined that the following directors are "independent directors"“independent directors” as defined by the rules and regulations of The Nasdaq Stock Market LLC ("NASDAQ"(“NASDAQ”): Mses. Bleil and McGlynn, Messrs. Essner, Kelly, Raab, Sblendorio, and Wheeler and Whitman, and Dr. Love.

Roberts.

Board Leadership Structure

In February 2010, the Board elected Mr. Crowley as chairman of the Board, in addition to his role as chief executive officer, to succeed Donald J. Hayden, Jr. In September 2018, the Board appointed Mr. Raab as Lead Independent Director following Mr. Hayden'sHayden’s resignation. As Lead Independent Director, Mr. Raab is responsible for, among other things:

    •
leading executive sessions of the Board'sBoard’s independent directors,

•
advising the independent Board Committee chairs in fulfilling their responsibilities to the Board,

•
assisting the Board and the Company'sCompany’s officers in complying with the Company'sCompany’s governance guidelines, and

    •
    overseeing the process of evaluating, developing and compensating the chief executive officer.

officer evaluation process and advising the Compensation and Leadership Development Committee on chief executive officer compensation.

The Company currently combines the chairman and chief executive officer positions because it believes that, at this critical juncture in the Company'sCompany’s development, Mr. Crowley is best suited to oversee the development and implementation of the Company'sCompany’s strategic vision including our ongoing expansion as a fully integrated global commercial company. As previously announced, effective August 1, 2022, Mr. Crowley'sCrowley will transition to Executive Chair of the Board and Mr. Campbell will become chief executive officer of the Company; for further discussion please see the section title “Developments with Respect to the Company’s Named Executive Officers in 2021” below. Mr. Crowley’s tenure as chairman also reflects the Board'sBoard’s confidence in his leadership and vision for the Company and recognizes his accomplishments since joining the Company. The Company believes that the role of the Lead Independent Director, position,which is currently held by Mr. Raab, provides the Company with a governance structure that best advances the objectives of the Company while maintaining proper checks and balances on senior management, and providing the independent members of the Board with open and transparent communication regarding the Company'sCompany’s strategic planning activities.
13

TABLE OF CONTENTS

Risk Oversight Management

Environmental, Social & Governance (ESG) Program
Our BoardESG program reflects what we view as the effective management of critical environmental, social and governance principles that are fundamental to our organization. It is our belief that a sound governance structure, coupled with a socially and environmentally responsible mindset, provides risk oversightthe foundation for the Company primarily through the Auditcollective and Compliance Committee. Underinformed decision making and accountability across all facets of Amicus.
​


​​
Commitment to the Environment: Amicus is committed to producing transformative medicines for patients while practicing environmental responsibility and incorporating sustainability best practices in our operations. As a biotechnology company, our environmental footprint is relatively small in comparison to many other industries, yet we strive to minimize our footprint as much as possible. We recognize the pressing need to continuously identify and implement opportunities to achieve a reduction in greenhouse gas (GHG) emissions. Since 2020, we have made significant reductions in our physical footprint and established a hybrid approach working model, which reduces emissions associated with daily commuter travel and energy emissions produced from facility operations. As we look to enhance and promote sustainable practices in our existing and future facilities, we aspire to meet and exceed all environmental-related building standards currently in place and only occupy facilities that support our sustainability goals. The Amicus global technical operations team is further committed to improving our “green” credentials through our supply chain partners to reduce environmental impact. We have sustainability as a standing agenda item in our Quarterly Business Reviews with a growing number of vendors and we will periodically assess the progress of these programs and partners to help drive change. We are also partnering with our manufacturing vendors to manage the carbon footprint resulting from the processes used to manufacture our products and we are committed to reviewing and minimizing the environmental impact of future proposal submissions. To this end, Amicus encourages stockholders to voluntarily elect to receive future proxy and annual report materials electronically to help contribute to our sustainability efforts, which helps us reduce our impact on the environment. The numbers below show the environmental impact that the adoption of electronic delivery of proxy materials would have, based on stockholder data collected in preparation for the 2021 annual meeting:
​
​
​​
​
​
​​

​
14

TABLE OF CONTENTS

​

​​
Commitment to the Rare Disease Community: At Amicus, our employees strive to be champions of the rare disease community through volunteering, giving, and engagement opportunities to support the communities in which we serve. Amicus has proudly developed programs, services, and activities designed to enhance the lives of the members of the rare disease community. Each year the Company awards each employee two (2) volunteer days to encourage giving back to their local communities. Through our corporate social responsibility initiative, Healing Beyond Disease, we are proud to have developed a program to provide charitable contributions that help patient and professional non-profit healthcare-related organizations deliver programs, services, and activities to enhance the lives of their rare disease communities. At Amicus, there is a shared purpose of improving public health, patient experiences, and outcomes with a focus on educational, advocacy, and access initiatives related to those disease areas on which the company focuses its development and therapeutic programs. Amicus does not receive any significant value in terms of goods or services in return for its charitable support and matches employee donations to approved foundations up to $500 per year per employee. The graphic below quantifies the amount given in 2021:
​
​
​​
​
​
​​

​
​
​​
Commitment to our Employees and Diversity, Equity and Inclusion: We also strive for our people to have a meaningful impact on organizational performance and enable a competitive advantage. We have almost 500 employees across the U.S. and internationally who are key to advancing our programs and who contribute to our culture of passion, dedication, and excitement for the work that we do. Our Board and Senior Leadership Team are committed to broad human capital philosophies, practices, and risk management to create value and support our mission. Attracting and retaining talented team members, and creating a viable and consistent work experience, is an integral part of our competitive strategy, which drives long-term value and risk mitigation. To that end, the Compensation and Leadership Development Committee and the full Board review our key human capital programs and process on a regular basis, including our talent pipeline, turnover, workplace culture, inclusion and engagement, and workforce risk. Goals of maintaining gender diversity and increasing overall diversity and culture are embedded in our corporate and individual goals and reinforced through our compensation management decisions.
​
​
​​
​
​
​​

​
15

TABLE OF CONTENTS

​
​​
Amicus management reviews pay parity bi-annually in an on-going endeavor to ensure equal treatment across the organization for equal work and makes market adjustments as needed. The Compensation and Leadership Development Committee does the same for the executive levels of the Amicus workforce and reviews pay parity results for all levels on an ongoing basis.
​
​
​​
​
​
​​

​
​

​​
Commitment to Governance and Risk Oversight: Finally, a robust governance and risk oversight structure is the foundation that allows our environmental and social initiatives to operate and grow. Our Board provides risk oversight primarily through its Enterprise Risk Management Program (“ERM Program”). Through this ERM Program, the Board delegates various oversight responsibilities to its committees which, in turn, provide regular updates to the Board on key risk issues and mitigation strategies in conjunction with management updates. At the business level, the President and Chief Compliance Officer co-chair the Global Risk Committee, which is comprised of the various department heads, and meets periodically to discuss potential or emerging areas of concern. Senior management is responsible for the day-to-day identification and management of risks with the Chief Compliance Officer having a dotted line to the Audit and Compliance Committee, providing quarterly updates on key developments from the global risk committee and any reports of violations of the Code of Conduct or other policies. The Audit and Compliance Committee oversees all matters related to the ERM Program, as well as risks related to financial, compliance, data privacy and cybersecurity risks, and apprises the Board of any developments under the ERM Program throughout the year. Our risk management structure, and matters overseen by the Nominating and Corporate Governance Committee, Compensation and Leadership Development Committee, and Science and Technology Committee are as follows:
​

For more information on our Risk Management Action Plan, the Company identifies risks utilizing various methodologies, including interviews with senior employees and members of the Board. We then evaluate the identified risks and implement procedures and activities, as necessary, which are designedESG initiatives, please refer to manage and mitigate such risks. We present reportsour inaugural ESG report, available in digital format on this risk identification, management and mitigation process along with regular updates on compliance issues generally to the Audit and Compliance Committee, who provides guidance and feedback to senior management. The Audit and Compliance Committee apprises the Board of any developments under this plan throughout the year. The Chief Compliance Officer has a dotted line reporting to the Audit and Compliance Committee and provides quarterly updates on the development of the Compliance Program and any reports of violations of the Code of Conduct or other policies.our website at www.amicusrx.com/responsibility/.
16

TABLE OF CONTENTS

Code of Conduct and Ethics

We have adopted a codeCode of conductConduct and ethics that applies to all of our employees, including our principal executive officer and principal financial and accounting officer, and our directors. The text of the codeCode of conductConduct and ethics is posted on our web site atwww.amicusrx.comwww.amicusrx.com and will be made available to stockholders without charge, upon request, in writing to The Office of the Corporate Secretary, c/o Amicus Therapeutics, Inc. at 1 Cedar Brook Drive, Cranbury, New Jersey 08512.3675 Market Street, Philadelphia, Pennsylvania 19104. Disclosure regarding any amendments to, or waivers from, provisions of the codeCode of conductConduct and ethics that apply to our directors, principal executive and financial and accounting officers will be included in a Current Report on Form 8-K within four business days following the date of the amendment or waiver, unless web site posting of such amendments or waivers is then permitted by the rules of NASDAQ.

Director Attendance

During the year ended December 31, 2018,2021, there were twelveeleven meetings of our Board, and the various committees of the Board met a total of twenty-onetwenty-four times. NoEach director attended fewer than 90%75% or more of the total number of meetings of the Board and of Committeesthe committees of the Board on which he or she served during 2018.2021, with no director falling below 90% attendance except for Dr. Roberts who joined the Board June 10, 2021. Of the directors up for election in 2022, Mr. Crowley attended 100%, Mr. Raab attended 92%, Mr. Sblendorio attended 100%, Mr. Kelly attended 100% and Ms. McGlynn attended 100% of the meetings of the Board and various committees of the Board of which they are members. The Board has adopted a policy under which each member of the Board is strongly encouraged to attend each Annual Meeting of our Stockholders. All of the directors serving at the time attended our 20182021 Annual Meeting of Stockholders.

Furthermore, in 2021 the Company’s endeavors to consummate the ARYA-Caritas transaction (described in further detail below under the heading “Developments with Respect to the Company’s Named Executive Officers in 2021”) resulted in a significantly higher time commitment from each director than prior years. In addition to the 24 meetings of the Board and committees of the Board, directors attended thirteen additional update calls with legal advisors, accountants and various other consultants, and reviewed, evaluated and discussed a substantially greater number of board materials in preparation for the anticipated launch, and subsequent unwinding of, a newly formed, fully-funded, publicly-traded gene therapy company. Despite this atypical year, director attendance at meetings of the Board and the various committees of the Board remained extremely high, with near perfect attendance, consistent with years past, as detailed above. The ARYA-Caritas transaction was ultimately terminated prior to the closing of such transaction.
Committees of the Board and Meetings

Our Board has an Audit and Compliance Committee, a Compensation and Leadership Development Committee, a Nominating and Corporate Governance Committee and a Science and Technology Committee, each of which has the composition and responsibilities described below.


Audit and Compliance Committee.Committee. Our Audit and Compliance Committee met sevenfive times during 2018.2021 and participated in five additional update calls, primarily relating to the Caritas-ARYA transaction. The current members of our Audit and Compliance Committee are Messrs. Essner, Kelly, Raab, Sblendorio Essner and Raab.Whitman. Mr. Sblendorio is the Chair of the Audit and Compliance Committee.

Our Board has determined that Mr. Sblendorio is an Audit and Compliance Committeea financial expert within the meaning of Item 407(d)(5) of Regulation S-K and has "accounting“accounting or related financial management expertise"expertise” within the meaning of the rules and regulations of NASDAQ. Our Audit and Compliance Committee was established in accordance with Section 3(a)(58) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"“Exchange Act”). Our Audit and Compliance Committee assists our Board in its oversight of the integrity of our financial statements, our independent registered public accounting firm'sfirm’s qualifications, and independence and the performance of our independent registered public accounting firm.

firm and our compliance program.

Our Audit and Compliance Committee'sCommittee’s responsibilities include:

    •
appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;

•
overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of certain reports from our independent registered public accounting firm;

•
reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;

•
monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics;

•
reviewing the Company’s Code of Conduct, including adherence thereto, and monitoring our Compliance Program andcompliance programs generally, periodically reporting periodically to the full Board;
17

•

TABLE OF CONTENTS

overseeing matters related to the Company’s compliance and enterprise risk management programs, processes and policies;
monitoring cybersecurity risk and reporting periodically to the full Board;

•
establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns;

•
meeting independently with our independent registered public accounting firm and management;

•
meeting independently with our Chief Compliance and Risk Officer; and

•
preparing the Audit Committee report required by SEC rules.

All audit and non-audit services to be provided to us by our independent registered public accounting firm must be approved in advance by our Audit and Compliance Committee.

NASDAQ rules require that all members of the Audit and Compliance Committee be independent directors, as defined by the rules of NASDAQ and the SEC. Our Board has determined that all the members of the Audit and Compliance Committee satisfy the independence requirements for service on the Audit and Compliance Committee.

A copy of the Audit and Compliance Committee written charter is publicly available on our web site atwww.amicusrx.com.www.amicusrx.com.

Compensation Committee.and Leadership Development Committee. Our Compensation and Leadership Development Committee met foureight times during 2018.2021. Mses. Bleil and McGlynn, Dr. Roberts, and Mr. Wheeler are the members of our Compensation Committee.and Leadership Development Committee, and Ms. McGlynn is the chair of the Compensation Committee.committee. Our Compensation and Leadership Development Committee assists our Board in the discharge of its responsibilities relating to the compensation of our executive officers. The Compensation and Leadership Development Committee has retained Pay Governance, LLC ("(“Pay Governance"Governance”) as its independent executive compensation consultant. Pay Governance reports directly to the Compensation and Leadership Development Committee and provides guidance on matters including trends in executive and non-employee director compensation, the development of certain


executive compensation programs, determination of the Company peer group and other matters as directed by the Compensation and Leadership Development Committee. Pay Governance does not provide any other services to the Company. Based on the consideration of the various factors as set forth in the rules of the SEC, the Compensation and Leadership Development Committee has determined that its relationship with Pay Governance and the work of Pay Governance on behalf of the Compensation and Leadership Development Committee has not raised any conflict of interest.

Our Compensation Committee'sand Leadership Development Committee’s responsibilities include:

    •
reviewing and approving executive officer compensation includingrecommending to the Board for approval, the compensation of our Chief Executive Officer;

•
reviewing and approving compensation for executive officers other than the Chief Executive Officer;
overseeing compensation for directors and Board committee members;
overseeing the evaluation of performance of our senior executives;

•
overseeing and administering, and making recommendations to our Board with respect to our cash and equity incentive plans;

•
reviewing and approving potential executive and senior management succession plans;

•
reviewing and approving non-routine employment agreements, severance agreements and change in control agreements;

•
reviewing and recommending to the Board organizational and leadership development plans and programs;
assessing and monitoring the Company’s organizational health, leadership development programs and processes designed to attract, develop, motivate and retain employees;
assessing and monitoring diversity and pay equity across all levels of the Company, including the review of programs and initiatives related thereto, periodically updating the Board;
reviewing and recommending to the Board for approval the annual corporate goals and objectives; and

•
reviewing the Company'sCompany’s performance against the annual corporate goals and objectives and recommending to the Board a corporate multiplier which represents the percentage of achievement against the corporate goals and objectives.
18

TABLE OF CONTENTS

Subject to the requirements of applicable law and our governing documents, the Compensation and Leadership Development Committee may delegate any of its responsibility to subcommittees as it deems necessary or appropriate in its sole discretion. Our Board has determined that the members of our Compensation and Leadership Development Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC.

A copy of the Compensation Committee'sand Leadership Development Committee’s written charter is publicly available on our web site atwww.amicusrx.com.www.amicusrx.com.

Further discussion of the process and procedures for considering and determining executive compensation, including the role that our executive officers play in determining compensation for other executive officers, is included below in the section entitled "Compensation“Compensation Discussion and Analysis."

”

Please also see the report of the Compensation and Leadership Development Committee set forth elsewhere in this Proxy Statement.

Nominating and Corporate Governance Committee.Committee. Our Nominating and Corporate Governance Committee met five times during 2018.2021. Mses. Bleil and McGlynn Mr.and Messrs. Raab and Dr. LoveWhitman are the members of our Nominating and Corporate Governance Committee. Mr. Raab chairs the Nominating and Corporate Governance Committee.

Our Nominating and Corporate Governance Committee'sCommittee’s responsibilities include:

    •
recommending to our Board the persons to be nominated for election as directors and to each of the Board's Committees;

•
Board’s committees;
conducting searches for appropriate directors;

•
reviewing the size, composition and structure of our Board;

•
developing and recommending to our Board corporate governance principles;

•
overseeing a periodic self-evaluation of our Board and any Board Committees;committees; and

•
overseeing compensation and benefits for directorsmonitoring Company issues related to activism, corporate social responsibility, sustainability and Board Committee members.philanthropy, periodically reporting to the Board.

Our Board has determined that the members of our Nominating and Corporate Governance Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC.

A copy of the Nominating and Corporate Governance Committee'sCommittee’s written charter is publicly available on our web site atwww.amicusrx.com.www.amicusrx.com.

Science and Technology Committee.Committee. Our Science and Technology Committee met fivesix times in 2018.2021. Ms. Bleil, Messrs. Kelly and Wheeler, and Dr. Love and Mr. WheelerRoberts are currently members of our Science and Technology Committee. Dr. LoveMr. Wheeler serves as Chair of the committee.

Our Science and Technology Committee'sCommittee’s responsibilities include:

    •
identifying and discussing new and emerging trends in pharmaceutical science, technology and regulation to ensure that the Company makes well informed choices in the investment of its Researchresearch and Developmentdevelopment resources;

•
reviewing, evaluating and advising the Board regarding the quality, direction and competitiveness of the Company's ResearchCompany’s research and Developmentdevelopment programs;

•
overseeing risk management in the areas of product quality and safety, GxP, and pharmacovigilance, including development and implementation of policies regarding the same;
reviewing, evaluating and advising the Board regarding the Company'sCompany’s overall manufacturing strategy to ensure that the Company makes well informed choices in the investment in manufacturing capabilities and secures appropriate levels of drug supply and drug product;

•
reviewing, evaluating and advising the Board regarding the Company'sCompany’s clinical and regulatory strategy, goals and objectives, and progress in achieving the clinical and regulatory strategy, goals and objectives; and

•
reviewing and making recommendations to the Board on the Company'sCompany’s internal and external investments in science and technology.

technology and evaluating the Company’s current scientific resource and personnel needs.

Our Board has determined that the members of the Science and Technology Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. A copy of the Science and Technology Committee'sCommittee’s written charter is publicly available on our web site atwww.amicusrx.com.www.amicusrx.com.
19

TABLE OF CONTENTS

Policies Governing Director Nominations

Director Qualifications.Qualifications and Skills. Our Nominating and Corporate Governance Committee is responsible for reviewing with the directors from time to time the appropriate qualities, skills and characteristics desired of members of the Board in the context of the needs of the business and the composition of the Board. This assessment includes consideration of the following minimum qualifications that the Nominating and Corporate Governance Committee believes must be met by all directors:

    •
a reputation for integrity, honesty and adherence to high ethical standards;

•
the ability to exercise sound business judgment;

•
substantial business or professional experience and the ability to offer meaningful advice and guidance to the Company'sCompany’s management based on that experience; and

•
the ability to devote the time and effort necessary to fulfill their responsibilities to the Company.

The Nominating and Corporate Governance Committee also considers numerous other qualities, skills and characteristics when evaluating director nominees, including whether the nominee has specific strengths that would augment existing skills and experience of the Board, such as an understanding ofexpertise and experience in science & technology, drug development, accounting, governance,healthcare provision & payment, regulatory, commercialization, pricing & reimbursement, public policy, finance & capital markets, talent management, Biopharma manufacturing, compliance or commercializationinternational life science – and whether the nominee hasbrings diversity or leadership experience withas a chief executive officer/chief operating officer or board director within public companies or other sophisticatedcomplex organizations. The following matrix highlights each director’s primary skills or knowledge in these areas as identified by the Nominating and complex organizations.

Corporate Governance Committee. As the matrix focuses solely on primary skills and knowledge, the absence of a mark does not necessarily indicate that the director does not possess such skill or knowledge.

20

TABLE OF CONTENTS

Process for Identifying and Evaluating Director Nominees.Nominees. Our Nominating and Corporate Governance Committee has established a process for identifying and evaluating nominees for director. Although the Nominating and Corporate Governance Committee will consider nominees recommended by stockholders, it believes that the process it uses to identify and evaluate nominees for director is designed to produce nominees that possess the educational, professional, business and personal attributes that are best suited to further the Company'sCompany’s mission. Our Nominating and Corporate Governance Committee may identify nominees through the use ofusing professional search firms that may utilize proprietary screening techniques to match candidates to the Nominating and Corporate Governance Committee'sCommittee’s specified qualifications. The Nominating and Corporate Governance Committee may also receive recommendations from existing directors, executive officers, key business partners, and trade or industry affiliations. Our Nominating and Corporate Governance Committee will evaluate nominations at regular or special meetings, and in evaluating nominations, will seek to achieve a balance of knowledge, experience and capability on the Board and to address the membership criteria set forth above under "Director“Director Qualifications."” The Board itself is ultimately responsible for recommending candidates for election to the stockholders or for appointing individuals to fulfill a vacancy. Although theThe Board’s objective is to form a diverse Board does not have a policy with regard to the considerationof Directors where diversity includes, ethnicity, gender, veteran status, age, perspective, skill, experience, competency, culture, disability and LGBTQ status, resulting in effective decision-making, guidance, risk management and overall Board effectiveness. These dimensions of diversity in identifying director nominees,are among the various factors the Nominating and Corporate Governance Committee considers in selecting candidates for nomination to the Board areand focusing on these ensured the benefitsNominating and Corporate Governance Committee was able to receive diverse candidate slates and led to the Companyappointments of national origin, gender, race, scientificBurke W. Whitman, Lynn D. Bleil, Michael A. Kelly and pharmaceutical experience and cultural diversity in board composition.Eiry W. Roberts, M.D.

​
Board Diversity Matrix (as of April 15, 2022)*
​
​
Total Number of Directors
​​
11
​
​
Part 1: Gender Identity
​​
Female
​​
Male
​
​
Directors
​​
3
​​
8
​
​
Part II: Demographic Background
​​
​​
​
​
African American or Black
​​
—
​​
1
​
​
White
​​
3
​​
6
​
​
Did Not Disclose
​​
—
​​
1
​
​
Veteran Status
​​
—
​​
2
​
 *
Per Nasdaq’s board diversity requirements; inapplicable categories considered by the Company have been omitted.
Procedures for Recommendation of Director Nominees by Stockholders.Stockholders. The Nominating and Corporate Governance Committee will consider director candidates recommended by our stockholders. In evaluating candidates recommended by our stockholders, the Nominating and Corporate Governance Committee applies the same criteria set forth above under "Director“Director Qualifications."” Any stockholder recommendations of director nominees proposed for consideration by the Nominating and Corporate Governance Committee should include the nominee'snominee’s name and qualifications for Board membership and should be addressed in writing to the Nominating and Corporate Governance Committee, care of: Amicus Therapeutics Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512,3675 Market Street, Philadelphia, Pennsylvania 19104, Attention: Corporate Secretary. In addition, our Restated By-laws permit stockholders to nominate directors for consideration at an annual stockholder meeting in accordance with certain procedures described in this Proxy Statement under the heading "Stockholder“Stockholder Proposals and Nominations for Director."”

Compensation and Leadership Development Committee Interlocks and Insider Participation.Participation    Ms.. Mses. Bleil Ms.and McGlynn, and Mr. Wheeler and Dr. Roberts are the members of our Compensation and Leadership Development Committee. None of the members of our Compensation and Leadership Development Committee has ever been an officer or employee of the Company. None of our executive officers serves as a member of the Boardboard of Directorsdirectors or Compensation Committee,compensation committee, or other committee serving an equivalent function, of any entity that has one or more of its executive officers serving as a member of our Board or our Compensation and Leadership Development Committee.

Stockholder Communications to the Board

Our Board provides a process for stockholders to send communications to the Board. Any stockholders who wish to address questions regarding our business directly with our Board, or any individual director, should direct his or her questions in writing to the Chairman of the Board or the Secretary of the Board, c/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.3675 Market Street, Philadelphia, Pennsylvania 19104. Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in the communications.

21

TABLE OF CONTENTS

Executive Officers

The following is a brief summary of the background of each of our executive officers:

John F.officers, except for Messrs. Crowley 52,and Campbell whose backgrounds may be found above under “Our Board of Directors”:

Daphne Quimi, 56, has served as Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005, except for the period during April 2011 through August 2011 during which time he served as Executive Chairman. Mr. Crowley has also served as a director of Amicus since August 2004, with the exception of the period from September 2006 to March 2007 when he was not an officer or director of Amicus while he was in active duty service in the United States Navy (Reserve). Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporation in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Mr. Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.

Bradley L. Campbell, 43, has served as President and Chief Operating Officer since January 2015. Mr. Campbell served as Chief Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr. Campbell served as Senior Vice President, Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr. Campbell served as Senior Product Manager of Myozyme© for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr. Campbell has also worked in sales & marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates. Mr. Campbell is also a director for Progenics (NASDAQ: PGNX) and a board member of BioNJ. Mr. Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School.

Daphne Quimi, 53, was appointed as the Company'sCompany’s Chief Financial Officer onsince January 1, 2019. Previously she served as the Company’s Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi brings extensive experience in public accounting and financial reporting. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A. from the Stern School of Business of New York University. She serves on the board of Amylyx Pharmaceuticals, Inc. Ms. Quimi is also a certified public accountant in New Jersey.

Ellen S. Rosenberg 56, 59, has served as our Chief Legal Officer and Corporate Secretary since December 2018 and our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served as a Senior Vice President of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA. Ms. Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance, product launches, risk management, litigation, investigations and compliance matters. Ms. Rosenberg also has significant experience building and developing legal teams and the in-house legal function. Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Carey Law School.

David M. Clark 44, 47, has served as our Chief People Officer since October 2018. Mr. Clark was previously Vice President of Global Human Resources (HR) at Alibaba Group, headquartered in Hangzhou, China, from September 2016 to August 2018. Prior to that, DavidMr. Clark spent eight years at American Express, where he was Senior Vice President of HRHuman Resources and Chief Learning Officer. While there, DavidMr. Clark was a senior HR Business Partner and led the transformation of learning, leadership development and performance management. Previously, DavidMr. Clark was a Commissioned Officer on the White House senior staff. As Deputy Assistant to the President of the United States, he led the recruitment and development of the 4,000 most


senior leaders in the U.S. government. DavidMr. Clark received a B.S. in political science from Indiana State University. He is an Eagle Scout and serves on the National Executive Board of the Boy Scouts of America (BSA). DavidAmerica. Mr. Clark is also the ChairmanChairman-Emeritus of the Board of the Make-A WishMake-A-Wish Foundation of America.

Hung Do, Ph.D.Ph.D., 51,54, has served as Chief Scientific Advisor since September 2021 following his role as Chief Science Officer, a position he held since July 2015. Dr. Do was as an executive officer of the Company in 2021 until transitioning into his part-time role. Previously, he served as the Company’s Senior Vice President, Discovery Biology since December 2013. Prior to joining Amicus, Dr. Do was a co-founder and Chief Scientific Officer of Callidus Biopharma, Inc. ("Callidus"(“Callidus”), a privately held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof of concept for ERTs and served as the project leader for a second generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals, Inc., which was acquired by Genzyme. Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University and was a post-doctoral fellow in Hematology/Oncology at Emory University.

22

Jay Barth, M.D., 55, has served as Chief Medical Officer since March 2014. Prior to joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics from 2009 to 2014. He most recently served as PTC Therapeutics' Senior Vice President, Clinical Development. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc.; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc. Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School Of Medicine.

Samantha Prout, 41, has served as Global Controller since March of 2018 and Principal Accounting Officer since June of 2018. Prior to joining Amicus, Ms. Prout spent nearly three years at NRG Energy ("NRG"), first as Controller for Home Solar division, then as the Director of Financial Reporting. Prior to joining NRG, Ms. Prout spent over 15 years at KPMG LLP, the final nine as an Audit Senior Manager serving the life science practice in NJ. Ms. Prout received a Bachelor of Arts from Gettysburg College and is a certified public accountant.TABLE OF CONTENTS



COMPENSATION DISCUSSION AND ANALYSIS—2018

2021

Executive Summary

The Compensation and Leadership Development Committee, in consultation with the Board, is responsible for establishing, implementing and overseeing our overall compensation strategy and policies, including our executive compensation program, in a manner that supports our business objectives. Based on the events described below, ourOur Compensation and Leadership Development Committee determined that in 2018,2021, the Company significantly advancedcontinued its advancement as a leading orphan and rare disease company with global commercial operations and a diversified product pipeline. SpecificThe specific milestones achieved in 20182021 in support of the Company'sCompany’s business strategy includeand this conclusion by the following:

    •
    We made significant progress inCompensation and Leadership Development Committee are described below under the global commercial launch of Galafold (migalastat) for the treatment of people living with Fabry disease who have amenable genetic variants or mutations, exceeding our corporate revenue goal. During the year ended December 31, 2018, Galafold® revenue totaled approximately $91.2 million.

    •
    In 2018, we exceeded our regulatory goal, obtaining approvals for Galafold® in several key geographies, including the U.S.heading “Annual Cash Incentive Plan”.
Our Compensation and Japan.

•
We achieved clinical program milestones for the Pompe program allowing us to meet our Pompe goal at target. We reported a series of positive data from a Phase 1/2 clinical study to evaluate Pompe disease patients treated with our novel treatment paradigm AT-GAA for up to 18 months. We also initiated a global pivotal study of AT-GAA (ATB200-03, also known as PROPEL) which is expected to enroll approximately 100 participants with late-onset Pompe disease at up to 90 global sites. We successfully scaled up manufacturing of our Pompe biologic to commercial scale (1,000L) for our pivotal PROPEL study and commercial supply. Our supply agreement with WuXi Biologics and current capacity are expected to produce sufficient quantities to serve the entire Pompe population as quickly as possible after receipt of applicable regulatory approvals.

•
We overachieved on the pipeline objective of acquiring or licensing additional preclinical or clinical programs focused on rare metabolic diseases entering 2019. Two clinical stage gene therapies are in CLN3 and CLN6 Batten disease. The CLN6 Batten disease Phase 1/2 study completed target enrollment, with 12 patients receiving a single administration of adeno-associated virus serotype 9 AAV9-CLN6 gene therapy. We expect to report additional two-year data from CLN6 Batten disease Phase 1/2 study in 2019.

•
With 14 new gene therapy programs for LSDs, we have established a leading portfolio of medicines for people living with rare metabolic disorders, including CLN6, CLN3, CLN8 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder and one additional undisclosed rare metabolic disorder. For Fabry and Pompe we were able to create differentiated novel constructs and have those constructs manufactured into AAV and dosed in animal models within two months of initiating the collaboration with the University of Pennsylvania.

•
We made significant progress in building out the long-term research and early-development strategy, developing a staffing plan, a facilities plan, and a leadership/governance plan that we began to execute on in the fourth quarter of 2018.

•
We strengthened our financial position in 2018, ending the year with approximately $500 million of cash and cash equivalents, an amount that is expected to fund ongoing operations into at least mid-2021 thereby exceeding our goal of ending the year with a minimum of 18 months of cash. In addition, in 2018 we spent $189 million, which is approximately $10 million to $35 million lower than the 2018 corporate budget of $200 million to $225 million. Finally, we raised $464 million in capital in 2018 in what we believe was an efficient manner. We raised $314 million in a follow-on equity offering. We also completed a $150 million debt financing to provide concurrent financing

      for the Celenex, Inc. acquisition (with no equity dilution) to ensure what we believe is a very strong balance sheet at the end of the year.

        Our CompensationLeadership Development Committee adheres to a long-standinglongstanding pay-for-performance philosophy.philosophy, and in 2021 we exceeded most of our corporate goals which resulted in an annual corporate bonus multiplier of 102%. The Compensation and Leadership Development Committee evaluates our compensation program, taking into consideration best practices and emerging trends, stockholder input as well as data and feedback provided by our independent executive compensation consultant, Pay Governance. In the past year, we have continued to take measures to align our compensation program with stockholder interests including the following actions:

    •
Base salaries comprise approximately 14%12% of our current named executive officers'officers’ total compensation on an aggregate basis (or, on average, approximately 14% of their direct compensation), with Mr. Crowley's 2018Crowley’s 2021 salary representing approximately 9%7% of his total compensation and, for our other named executive officers, representing between 17% and 22%(or 8% of their total compensation. For 2018, the Compensation Committee determined that Mr. Crowley would receive an increase in his base salary of 3%direct compensation). Additionally, approximately 11%8% of Mr. Crowley'sCrowley’s total compensation in 20182021 was represented by payments we makemade to him for medical expenses and associated tax liabilities incurred for the treatment of a rare medical condition afflicting two members of Mr. Crowley'sCrowley’s immediate family.

•
A large portionmajority of our named executive officersofficers’ compensation was represented by long-term incentives, including the grant date fair value of equity awards, which are inherently performance based. Approximately 74%79% of Mr. Crowley'sCrowley’s total compensation (or 87% of his direct compensation) was in the form of long-term incentives. For our other named executive officers, other than Mr. Crowley, 68% to 71%on average, approximately 77% of their total compensation (or, on average, approximately 79% of their direct compensation) for 20182021 was represented by long-term incentives.

•
For 2018,2021, the Compensation and Leadership Development Committee determined that Mr. Crowley, along with the Senior Leadership team,Team, including all of our named executive officers, would continue to receive1/ 1/3 the value of annual equity grants in Stock Options,1/ 1/3 in Restricted Stock Units ("RSUs"(“RSUs”) and1/ 1/3 in Performance Restricted Stock Units ("PRSUs"(“PRSUs”). The PRSUs utilized performance measures of relative total shareholderstockholder return, revenue and regulatory, strategic pipeline metrics. Utilizingand diversity goals. Similar to stock options, utilizing PRSUs aligns the management team with shareholdersstockholders and strengthens our pay for performance philosophy, because these awards only deliver value to our named executive officers if the Company achieves the long-term performance goals selected.

•
Consistent withdetermined by the Compensation and Leadership Development Committee.
The PRSUs granted in 2019, which had a three-year measurement period ending in 2021, paid out at 97.68% of target reflecting the Company’s strong absolute and relative share price performance and commercial progress over this period.
Additionally, our pay-for-performance philosophy,Compensation and in recognitionLeadership Development Committee made no COVID-19 adjustments to either the Company’s annual cash incentive program or the goals underlying the outstanding PRSU awards. As described more fully below under “The Corporate Multiplier”, the Compensation and Leadership Development Committee’s determination of our stronga 102% corporate multiplier reflects the Company’s overall positive performance against stated corporate objectives, with most corporate objectives fully accomplished or exceededthe goals established and additional achievements beyondexecuted on during the stated objectives,continuation of the Compensation Committee determined that the corporate multiplier used in determining cash bonuses for our named executive officers for 2018 should be set at 116.5%, resulting in bonuses above target levels. This determination is described in greater detail beginning on page 29 under the section titled "The Corporate Multiplier".

        The results of our compensation program in 2018 show a clear heavy weighting on performance based compensation for not only the chief executive officer, but for all named executive officers.

COVID-19 pandemic.
23

GRAPHICTABLE OF CONTENTS

GRAPHIC


The graphs above display the base salary, cash bonus, stock option value, RSU value and PRSU value of our CEOchief executive officer (top graph) and our NEOs (excluding the CEO)other named executive officers (bottom graph). The medical expense benefit that our CEOchief executive officer receives is excluded from his chart.

    graph.

Stock Ownership Guidelines

        As of January 1, 2018, we implemented

We maintain stock ownership and retention guidelines for our directors and named executive officers to ensure that each of them has a long termlong-term equity stake in Amicus, in order to both closely align the interests of directors and executive officers to those of our shareholdersstockholders and to further our commitment to corporate governance.


Under the stock ownership guidelines, directorscertain executive officers and executive officersall non-employee directors must maintain a multiple of their annual retainer or salary, as applicable, as follows:

​
Position
​
​
Position
Stock Retention Amount​
​
Chief Executive Officer
​​
4 times executive'sexecutive’s base salary
​
President​
President
​​
2 times executive'sexecutive’s base salary
​
​
Other Executive Officers
​​
1 time executive'sexecutive’s base salary
​
Directors​
Directors
​​
3 times director'sdirector’s annual retainer
​
​
​​
​

        Each

Directors and executive officer or director hasofficers have five years from the date of implementation of the policy (or, if later, from date of hire) to attain the required stock ownership. Stock ownership includes shares of common stockCommon Stock and any restricted stock units (including any vested PRSUs) that were settled and deferred into the Stock Deferral Plan (as defined below). All named executive officers and directors have met or are on track to meet the stock ownership guidelines.guidelines, including David M. Clark, Chief People Officer, who is a named executive officer for the first time this year. The Compensation and Leadership Development Committee of the Board monitors compliance with this policy.
24

TABLE OF CONTENTS

Prohibition on Hedging and Pledging
The Company considers it inappropriate for persons employed by or associated with the Company to engage in certain transactions related to the securities of the Company (“Subject Securities”) that could result in their interests no longer being aligned with the same interests and objectives as other stockholders of the Company. Therefore, as part of its anti-hedging and anti-pledging policy, the Company restricts these persons from hedging, engaging in short-sales, transacting in publicly traded options, and will takepledging Subject Securities.
Certain hedging and monetization transactions involve the establishment of a short position in the Subject Securities and limit or eliminate a person’s ability to profit from an increase in the value of the Subject Securities. Accordingly, these transactions can cause a person’s interests to be misaligned with other stockholders of the Company. The Company therefore prohibits its directors, executive officer and employees from engaging in any actions necessaryhedging and monetization transactions involving the Subject Securities. The Company’s directors and executive officers are also prohibited from engaging in short sales of Subject Securities (sales of securities that are not then owned).
Subject Securities held in a margin account or pledged as collateral for a loan may be sold without a person’s consent if he or she fails to ensure compliance.

    meet a margin call or defaults on a loan, which may occur at a time when the covered person is aware of material nonpublic information or is otherwise not permitted to trade in Company securities. Therefore, our directors, executive officers and employees are prohibited from engaging in these activities.

Clawback Policy

We also have a policy for recoupment of performance basedperformance-based compensation in the event of a financial restatement. Our policy provides that in the event of a financial restatement, the Board will seek to recover any incentive basedincentive-based compensation and equity awards made to an executive officer during the three-year period preceding a restatement. In determining whether and to what extent a recoupment is necessary, the Board maywill consider (1) the executive officer'sofficer’s intentional misconduct or gross negligence that was a contributing factor to the restatement; (2) the amount of incentive compensation or equity award predicated on achieving financial results that were part of the restatementrestatement; and (3) the difference in the amount of incentive compensation or equity award that would have been awarded based upon the restatement.

Other factors that the Board can consider include (1) whether the recoupment would violate law or prejudice a claim; (2) other penalties or repercussions, instead of recoupment; and/or; (3) the nature of events leading to a restatement.

The Board retains the discretion to amend the policy as appropriate.

Executive Compensation

We describe our executive compensation program below and provide an analysis of the compensation paid and earned in 20182021 by our "named“named executive officers"officers”—our chief executive officer, chief financial officer, andour three other most highly compensated executive officers. In 2018,officers and one former executive officer. For 2021, our named executive officers were:

    •
    are:
Chairman and Chief Executive Officer, John F. Crowley;

•
Chief Financial Officer, William D. Baird, III;

•
Daphne Quimi;
President and Chief Operating Officer, Bradley L. Campbell;

•
Chief Medical Officer, Jay Barth, M.D.; and

•
Chief Legal Officer and Corporate Secretary, Ellen S. Rosenberg.
    Rosenberg;
Chief People Officer, David M. Clark; and
Chief Scientific Advisor (formerly Chief Science Officer), Hung Do.
25

TABLE OF CONTENTS

Executive Compensation Governance Practices

Below we summarize certain executive compensation-relatedcompensation related governance practices that we follow and that we believe serve our stockholders'stockholders’ long-term interests.

What We Do
✔
​​
Maintain an executive compensation program designed to align pay with performance
✔
​​
Conduct an annual say on pay advisory vote
✔
​​
Seek input from, listen to and respond to stockholders
✔
​​
Have double trigger on executive severance arrangements and executive stock option grants
✔
​​
Prohibit hedging and pledging of company stock
✔
​​
Retain an independent compensation consultant
✔
​​
Maintain stock ownership guidelines for executives and directors
✔
​​
Maintain a clawback policy
What We Do NOT Do
✘
​​
Provide executives with tax gross-ups other than for Company required relocations
✘
​​
Provide guaranteed bonuses

        What We Do:

    •
    Maintain an executive compensation program designed to align pay with performance

    •
    Conduct an annual say-on-pay vote

    •
    Seek input from, listen to and respond to stockholders

    •
    Have double-trigger“Say on executive severance arrangements and executive stock option grants

    •
    Prohibit hedging and pledging of company stock

    •
    Retain an independent compensation consultant

    •
    Maintain stock ownership guidelines for executives and directors

    •
    Maintain a claw-back policy

        What We Do Not Do:

    •
    Provide Executives with Tax Gross-ups other than for Company required relocations

    •
    Provide guaranteed bonuses

    "Say-on-Pay"Pay” Consideration

At our 20182021 annual meeting of stockholders, approximately 98% of the shares voted at the meeting approved, on an advisory basis, the compensation of the named executive officers. In additionlight of stockholders’ strong support of our most recent say-on-pay proposal, the Compensation and Leadership Development Committee did not undertake fundamental changes to our executive compensation programs following the voting at the2021 annual meeting of stockholders. Nonetheless, we continue to solicit the input of our stockholders and in 2021 our investor relations team proactively engaged with major stockholders, representing approximately 75% of shares outstanding, on the Company'sCompany’s pay practices. TheAs evidenced by the voting detailed above, the vast majority of the shares voted approved the 'say-on-pay'‘say on pay’ advisory proposal and the Compensation and Leadership Development Committee continues to focus on pay practices that align compensation with performance. The Compensation Committee placed a continued emphasis on performance-based pay, in tying one third of the targeted equity compensation value to the performance of Amicus in Total Shareholder Return and pipeline and revenue goals over three years. The CompensationLeadership Development Committee monitors and considers the results of the annual advisory 'say-on-pay'“say on pay” proposal and feedback received from stockholders.

Objectives and Philosophy of Executive Compensation

We are a global patient-dedicated biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patientspeople living with rare metabolicgenetic diseases. We operate in an extremely competitive, rapidly changing and heavily regulated industry, and the long-term success of our business requires a high degree of innovation and adaptability. We believe that the skill, talent and dedication of our executive officers are critical factors affecting our long-term success, especially at this critical time in our history as we execute our business strategy. Therefore, our compensation program for our executive officers, including our named executive officers, is designed to attract, retain and motivate the best possible executive talent. Utilizing a pay-for-performance compensation philosophy, we have designed a program that provides the ability to differentiate the total compensation mix of our named executive officers based on their demonstrated performance and their potential to contribute to our long-term success.

Our compensation philosophy is to:

    •
provide our executives a competitive total compensation opportunity relative to the organizations with which we compete for executive talent;

•
attract and retain individuals of superior ability and managerial talent who can successfully perform and succeed in our environment;

    •
    increase the incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual compensation earned through our pay for performance compensation program to the achievement of corporate goals; and

    •
deliver pay in a cost efficientcost-efficient manner that aligns employees'employees’ compensation with stockholders'stockholders’ long-term interests.
26

TABLE OF CONTENTS

Our compensation program is designed to reward the accomplishment of our corporate goals in a manner consistent with the Company'sCompany’s values, which stresses not only results but also how those results are attained. In order to meet the objectives of our compensation philosophy, we maintain a robust goal setting and performance management program.

The chief executive officer established general individual goals for the named executive officers, other than himself, at the beginning of 20182021 that were specific to such executive officer'sofficer’s area of expertise and supported our corporate goals for the year. For 2018,2021, annual cash incentive bonuses for our named executive officers other than Mr. Crowley were determined by the combination of both the corporate multiplier and an individual multiplier. For Messrs. Baird, Campbell, Dr. BarthClark and Ms.Do, and Mses. Quimi and Rosenberg, the attainment of individual goals was assessed within a range of 0-133%0 to 133% multiplier for each individual; this individual multiplier, wasalong with the final corporate multiplier, were applied to the final corporate multipliertarget bonus to determine final annual incentive bonus payouts.

The Compensation and Leadership Development Committee believes that the corporate multiplier should continue to be the mosta significant factor in determining bonus payouts because it closely aligns our named executive officers'officers’ compensation with the interests of our stockholders,stockholders. The Compensation and that some portion of an executive's compensation should be linked to individual performance, which we believe is consistent with our peers. The CompensationLeadership Development Committee believes that including the individual multiplier for named executive officers, other than Mr. Crowley, as a component of such named executive officers'officers’ bonus payouts is important to incentivize our officers during this crucial time in Amicus' history as we complete our transformation intoexpand as a global commercial biotechnology company. However, because of Mr. Crowley'sCrowley’s influence on the overall performance of Amicus, the Compensation and Leadership Development Committee believes it is appropriate and in the best interests of our stockholders to continue to base Mr. Crowley'sCrowley’s cash bonus solely on the Board’s determination, with the Compensation Committee's determination regardingand Leadership Development Committee’s recommendation, of the achievement of corporate objectives without regard to an individual multiplier.

Risk Analysis of Compensation Policies and Practices

The Compensation and Leadership Development Committee is aware that compensation arrangements, if not properly designed, could encourage inappropriate or excessive risk taking. We believe that our overall compensation program encourages our named executive officers and other employees to focus on both short-term and long-term objectives and does not encourage excessive risk taking. While the value of stock options is inherently tied to the performance of the Company, and an important part of our current and future performance based compensation, ourOur stock options vest over multiple years and thetheir value is not directly linked to the achievement of short term defined metrics. To enhance this posture, the Committee made the decision, starting in 2017, to award performance-basedperformance based restricted stock unit grants in addition to market pricedstock options and restricted stock units. In addition, cash incentive bonuses tied to the achievement of Company and individual goals have historically made up a small percentage of our executive officers'officers’ total compensation package. For example, in 2018, payouts under our cash incentive bonus plan represented approximately 19% of the total compensation, or 13% of direct compensation awarded to our named executive officers. The Nominating and Corporate Governance Committee implemented stock ownership guidelines, which will ensure significant amounts of actual share ownership over time for our executive officers, and such a holding requirement can serve to mitigate excessive risk taking.taking and foster an ownership mentality among our senior leaders. Further, we operate as a single business unit and therefore are not exposed to the risks that may be associated with operating through several segments, such as one business unit being significantly more profitable than another or having a compensation structure that is significantly different than that of other units. The Compensation


and Leadership Development Committee will continue to review risk as one of the elements it considers in the planning process for executive compensation in the future.

Compensation Program Elements and Pay Level Determination

Each year the Compensation and Leadership Development Committee reviews and determines base salaries, annual cash incentiveincentives and long-term incentive awards for all executive officers. In setting our executive compensation programs, the Compensation and Leadership Development Committee reviews market data at the 25th, 50th, and 75th percentile and generally targets aggregate total direct compensation for the named executive officers as a group to approximately the 50th percentile of our peer group (as discussed below). Actual compensation levels for each named executive officer depend on factors such as individual performance, Company performance, skills/capabilities, overall impact/contribution, experience in position, criticality of position and internal equity. For 2018,2021, the base salaries, annual cash incentives and long-term incentive awards determination for all named executive officers, includingexcluding our chief executive officer, were approved by our Compensation and Leadership Development Committee, which is comprised solely of independent directors. For the chief executive officer, the base salary, annual cash incentives and long-term incentive awards were recommended by the Compensation and Leadership Development Committee to the Board, which reviewed and approved the final compensation. The Compensation and Leadership Development Committee considered all the information presented (including external competitiveness, the individual'sindividual’s performance, Company performance and internal equity) and applied its collective knowledge and discretion to determine the compensation for each named executive officer.

As part of the compensation evaluation process, the chief executive officer presents to the Compensation and Leadership Development Committee an individual assessment of each named executive officer'sofficer’s performance, excluding the chief executive officer'sofficer’s performance, over the prior year, as well as the recommended compensation action for each such named executive officer. Based on corporate and individual performance, the chief executive officer makes a compensation recommendation for each such named executive officer which includes actions on base salary, bonus and long-term incentive grant target value. Individual goals and objectives are established at the beginning of each year and are designed to support the achievement of the yearly corporate goals. All employees, including the named executive officers, participate in annual individual goal setting as well as mid-year and year-end performance reviews.

The results of the named executive officer's performance (other than the performance of the chief executive officer) are a determination by each such named executive officer's supervisor, the chief executive officer, withofficer’s recommendations may also take into account input from otherthe executive’s peers and direct reports, as appropriate, butappropriate. The

27

TABLE OF CONTENTS

recommendations of the chief executive officer are afforded significant weight by the Compensation and Leadership Development Committee, because of his familiarity with the day-to-day performance of his direct reports. However, the final determination of each executive officer’s pay, other than that of the chief executive officer, is made by the Compensation and Leadership Development Committee.
The chief executive officer'sofficer’s performance is assessed by all independent directors under the leadership of our Lead Independent Director. The Compensation and Leadership Development Committee bases its recommendation to the Board for the chief executive officer'sofficer’s compensation upon this assessment, butand the final determination of the chief executive officer'sofficer’s compensation is made by the Board.
Long-term incentive grants are based on an executive'sexecutive’s level within the organization, competitive data for our peer group, and in the case of our named executive officers, several other factors which are more fully described below under "Long-Term“Long-Term Incentive Programs"Programs”. Long-term incentive grants are designed to motivate and retain the executive team to best achieve the Company'sCompany’s goals and implement our business strategy, thereby increasing stockholder value.

Developments Withwith Respect to the Company'sCompany’s Named Executive Officers in 2018

2021

Effective September 28, 2021, Chief Science Officer Hung Do amended his employment agreement with the Company and was appointed Chief Scientific Advisor. Furthermore, on September 29, 2021 it was announced that, in connection with the anticipated closing of the ARYA Sciences Acquisition Corp IV’s (“ARYA”) acquisition of the Company’s gene therapy portfolio, President and COO Bradley Campbell would succeed John Crowley as the Company’s CEO, with Mr. Crowley becoming the CEO of the newly formed company, Caritas Therapeutics, Inc. (“Caritas”). In 2018, ourthe same announcement, it was also disclosed that Chief Financial Officer William D. Baird III announced his resignation effective January 1, 2019, and Daphne Quimi was appointedhad assumed Samantha Prout’s role as Principal Accounting Officer in anticipation of Ms. Prout’s transition to Caritas.
On February 24, 2022, the Company announced the termination of the business combination agreement with ARYA and that Mr. Crowley will remain CEO of the Company until August 1, 2022, at which time he will then transition to the position, effective onrole of Executive Chair of the same date. Also in 2018, Ellen Rosenberg was promoted to Chief Legal Officer and Corporate Secretary.

Board. Mr. Campbell will succeed him as CEO at that time.

Role of Independent Compensation Consultant

The Compensation and Leadership Development Committee has engaged Pay Governance to assist the Compensation and Leadership Development Committee by providing ongoing executive compensation consulting. The Compensation and Leadership Development Committee has concluded that Pay Governance's work does not raise any conflict of interest. The Compensation Committee has also


consideredreviewed the independence of Pay Governance. BecauseGovernance; because of the policies and procedures that Pay Governance and the Compensation and Leadership Development Committee have in place, the Compensation and Leadership Development Committee is confident that the advice it receives from executive compensation consultants at Pay Governance is objective and not influenced by Pay Governance'sGovernance’s or its affiliates'affiliates’ relationships with the Company or its officers.officers and has concluded that Pay Governance’s work does not raise any conflict of interest.

28

TABLE OF CONTENTS

Peer Group

The Compensation and Leadership Development Committee, with the helpadvice and analysis of its independent executive compensation consultant Pay Governance, established the peer group set forth below as a reference point for assessing named executive officer target compensation against market competitive data. The Compensation and Leadership Development Committee, upon advice offrom Pay Governance, selected the companies that comprise our peer group through a robust screening process that considered publicly traded U.S. biopharmaceutical companies that were similar to Amicus in size, market capitalization and business operating model and operate in geographic locations that generally have similar pay levels. Three companies (Cytokinetics, Theravance Biopharma(Editas Medicine, Inc., Intercept Pharmaceuticals, Inc., and Ziopharm Oncology)Neurocrine Biosciences, Inc.) were removed from the peer group established last yearyear. Editas was removed as it lacked commercial revenue, has an early-stage pipeline, and focuses on genome editing. Intercept was removed due primarily to changesa decline in structure or size, includingits market capitalization.capitalization while Neurocrine was removed due to both its high market capitalization and its focus on gene therapy. The Compensation and Leadership Development Committee replaced these entities with four companies (Clovis Oncology, Editas Medicines, Global Blood TherapeuticsMedicine, Intercept Pharmaceuticals and Neurocrine Biosciences) with Bluepoint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc. and Travere Therapeutics, Inc. upon the recommendation of Pay Governance due to each company'stheir similarity to Amicus based on the criteria set forth above. The Compensation and Leadership Development Committee intends to continue reviewing and revising the peer group periodicallyannually to ensure that it continues to reflect publicly traded companies of similar size and business model.

​
Acadia Pharmaceuticals
​​
Acceleron
​​
Agios Pharmaceuticals
​
ACADIA​
Alkermes
​​
Bluebird Bio
​​
Bluepoint Medicines Corporation
​
​
Deciphera Pharmaceuticals
​​
Exelixis
​​
FibroGen
​
​
Global Blood Therapeutics
​Sage Therapeutics​
Insmed
​​
Ionis Pharmaceuticals
​
Acceleron​
Ironwood Pharmaceuticals
​Insmed​
PTC Therapeutics
Sarepta​​
Sage Therapeutics
​
Agios​
Travere Therapeutics
​​
Ultragenyx Pharmaceuticals
​Intercept Pharmaceuticals​
Spark Therapeutics
Bluebird BioIonis PharmaceuticalsUltragenyx Pharmaceutical
Clovis OncologyNeurocrine Biosciences
Editas MedicinesPTC Therapeutics​

Elements of Compensation

Our executive compensation consists primarily of base salary, annual cash incentive plan, and long-term incentive program, each of which plays an important role in our pay-for-performancepay for performance philosophy and in achieving our compensation program objectives. For each element of compensation, we target an overall executive compensation program that is competitive with market data.

Base Salaries

Base salaries are paid to our named executive officers to provide a level of compensation that is both competitive with the external market and is commensurate with each named executive officer'sofficer’s scope of


responsibilities, past performance, experience and skills. The base salary for each of our named executive officers was as follows:

​
​​
Base salary at
December 31,
​
​
Name and Principal Position
​​
2020
​​
2021
​
​
John F. Crowley
 Chairman and Chief Executive Officer
​​
$720,000
​​
$741,598 
​
​
Daphne Quimi
 Chief Financial Officer
​​
$452,000
​​
$470,080 
​
​
Bradley L. Campbell
 President and Chief Operating Officer
​​
$515,904
​​
$552,018 
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate Secretary
​​
$452,389
​​
$470,485 
​
​
David M. Clark
 Chief People Officer
​​
—(1)
​​
$440,274 
​
​
Hung Do
 Former Chief Science Officer
​​
$427,063
​​
$217,802(2)
​
 (1)
Mr. Clark was not a named executive officer in 2020.
 (2)
Represents Dr. Do’s base salary following his transition from a full-time employee as Chief Science Officer to a part-time employee as Chief Scientific Advisor.
 
 Base salary at
December 31,		 
Name and Principal Position
 2017 2018 

John F. Crowley

 $619,068  637,640 

Chairman and Chief Executive Officer

       

William D. Baird, III

  408,447  418,658 

Chief Financial Officer(1)

       

Bradley L. Campbell

  450,105  468,109 

President and Chief Operating Officer

       

Jay Barth, M.D. 

  444,548  457,885 

Chief Medical Officer

       

Ellen S. Rosenberg

  412,000  426,420 

Chief Legal Officer and Corporate Secretary

       
(1)
Mr. Baird resigned as Chief Financial Officer, effective January 1, 2019, and departed the Company on February 8, 2019.

The base salary increases for each of our named executive officers set forth above reflect merit increases and cost-of-living adjustments for 2018.2021.

29

TABLE OF CONTENTS

Annual Cash Incentive Plan

We maintain an annual cash incentive program to motivate and reward the attainment of annual strategic, operational, financial and individual goals. For all program participants, annual target cash incentive opportunities are expressed as a percentage of base salary, which we believe is consistent with market practice. The target bonus percentages of base salary were generally determined by level in the organization in accordance with market-based considerations and contractual entitlements. In 2021, following a review of market data, the target bonus percentages for our officers (other than the chief executive officer and president) was increased from 40% of base salary to 45% of base salary.
The target bonus percentages for 20182021 are as follows:

​
Position
​​
Position
20182021 Target
Bonus % of
Base Salary
​

​

Chief Executive Officer

​​60
65%
%​

President

​
President
​50​%
50%
​

​

Other ChiefNamed Executive Officers

​​40
45%
%

Senior Vice Presidents

35%

Vice Presidents

30%​

For 2018,2021, bonuses awarded under the plan to our named executive officers, other than Mr. Crowley, were determined based on both the corporate multiplier and an individual multiplier. Historically, theThe corporate multiplier generally rangedranges from 50% to 150%160%, with the Compensation and Leadership Development Committee having final discretion to adjust the upper or lower limits as appropriate. In Q4 2018, the Compensation Committee modified the annual cash incentive program to cap the corporate modifier at 160%, effective January 1, 2019. For bonuses related to 20182021 performance, the corporate multiplier was determined to be 116.5%102% based on the Company'sCompany’s performance for the reasons discusseddescribed below.


In order to determine bonus calculations under the plan, the target bonus for each eligible named executive officer, other than Mr. Crowley, was determined by first multiplying the officer'sofficer’s target bonus percentage of base salary by the 116.5%102% (the corporate multiplier) and then multiplying such result by his or her individual multiplier. Mr. Crowley'sCrowley’s bonus under the plan was determined by multiplying the 116.5%102% corporate multiplier by his target bonus percentage of 60%65% of base salary, which results in a 20182021 bonus of approximately 70%66% of Mr. Crowley'sCrowley’s base salary. The table below titled "Calculation“Calculation of Annual Cash Incentive Bonuses"Bonuses” further demonstrates the calculation of the 20182021 annual bonuses paid to our named executive officers.

The Corporate Multiplier

On an annual basis, the Board works with management to set Company goals and objectives that are challenging and reflect an ambitious timetable for the execution of the Company'sCompany’s strategies commensurate with our short and long-term business plan. The Company'sCompany’s internal goals and objectives reflect complex assumptions based on internal analyses and projections and are intended to encourage the Company to pursue its business plan in an expedited aggressive manner. Once the Company'sCompany’s goals and objectives have been developed,are proposed, they are reviewed by the Compensation and Leadership Development Committee and finally approvedthen recommended for approval by the full Board.

The Compensation and Leadership Development Committee periodically reviews the Company’s goals and, from time to time, may choose to recommend revisions to the Board.

At the time the goals and objectives are set, the Compensation and Leadership Development Committee believes that their full attainment will be appropriately challenging and may not be reached, despite great effort, due in part to internal and external factors, many of which may be out of the Company's control.factors. However, while total achievement of all goals and objectives set at the beginning of the year may not be expected, the Compensation and Leadership Development Committee considers the achievement of the corporate objectives in its sole discretion in setting the corporate multiplier and holds management accountable to significantly advance the Company'sCompany’s business objectives throughout the year in order to achieve at least a 100% corporate multiplier.

        For 2018, our corporate objectives were as follows:

    1.
    Advance global launch of Galafold with patient focus and highest business integrity

    •
    Establish US and Japan commercial organizations ready for launch and achieve relevant launch milestones

    •
    Achieve $84M of product revenue excluding US and Japan

    2.
    Obtain regulatory approvals in key geographies

    •
    Obtain US NDA and Japan J-NDA approvals

    •
    Initiate supportive Galafold clinical studies

    3.
    Advance activities to enable submission of a marketing application for the Pompe Program as soon as possible in both the US and EU

    •
    Enroll first patient in registration-directed study supporting full approval in 3Q18

    •
    Ensure availability of 1000L IMP and conduct activities to support potential marketing applications

    4.
    Evaluate and advance research opportunities to develop clinical candidates for 2019 and beyond

    •
    Acquire / license additional preclinical and/or clinical programs focused on rare metabolic diseases

    •
    Advance next generation Fabry program(s)

    5.
    Maintain financial strength

    •
    Finish 2018 with minimum 18 months of cash

    •
    Manage net cash spend within Board approved budget
30

TABLE OF CONTENTS

The Compensation and Leadership Development Committee then reviews corporate performance against each of the pre-established targets and weighting to determine the extent to which such goals were attained. The Compensation Committee'sand Leadership Development Committee’s rationale behind its subjective determination of both the attainment of corporate goals and the percentage completed for each such goal is described below. These objectives were established at the beginning of 2021 and were reflective of the corporate strategy at that time. In early 2022 the Company announced a strategic portfolio realignment and established corporate goals reflective of this shift which will be disclosed in the 2023 proxy statement.
In reaching its determination on the corporate multiplier for 2018,2021, the Compensation and Leadership Development Committee applied the percentage that the Compensation and Leadership Development Committee determined was completed against the pre-established weighting of the corporate objectives as follows:


Objective
 Weighting Percentage
Completed		 Score 
Advance global launch of Galafold with patient focus and highest business integrity          
  • Establish US and Japan commercial organizations ready for launch and achieve relevant launch milestones          
  • Achieve $84M of product revenue excluding US and Japan  25% 125% 31.25%
(Fabry) Obtain regulatory approvals in key geographies          
  • Obtain US NDA and Japan J-NDA approvals          
  • Initiate supportive Galafold clinical studies  15% 125% 18.75%
(Pompe) Advance activities to enable submission of a marketing application as soon as possible in both the US and EU          
  • Enroll first patient in registration-directed study supporting full approval in 3Q18          
  • Ensure availability of 1000L IMP and conduct activities to support potential marketing applications  35% 100% 35%
Evaluate and advance research opportunities to develop clinical candidates for 2019 and beyond          
  • Acquire / license additional preclinical and/or clinical programs focused on rare metabolic diseases          
  • Advance next generation Fabry program(s)  10% 90% 9%
Maintain financial strength          
  • Finish 2018 with minimum 18 months of cash          
  • Manage net cash spend within Board approved budget  15% 150% 22.5%
TOTAL SCORE  100%    116.5%

    2018

    The Compensation and Leadership Development Committee elected to round the percentages displayed above up to the nearest whole number in arriving at a 2022 corporate multiplier of 102%, which was approved by the Board.
    2021 Corporate Objectives Measurement

As stated above, the Company and the Compensation and Leadership Development Committee established objectives for 20182021 and thoroughly reviewed the company'scompany’s performance in achieving those objectives. For example, in establishing launch objectives in December 2017, it was unclear if and when the US and Japan approvals for Galafold would occur. Under a standard FDA review, the PDUFA date would be mid-December 2018 and there would be minimal or no US revenues for 2018. Given this uncertainty, the revenue target excluded any US or Japan revenues. For the US and Japan, once the timelines for commercial launch became clear, management communicated to the Board the relevant launch milestones and key metrics for each country and the performance in these regions was evaluated against the agreed upon launch milestones. In evaluating the performance, the Board considered the over achievement of the revenue target ($91 million), the overachievement of the US launch targets and the physician engagement in Japan.

        In obtaining regulatory approvals, the Board considered that the Japan approval was three months earlier than expected with what we believe is a strong label and all mutations/variants included, and the US approval was four months earlier than expected with what we believe is a strong label and all mutations/variants included. The Board considered relevant that management overcame significant challenges to obtain a high-quality labels in these geographies.


•
For the Galafold® revenue goal, we ended the year with approximately $300 million in revenue, calculated on a constant currency basis, meeting the target of $300 million. We also achieved expanded access of Galafold and ended the year with five additional countries accepting Galafold reimbursement versus the target of two.

For the Pompe program, 2018 was a year of what we view as tremendous progress. The Company continuedsubmitted the BLA to release data from the ongoing Phase1/2 trial throughout the year. Additionally, management was able to obtain significant regulatory flexibility from both US and EU regulatorsFDA on the Phase 3 clinical trial design, which could lead to a broader label. Although the Company did not achieve Phase 3 enrollment initiation in 3Q18, the Company initiatedJuly 2021. We also made submissions in Europe and the first patient was dosedUK and significantly advanced the Pompe program with Early Access to Medicines Scheme (EAMS) approval in Europe and the Phase 3 trialapproval of a free-of-charge access program in 4Q18.

        Separately, the Company made significant progressJapan.

For our Gene Therapy and overachieved on manufacturing with 1000L production of ATB200 and demonstrating comparability between 250L and 1000L material. With these successes, the Company was able to dose all Phase 3 patients with 1000L material.

        The Company overachieved on the pipeline objective of acquiring or licensing additional preclinical or clinical programs focused on rare metabolic diseases entering 2019. At the end of 2018, the Company had two gene therapy (GTx) programsPipeline goal, management in the clinic (CLN6 and CLN3), with CLN6 expected to deliver a meaningful interim update on efficacy in mid-2019. The Company has also assembled a robust portfolio of 12 additional GTx programs, including programs in Pompe and Fabry disease. Finally, the Company has made significant progress in building out the long-term research and early-development strategy, developing a staffing plan, a facilities plan, and a leadership/governance plan that we began to execute on in 2018.

        The Company balanced the achievement on building the pipeline through business developmentconsultation with the factScience and Technology Committee and the Compensation and Leadership Development Committee, made strategic decisions to terminate the CLN6 program and delay certain deadlines, resulting in less than 100% goal achievement.

In 2021, management completed a private placement of equity that it did not advance Fabry Enzyme Replacement Therapy (ERT) to a subsequent milestone. While the Company completed further characterization and optimization of the internal Fabry ERT (which will help inform the Fabry GTx program), the strategic decision was made not to invest the significant capital to complete manufacturing scale up and IND-enabling preclinical studies as it was ultimately successfulresulted in bringing in a Fabry GTx.

        The Company ended the year with approximately $500$200 million of cash, extending the runway to self-sustainability and cash equivalents, representingprofitability under the current operating budget.

In our second year of introducing a cash runway.people and culture goal, we strengthened our organization by identifying successors for critical roles across the Company. Additionally, we continued to strengthen our culture of diversity and inclusion through increased focus on diverse and inclusive recruiting and hiring strategies. In addition, the 2018 cash spend was $189 million, which is approximately $10 million to $35 million lower2021, more than the 2018 corporate budget60% of $200 million to $225 million. In 2018, the Company raised $464 million in capital in what we believe was an efficient manner. The Company raised $314 million in a follow-on equity offeringour hires were diverse and $150 million in a debt financing to provide concurrent financing for the Celenex acquisition (with no equity dilution) and to ensure what we believe is a very strong balance sheet at the end50% of the year.members of our executive committee were women.
31

TABLE OF CONTENTS

Finally, in evaluating the overall corporate performance for 2018,2021, the Compensation and Leadership Development Committee determined that the Company had significantly outperformed its peers and industry benchmarks, had demonstrated high quality execution across the business and had positioned the Company for continued success in 20192022 and beyond. As such, the Compensation and Leadership Development Committee evaluated these achievements and arrived atrecommended a 116.5%102% corporate modifier for 2018.

    2021, which was approved by the Board.

The Individual Multiplier

Design

While we believe that the corporate multiplier should remain the mosta significant factor in the bonus calculation, the Compensation and Leadership Development Committee believes it is important to recognize and separately incentivize the individual performance of our named executive officers (excluding the chief executive officer) as we advance towards our goal of becoming a fully integrated pharmaceutical company. We therefore determined that the individual multiplier for Messrs. BairdCampbell, Clark and Campbell, Dr. Barth,Do and Ms.Mses. Quimi and Rosenberg, would range from 0-133% based on performance described below. As noted above, the Compensation and Leadership Development Committee continues to believe that Mr. Crowley'sCrowley’s bonus should be determined solely by reference to the corporate multiplier.

However, the Compensation and Leadership Development Committee periodically reviews and discusses its evaluation of the chief executive officer’s performance and accomplishments in executive session along with the Lead Independent Director of the Board and without the presence of the chief executive officer as part of its year-end executive officer review process.

The individual multiplier for each executive is determined after considering several factors including achievement of individual objectives, departmental or organizational performance and other significant accomplishments. Individual objectives are necessarily tied to the particular area of expertise of the executive and are designed to support the Company'sCompany’s achievement of its corporate goals. Individual goals are evaluated based on leadership and performance on specific functional goals that are tied to the corporate goals.

These objectives are set with the belief that full achievement will be difficult and challenging, but attainable, so long as the officer is fully committed to the accomplishment of such objectives through significant effort and dedication to the Company'sCompany’s strategies and an ability to quickly adapt to a constantly evolving business environment.

Individual performance objectives of our named executive officers, other than Mr. Crowley,the chief executive officer, are setdetermined by the executive officer to whom each such named executive officer reports, which for 20182021 was Mr. Crowley for all of our named executive officers. These objectives are neither reviewed nor approved by the Compensation Committee. Rather, these objectives serve as a measuring tool for our chief executive officer in formulating his recommendation to the Compensation Committee as to the appropriate individual multiplier for each named executive officer. During the annual review process, the Company'sCompany’s chief executive officer discusses with the Compensation and Leadership Development Committee his overall evaluation for each such executive, which includes each such executive'sexecutive’s performance and accomplishments as they relate to the Company'sCompany’s corporate goals, departmental performance, and other significant accomplishments. While the Compensation and Leadership Development Committee relies in part on the chief executive officer'sofficer’s evaluation of the other named executive officers, it also considers the degree of difficulty in attaining the Company'sCompany’s goals and such executive'sexecutive’s accomplishments. In considering the degree of difficulty, the Compensation and Leadership Development Committee considers factors such as the influence of external events, including unanticipated clinical events and regulatory timelines, and the effort expended by executives. The Compensation Committee reviews and discusses its evaluation of the Company's chief executive officer's performance and accomplishments in executive session along with the Lead Independent Director of the Board and without the presence of the chief executive officer. Upon the completion of such process, the Compensation and Leadership Development Committee subjectively determines the individual multiplier for each named executive officer, other than the chief executive officer, based on the Compensation Committee'sand Leadership Development Committee’s subjective determination of such officer'sofficer’s satisfaction of the applicable goals.

    2018

2021 Determinations

In determining the individual multiplier for our named executive officers (excluding the chief executive officer), the Compensation and Leadership Development Committee noted each such executive officer'sofficer’s individual and departmental performance throughout the year and how those performances supported the Company'sCompany’s achievement of its corporate goals. The specific individual factors that the Compensation and Leadership Development Committee noted in subjectively determining each such named executive officer'sofficer’s individual multiplier were as follows:

Bradley L. Campbell, President and Chief Operating Officer (120%(110% Individual Multiplier)

•
Provided overall leadership
•
Advanced the global launch of Galafold® with approximately $300M in global product revenue with patient focus and highest business integrity;
•
Continued the global expansion of Galafold® commercial availability with label expansion and regulatory submissions and approvals in additional geographies; and
Partnered in leading the design of Caritas, the proposed spin-off of the continued build out of the international commercial organization and successful launch of Galafold Ex-US,Amicus gene therapy business via a merger with high level of patient uptake in areas with reimbursement;

•
Provided overall leadership in launching the US and Japan commercial organizations, exceeding our goals and expectations; and

•
Oversaw the successful manufacturing efforts for ATB200, including successful engineering batches at 1,000 liter commercial scale.
ARYA IV, a special purpose acquisition company (commonly referred to as a “SPAC”).

    William D. Baird, III,Daphne Quimi, Chief Financial Officer (100%(130% Individual Multiplier)

    •
    Significantly strengthened the balance sheet through the leadership and execution of a $314 million equity financing and subsequent $150 million debt financing, the proceeds of which were used to acquire Celenex, Inc.;

    •
    Provided strategic and financial leadership
Managed to the Board the Senior Leadership Team, Business Development,approved budget;
32

TABLE OF CONTENTS

Identified and the program steering teams throughout the year.

    Jay Barth, Chief Medical Officer (90% Individual Multiplier)

    •
    Led efforts among the clinicalimplemented cost efficiencies and regulatory teams to obtain regulatory approval for migalastata private placement of equity resulting in Japan$200M of cash; and the U.S.;

    •
    Delivered on the pipeline objective
Ended 2021 with a minimum of acquiring or licensing additional preclinical or clinical programs focused on rare metabolic diseases entering 2019. At the end of 2018, two gene therapy programs were in the clinic (CLN6 and CLN3), with CLN6 poised to deliver a meaningful interim update on efficacy in mid-2019, and

•
Played a key role in assembling a robust portfolio of 12 additional GTx programs, including programs in Pompe and Fabry disease.

    18 months cash on-hand.

Ellen S. Rosenberg, Chief Legal Officer and Corporate Secretary (105%(130% Individual Multiplier)

•
Negotiated a $314 million follow-on equity offering
Strategically partnered with multiple functions and $150 million debt financingled negotiations of multiple agreements in connectionsupport of the creation of Caritas and business combination with ARYA;
Led Board review of risk oversight and allocation to Board Committees of risk oversight responsibilities; and
Maintained SEC compliance in all of our activities.
David M. Clark, Chief People Officer (130% Individual Multiplier)
Led the Celenex acquisition;

•
Negotiatedorganizational, people, IT, facilities and corporate communications components of the acquisitioncreation of CelenexCaritas;
Led the implementation of the Company’s new Diversity, Equity and research collaborationInclusion efforts, resulting in overachieving the Company’s Culture and People goal; and
Partnered with Universitymultiple functions in the wind-down of Pennsylvania under which the Company acquiredheadquarters in Cranbury, NJ, while identifying a pipeline of 14 gene therapies; and

•
Streamlined global legal operationsnew facility in Princeton, NJ.
Hung Do, Chief Scientific Advisor (100% Individual Multiplier)
Successfully transitioned the Chief Science Officer role while continuing to support rapid commercial expansion, clinical development and manufacturing activities.

    the Company’s science department at a high level.

Calculation of Annual Cash Incentive Bonuses

The calculation of the named executive officers'officers’ individual cash incentive payments for service in 20182021 is summarized in the table below.

​
Name and Principal Position
​​
Corporate
Multiplier
(%)
​​
Individual
Multiplier
(%)
​​
Target
Bonus
(%)
​​
Base
Salary
($)
​​
Payout
($)
​
​
John F. Crowley
 Chairman and Chief Executive
 Officer
​​
102
​​
N/A
​​
65
​​
$741,598
​​
$491,679
​
​
Daphne Quimi
 Chief Financial Officer
​​
102
​​
130
​​
45
​​
470,080
​​
280,497
​
​
Bradley L. Campbell
 President and Chief Operating
 Officer
​​
102
​​
110
​​
50
​​
552,018
​​
309,682
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate
 Secretary
​​
102
​​
130
​​
45
​​
470,485
​​
280,738
​
​
David M. Clark
 Chief People Officer
​​
102
​​
130
​​
45
​​
440,274
​​
262,711
​
​
Hung Do
 Former Chief Science Officer
​​
102
​​
100
​​
45
​​
217,802
​​
99,971
​
Name and Principal Position
 Corporate
Multiplier
(%)		 Individual
Multiplier
(%)		 Target
Bonus
(%)		 Base
Salary
($)		 Payout
($)		 

John F. Crowley

  116.5  N/A  60 $637,640 $445,710 

Chairman and Chief Executive Officer

                

William D. Baird, III

  116.5  100  40  418,658  195,095 

Chief Financial Officer

                

Bradley L. Campbell

  116.5  120  50  468,109  327,209 

President and Chief Operating Officer

                

Jay Barth, M.D. 

  116.5  90  40  457,885  192,037 

Chief Medical Officer

                

Ellen S. Rosenberg

  116.5  105  40  426,420  208,647 

Chief Legal Officer and Corporate Secretary

                

    Long TermLong-Term Incentive Programs

We believe that long-term performance will be achieved through an ownership culture that rewards our executivesnamed executive officers for maximizing stockholder value over time and that aligns the interests of our employees


and management with those of stockholders. Our Amended and Restated 2007 Equity Incentive Plan, or the 2007 Plan, authorizes us to grant stock options, restricted stock, RSUs, PRSUs and other equity-based awards. We have historically elected to use stock options as the primary long-term equity incentive vehicle. We typically grant an initial stock option award to new employees and annual long-term incentive awards as part of our overall compensation program as well as option grants to reflect promotions, as necessary.

We continued our strategy for equity compensation of using a mix of non-qualified stock options, time based RSUs, and PRSUs.PRSUs for annual awards to our named executive officers. We utilize a value basedvalue-based approach to allocate equity, with one third of the assigned value to each named executive officers assigned to each such type of equity vehicle.vehicle in grants to each named executive officer. Under our current equity plan, for the named executive officers, our non-qualified stock option awards vest over a four yearfour-year period with 25% vesting one year after the vesting commencement date and the remainder vesting ratably each month thereafter in equal installments over a three year period, subject generally to continued employment or service with us. The non-qualified stock options expire ten years after the date of grant. RSU awards vest, subject generally to continued service with us, over a four yearfour-year period with 25% vesting each year upon the anniversary of the date of grant. PRSU awards vest over a three yearthree-year period based on the attainment of the applicable goals at the end of such period, subject generally to continued service with us through the end of such period.
33

TABLE OF CONTENTS

We use a mix of stock options, RSUs, and PRSUs as long-term incentive vehicles because we believe that:

    •
Stock options, RSUs and PRSUs, along with their vesting periods, provide a balanced mix to attract, motivate and retain executives;

•
Stock options are inherently performance based. Because all of the value received by the recipient of a stock option is based on the growth of the stock price, stock options enhance the executives'executives’ incentive to increase our stock price and maximize stockholder value;

•
RSUs help enhance executive actual stock ownership while helping to retain executives. Final value depends on the change in stock price over the vesting period;

•
PRSUs align executives with the goals of the company and its shareholders,stockholders, while still assisting in the retention of our executives. Final value depends on company performance and the change in stock price over the vesting period;

•
Stock options, RSUs and PRSUs help to provide a balance to the overall executive compensation program as base salary and our annual performance bonus program focus on short-term compensation, while long-term incentives reward executives for increases in stockholder value over the longer term.

        On December 21, 2018, the Board revised the Amicus Amended and Restated 2007 Equity Incentive Plan to provide each eligible participant with accelerated vesting and extended exercise periods, upon such participant's termination of employment, if such participant met the "Retirement Criteria" (as defined below), as described more fully below in the Section entitled "Severance Benefits and Change of Control Arrangements".

Initial Equity Grants

        Named executive officers who join us are typically awarded initial equity grants, which typically is a mix of Stock Options and RSUs. The options portion of the grants has an exercise price equal to the closing price of our Common Stock on the date of grant. Our goal is to create a total compensation package for new executives that is competitive with other biotechnology companies and that will enable us to attract high quality people. No such initial grants were made to any named executive officer in 2018.


Stock Option, Restricted Stock Unit Awards, Performance Restricted Stock Unit Awards

The Compensation and Leadership Development Committee believes that providinggranting annual equity awards provides management with a strong link to long-term corporate performance and the creation of stockholder value, as well as providing continued retention via long-term vestingvesting. In 2021, the Compensation and Leadership Development Committee continued the approach of having such annual equity grants consistingconsist of fair market value stock options, RSUs and PRSUs.

The Compensation and Leadership Development Committee determines the value and corresponding number of shares subject to options, RSUs or PRSUs that are granted to our named executive officers in its sole discretion. In applying that discretion, the Compensation and Leadership Development Committee takes into account a number of factors including the current price of our Common Stock, peer group data, each individual'sindividual’s role and performance and recent Company developments. All of the stock option and RSU awards are subject to four-year vesting schedules. The 20182021 stock option and RSU grants are described in the section entitled "Grants“Grants of Plan-Based Awards."” The sizing of such LTI grants are based on a fixed dollar value at grant instead of a fixed number of shares. In determining the value of these LTI grants, the Black-Scholes option pricing model is used to estimate the grant date fair value of stock options, whereas the value of RSUs is the fair market value of the shares of Common Stock underlying such RSUs on the date of grant. Assumptions made in this valuation are discussed in our annual report for the year ended December 31, 2021, filed with the SEC on Form 10-K on February 24, 2022 (the “Form 10-K”) at Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Share-based Compensation. The Compensation and Leadership Development Committee determined that this methodology provides a greater level of sophistication in ensuringhelps to ensure that the value of LTI grants is aligned to the market.

The target value of the PRSU grants in 20182021 consisted of 33% of the total assigned equity compensation value to each named executive officer. The goals associated with these PRSUs were established by the Compensation and Leadership Development Committee as total shareholder return ("TSR") versus NASDAQ Biotechnology Index and a strategic pipeline goal. 50% ofapproved by the PRSUs granted were assigned to the TSR goal with 0-200% achievement of the number of target PRSU's and the remaining 50% of the PRSUs granted were based on the Company achieving certain revenue targets and clinical milestones. The PRSUs have a 3-year cliff vesting period.

Board. The Compensation and Leadership Development Committee believes that these goals are difficult and challenging to attain and appropriately align incentives with performance. The PRSUs have a 3-year cliff vesting period and were weighted as follows:

​
2021 PRSU Performance Metrics and Weightings
​
​
​TSR Goal (%)
​​
Regulatory Goal
(%)
​​
Pipeline Goal
(%)
​​
People Goal
(%)
​
​
50
​​
20
​​
20
​​
10
​
The total stockholder return (“TSR”) goal compares the TSR of the Company’s common stock to the TSR of the NASDAQ Biotechnology Index over the three-year performance period. Achievement of the 2021 PRSU TSR goal will be determined in accordance with the following schedule, with straight line interpolation applied for performance falling between such levels:
​
Performance Level
​​
Three-Year TSR Ranking vs.
Performance Peer Group
​​
Percentage of Granted TSR
Shares to Vest
​
​
Maximum
​​
90th Percentile or higher
​​
200%
​
​
Above Target
​​
75th Percentile
​​
150%
​
​
Target
​​
50th Percentile
​​
100%
​
​
Threshold
​​
30th Percentile
​​
50%
​
​
Below Threshold
​​
Below 30th Percentile
​​
0%
​
34

TABLE OF CONTENTS

For confidential reasons, the Company does not disclose the specific regulatory, pipeline, and people performance goals associated with its PRSU grants until the end of the performance measurement period and level of achievement has been determined by the Compensation and Leadership Development Committee and approved by the Board.
We have typically awarded the largest equity grant in each grant cycle to our chief executive officer in recognition of his role as our principal executive officer, Chairman of the Board and primary decision maker for the Company. For these reasons, and based on annual peer data analysis, the Compensation and Leadership Development Committee awarded Mr. Crowley 106,603115,240 RSUs, 106,603115,240 PRSUs and options to purchase 154,076185,585 shares of Common Stock in our company-wide grant award in January 2018.

2021, with such awards valued at approximately $8,000,000 in the aggregate at the time of grant.

The 20182021 equity grants for other NEOsnamed executive officers are described in the section entitled "Grants“Grants of Plan-Based Awards."

” Factors that the Compensation and Leadership Development Committee and our chief executive officer considered in making these stock optionequity grants for other Executive Officersexecutive officers included (i) relative contribution toward achievement of current year corporate objectives, (ii) breadth of internal and external responsibilities, (iii) management responsibilities including managing direct reports, (iv) external benchmarking, and (v) tenure with Amicus.Amicus and (vi) the recommendations of our chief executive officer. The specific individual factors that the Compensation and Leadership Development Committee relied on for granting each award are substantially similar to those factors that contributed to a determination of the individual multiplier for each named executive officer discussed above under "2018“2021 Determinations."

    Partial ”

Settlement of 20172019 PRSU Grants

On April 6, 2021, the Compensation and Leadership Development Committee reviewed total net Galafold® revenue for the 12-months ended December 19, 2018,31, 2020, utilizing a constant, pre-established foreign exchange rate. This constituted the Company dosed the first patient in the pivotal study for our ATB200 program, the clinicalrevenue goal under the 20172019 PRSU grants made to each of our named executive officers. On April 11, 2019,Based on the total net Galafold® revenue criteria, the Compensation and Leadership Development Committee, reviewedwith the criteria andsupport of the Board, determined the performance component of the goal was achieved 18 days afterat 134.3% of the target date, December 1, 2018amount (as reflected in the below table), and that the PRSUs to be


table below).

distributed for this achievement was ratably interpolated to 81% of the target amount of the PRSU grant attributable to such target.

​
​​
Total Net Galafold® Revenue at December 31, 2020
​​
Measurement Dates
Percentage of the PRSU Grant
Attributable to the Target

On or prior to August 1, 2018

​​200
%​

After August 1, 2018 but​

​​
$275M+
​​
200%
​​
​
​
►
​​
$258.6M
​​
134.3%
​​
​
​
​​
$250M (“Target”)
​​
100%
​​
​
​
​​
$200M
​​
50%
​​
​
The PRSUs earned in connection with the satisfaction of the performance portion of this goal were delivered on December 31, 2021. This revenue goal accounted for 25% of the total 2019 PRSU grant.
On December 16, 2021, the Compensation and Leadership Development Committee reviewed the criteria associated with the pipeline portion of the 2019 PRSU grant and recommended to the Board that the goal was not met, which the Board agreed and approved 0% attainment. The pipeline performance goal accounted for 25% of the 2019 PRSU grants with the various levels of achievement described in the table below.
​
​​
Pipeline Performance Goal
​​
Percentage of the
Pipeline Units Earned
​​
​
​
​​
Initiate three clinical trials in new indications with a gene therapy and final 2-year CLN6 Phase 1/2 data formally compared to natural history data on or prior tobefore December 1, 2018

31, 2021
​​100
200%
%​​
​

​

​​
Initiate two clinical trials in new indications with a gene therapy and final 2-year CLN6 Phase 1/2 data formally compared to natural history data OR initiate three clinical trials in new indications with a gene therapy on or before December 19, 2018, date of first dosing

31, 2021
​​81
150%
%​​
​

After December 1, 2018 but​

​​
Initiate two clinical trials in new indications with a gene therapy on or priorbefore December 31, 2021 (“Target”)
​​
100%
​​
​
​
​​
Initiate one clinical trial in a new indication with a gene therapy on or before December 31, 2021
​​
50%
​​
​
​
►
​​
Company did not initiate any clinical trials with a gene therapy in a new indication on or before December 31, 2021
​​
0%
​​
​
​
​​
​​
​​
​
As the pipeline goal was not met, the shares attributable to this portion of the 2019 PRSU grants were forfeited. This pipeline goal accounted for 25% of the total 2019 PRSU grant.
35

TABLE OF CONTENTS

On January 14, 2022, the Board reviewed Pay Governance’s calculation of the TSR portion of the 2019 PRSU grants as of the December 31, 2021 measurement date and determined the Company’s three-year TSR performance was 128.2%, which placed it at the 64.1 percentile relative to its performance peers (Nasdaq Biotechnology Index), resulting in the TSR goal being achieved at 128.2% of the target amount (as reflected in the table below).
​
​​
Company Three-Year TSR Ranking vs.
Performance Peer Group
Three-Year TSR at December 31, 2021
​​
Percentage of
the PRSU Grant
Attributable to March 1, 2019

the Target
​​50
%​
​
​​
90th Percentile or higher
​​
200%
​​
​
​
​​
75th Percentile
​​
150%
​​
​
​
►
​​
64.1Percentile
​​
128.2%
​​
​
​
​​
50th Percentile (“Target”)
​​
100%
​​
​
​
​​
30th Percentile
​​
50%
​​
​
​
​​
Below 30th Percentile
​​
0%
​​
​

This TSR goal accounted for 50% of the 20172019 PRSU grants withgrants. As described above, the shares of common stock underlying the achievement of the 2019 revenue goal were delivered to each named executive officer on December 31, 2021, while the shares underlying the TSR goal were delivered January 14, 2022 upon the Compensation and Leadership Development’s recommendation, and the Board’s approval, of the TSR goal. The table below titled "Outstanding Equity Awards“Option Exercises and Stock Vested at Year-End" displayingYear End” includes the amount each named executive officer earned upon satisfaction of this goal.the TSR goal (which were delivered shortly after year-end).
In aggregate, the overall 2019 PRSUs paid out at 97.68% of target. The portiontable below reflects the total number of the PRSU awards made in 2017 to ourPRSUs each named executive officers subject to the attainment of a TSR goal is still outstanding and subject to resolution of such goal.

officer received from their respective 2019 PRSU grants:

​
Name and Principal Position
​​
Target
PRSUs
​​
Earned
PRSUs
​
​
John F. Crowley
 Chairman and Chief Executive Officer
​​
233,477
​​
228,049
​
​
Daphne Quimi
 Chief Financial Officer
​​
57,471
​​
56,135
​
​
Bradley L. Campbell
 President and Chief Operating Officer
​​
98,778
​​
96,482
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate
 Secretary
​​
61,063
​​
59,644
​
​
David M. Clark
 Chief People Officer
​​
50,287
​​
49,118
​
​
Hung Do
 Former Chief Science Officer
​​
61,063
​​
59,644
​
Non-Qualified Deferred Compensation Plans

Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan

The Company maintains the Amicus Therapeutics, Inc. Restricted Stock Unit Deferral Plan, as amended (the "Stock“Stock Deferral Plan"Plan”). The Stock Deferral Plan provides eligible non-employee directors and executives, including each of the named executive officers, with the voluntary opportunity to defer the receipt of RSUs (including settledearned PRSUs) otherwise payable to such eligible executives. After a deferral election is made, a participant'sparticipant’s account is credited with the deferred RSUs. All RSUs deferred under the Stock Deferral Plan are fully vested. The Company does not otherwise contribute to the Stock Deferral Plan and the amount a participant receives at the end of a deferral period is based solely on the value of the Company'sCompany’s stock at the end of the deferral period. Generally, a participant may voluntarily elect to re-defer any previously deferred RSUs for an additional period of not less than five years if, as required under the Code, such an election is made at least 12 months before the year in which the RSUs would otherwise be delivered.

Not only does the Stock Deferral Plan allow our eligible participants, including all of the named executive officers, to defer the federal income taxes otherwise payable upon the delivery of RSUs, but the Compensation and Leadership Development Committee believes that with respect to non-employee directors and executives who avail themselves of the deferral features of the Stock Deferral Plan, such personpersons will necessarily hold Company stock for a longer period of time. Accordingly, any RSUs deferred under the Stock Deferral Plan will continue to align such portion of our non-employee directors and named executive officers'officers’ compensation with the interests of our stockholders for a longer period of time than would be provided by typical vesting periods. Regardless of a participant'sparticipant’s election, any deferred RSUs will be distributed following the non-employee director or executive'sexecutive’s death, disability or separation of service from the Company.
36

TABLE OF CONTENTS

        All amounts deferred under the Stock Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the non-employee director's or executive's deferral will be subject to the general creditors of the Company.

    Amicus Therapeutics, Inc. Cash Deferral Plan

The Company maintains the Amicus Therapeutics, Inc. Cash Deferral Plan, as amended (the "Cash“Cash Deferral Plan"Plan”). The Cash Deferral Plan provides eligible executives, including each of the named executive officers and non-employee directors, with the voluntary opportunity to defer receipt of such participant'sparticipant’s base salary, bonus and/or director'sdirector’s fees, as applicable. Any such deferrals are credited to a bookkeeping account maintained for the participant. The participant may make periodic hypothetical investments of the account and gains and losses on such hypothetical investments will be credited to the participant'sparticipant’s account. A participant is fully vested in all amounts, including earnings deferred under the


Cash Deferral Plan. Distribution of the deferred amounts will generally be made on the distribution date elected by the participant. Generally, a participant may voluntarily elect to re-defer any previously deferred amount for an additional period of not less than five years if, as required under the Code, such an election is made at least 12 months before the year in which the amount would otherwise be delivered. Regardless of a participant'sparticipant’s election, any deferred amount will be distributed following a change in control of the Company or upon the participant'sparticipant’s death, disability or separation of service from the Company. The Company does not match any portion of a participant deferrals in the Cash Deferral Plan.

All amounts deferred under the Cash Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the amounts deferred by the participants, including all deemed gains and losses attributable thereto, will be subject to the claims of the general creditors of the Company.

Company in the event of the Company’s insolvency.

Other Compensation

Consistent with our compensation philosophy, we intend to continue to maintain our current benefits for our named executive officers, including medical, dental, vision and life insurance coverage. All employees receive Company paid term life insurance equal to two times annual base salary, up to a maximum benefit of $1,000,000.

In addition, we provide a Company match for our 401(k) Plan, subject to federal guidelines and plan maximums. We match $1 for each $1 a participant, including each named executive officer, defers into the plan up to 5% of such participant'sparticipant’s salary and bonus paid during the year.year, up to the IRS limit on eligible compensation. The match vests 100% on the participant'sparticipant’s one-year anniversary of employment at Amicus.

Furthermore, certain senior executives, including each named executive officer, are eligible to receive supplemental health benefits and financial consulting services. The value received from these benefits is calculated as imputed income and reflected in the “Summary Compensation Table” below.
Additional Chief Executive Officer Benefits

Our Company is engaged in a highly competitive industry, developing medicines for unique and complicated genetic disorders. As chief executive officer, Mr. Crowley has significant responsibility for leading our Company and managing its progress toward achieving our corporate goals. Mr. Crowley'sCrowley’s compensation reflects this responsibility and takes into account his unique circumstances.

As part of his overall compensation, Mr. Crowley receives significant payments and benefits from the Company related to the healthcare and other associated costs incurred by his family. These amounts reflect substantial costs incurred for the treatment of a rare medical condition afflicting two members of Mr. Crowley'sCrowley’s immediate family. We continuedcontinue to make monthly compensation payments of $66,667 to Mr. Crowley to help defray the substantial out-of-pocket medical expenses incurred by Mr. Crowley and his family, which we refer to as the Monthly“Monthly Medical Payments.” We agreed to make the Monthly Medical Payments to Mr. Crowley when we amended his employment agreement in December 2010 in order to compensate him for the loss of certain medical benefits previously afforded to Mr. Crowley resulting from the passing of federal legislation in 2010, as well as to limit the Company'sCompany’s exposure to Mr. Crowley'sCrowley’s expected growth in future medical expenses.

Termination-Based Compensation

Upon termination of employment under certain circumstances, our named executive officers are entitled to receive varying types of compensation. Elements of this compensation may include payments based upon a number of months of base salary, bonus amounts, acceleration of vesting of equity, health care coverage and other similar benefits. We believe that our termination-based compensation and acceleration of vesting of equity arrangements are in line with severance packages offered to named executive officers of other similar companies based upon market information and are otherwise appropriate given the executive'sexecutive’s role and service to the Company. We also have granted severance and acceleration of vesting of equity benefits to our named executive officers under their employment agreements in the event of a change of control if the executive is terminated within a certain period of time following the change of control. We believe that change of control-related benefits are necessary in order for our named executive officers to direct their full attention to the successful consummation of a transaction without distraction,distraction. For more information on termination-based compensation see the section entitled “Severance Benefits and Change of Control Arrangements.”
37

TABLE OF CONTENTS

COMPENSATION AND LEADERSHIP DEVELOPMENT COMMITTEE REPORT
The Compensation and Leadership Development Committee is comprised entirely of independent directors. The Compensation and Leadership Development Committee of our Board has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K, which appears in this Proxy Statement, with our management. Based on this review and discussion, the Compensation and Leadership Development has recommended to the Board that the Compensation Discussion and Analysis be included in this "double trigger" requirement maximizes stockholder value because it prevents an unintended windfallProxy Statement and our 2021 Annual Report on Form 10-K.
Members of the Amicus Therapeutics, Inc.
Compensation and Leadership Development Committee:
Margaret G. McGlynn, Chair
Lynn D. Bleil
Craig A. Wheeler
Eiry W. Roberts, M.D.
Notwithstanding anything to managementthe contrary set forth in any of our previous or future filings under the eventSecurities Act of a friendly1933, as amended (the “Securities Act”) or non-hostile change of control.the Exchange Act that might incorporate this proxy statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be “soliciting material” or “filed” with the SEC and shall not be deemed to be incorporated by reference into any such filing.
38

TABLE OF CONTENTS


Executive Compensation

Summary Compensation Table

SUMMARY COMPENSATION TABLE

The following table provides information regarding the compensation that we paid to each person serving as our principal chief executive officer, our principal financial officer, and each of our three other three most highly compensated executive officers during the years indicated belowand one former executive officer (collectively, the "named“named executive officers"officers”).

​
Name and Principal
Position
​​
Fiscal
Year
​​
Salary
($)
​​
Bonus(1)
($)
​​
Stock
Awards(2)
($)
​​
Option
Awards(2)
($)
​​
Change in
Pension
Value &
Non-
Qualified
Deferred
Compensation
Earnings
​​
All Other
Compensation
($)
​​
Total
($)
​
​
John F. Crowley
 Chairman and Chief
 Executive Officer
​​
2021
​​
$740,767(3)
​​
$491,679(3)
​​
$5,636,388
​​
$2,290,936
​​
—
​​
$830,262(4)
​​
$9,990,032
​
​
2020
​​
719,514
​​
514,800
​​
5,479,971
​​
2,492,491
​​
1,282,843
​​
825,505
​​
11,315,124
​
​
2019
​​
656,770
​​
476,815
​​
5,327,948
​​
2,334,850
​​
234,775
​​
821,505
​​
9,852,663
​
​
Daphne Quimi
 Chief Financial Officer
​​
2021
​​
469,385
​​
280,497
​​
1,620,431
​​
658,636
​​
—
​​
35,499(5)
​​
3,064,448
​
​
2020
​​
451,600
​​
228,712
​​
1,534,382
​​
697,894
​​
—
​​
34,639
​​
2,947,227
​
​
2019
​​
400,000
​​
212,960
​​
1,311,492
​​
538,808
​​
—
​​
17,487
​​
2,480,747
​
​
Bradley L. Campbell
 President and Chief
 Operating Officer
​​
2021
​​
550,629
​​
309,682
​​
2,818,195
​​
1,145,462
​​
—
​​
87,487(6)
​​
4,911,455
​
​
2020
​​
515,789
​​
368,872
​​
2,557,304
​​
1,163,159
​​
—
​​
33,694
​​
4,638,818
​
​
2019
​​
500,877
​​
378,788
​​
2,254,114
​​
987,822
​​
—
​​
19,538
​​
4,141,139
​
​
Ellen S. Rosenberg
 Chief Legal Officer and
 Corporate Secretary
​​
2021
​​
469,789
​​
280,738
​​
1,620,431
​​
658,636
​​
—
​​
20,998(7)
​​
3,050,592
​
​
2020
​​
452,288
​​
199,051
​​
1,461,322
​​
664,660
​​
87,751
​​
20,748
​​
2,885,820
​
​
2019
​​
439,213
​​
233,837
​​
1,393,462
​​
610,648
​​
—
​​
13,538
​​
2,690,698
​
​
David M. Clark
 Chief People Officer
​​
2021
​​
439,781
​​
262,711
​​
1,338,612
​​
544,092
​​
—
​​
35,725(8)
​​
2,620,921
​
​
2020
​​
—
​​
—
​​
—
​​
—
​​
—
​​
—
​​
—
​
​
2019
​​
—
​​
—
​​
—
​​
—
​​
—
​​
—
​​
—
​
​
Hung Do
 Former Chief Science
 Officer
​​
2021
​​
381,663(9)
​​
99,971
​​
1,690,916
​​
687,275
​​
—
​​
30,963(10)
​​
2,890,788
​
​
2020
​​
426,968
​​
187,908
​​
1,461,322
​​
664,660
​​
—
​​
31,248
​​
2,772,106
​
​
2019
​​
414,625
​​
200,678
​​
1,393,462
​​
574,732
​​
—
​​
22,129
​​
2,605,626
​
Name and Principal Position
 Fiscal
Year		 Salary
($)		 Bonus(1)
($)		 Stock
Awards(2)
($)		 Option
Awards(2)
($)		 Change in
Pension
Value & Non-
Qualified
Deferred
Compensation
Earnings(3)		 All Other
Compensation
($)		 Total
($)		 

John F. Crowley

  2018 $637,640(9)$445,710(9)$3,861,699 $1,654,347 $— $820,567(4)$7,419,963 

Chairman and Chief

  2017  619,068  588,734  2,385,162  1,044,082  94,189  881,845  5,613,080 

Executive Officer

  2016  601,037  299,316  254,169  2,198,129  31,539  815,178  4,199,368 

William D. Baird III

  2018  418,658  195,095  1,079,619  462,505  —  18,645(5) 2,174,522 

Chief Financial Officer

  2017  408,447  246,007  715,535  313,253     15,310  1,698,552 

  2016  396,550  131,655  91,500  832,036     15,316  1,467,056 

Bradley L. Campbell

  2018  468,109  327,209  1,411,802  604,817  —  16,710(6) 2,828,646 

President and Chief

  2017  450,105  428,050  874,544  382,867     71,816  2,207,382 

Operating Officer

  2016  427,450  177,392  152,000  960,178     53,146  1,770,666 

Jay Barth, M.D.,

  2018  457,885  192,037  996,591  426,933     18,790(7) 2,092,236 

Chief Medical Officer

  2017  444,548  267,751  596,284  261,045     14,560  1,584,188 

  2016  431,600  336,127  91,500  832,036     14,566  1,505,828 

Ellen S. Rosenberg

  2018  426,420  208,647  996,591  426,933     18,270(8) 2,076,862 

Chief Legal Officer

  2017  412,000  287.329  596.284  261,045     14,560  1,571,218 

and Corporate Secretary

                         
(1)
The 2018 amount represents bonuses earned in 2018 and paid in 2019.

(2)
The grant date fair value of time based restricted stock unit awards ("RSUs"), performance based restricted stock unit awards ("PRSUs") and option awards granted to our named executive officers was computed in accordance with FASB ASC Topic 718, Compensation—Stock Compensation. Assumptions made in this valuation are discussed in our annual report for the year ended December 31, 2018, filed with the SEC on Form 10-K on February 28, 2019 (the "Form 10-K") at Item 7—Management's Discussion and Analysis of Financial Condition and Results of Operations—Equity Compensation. These amounts reflect the stock price at the time of the grant. In accordance with SEC rules, the amounts reported in the Stock Awards column for 2018 include the grant date fair value of the RSUs and PRSUs granted during 2018. The grant date fair value for this purpose is required to be shown even where the PRSUs were not ultimately earned. The following table provides information regarding the 2018 PRSUs based on the expected performance outcomes (and is the grant date fair value of the award, as reflected in the Summary Compensation Table) and maximum performance outcomes:
 (1)
The 2021 amount represents bonuses earned in 2021 and paid in 2022.
 (2)
The grant date fair value of time-based restricted stock unit awards (“RSUs”), performance based restricted stock unit awards (“PRSUs”) and option awards granted to our named executive officers was computed in accordance with FASB ASC Topic 718, Compensation—Stock Compensation. Assumptions made in this valuation are discussed in our annual report for the year ended December 31, 2021, filed with the SEC on Form 10-K on February 24, 2022 (the “Form 10-K”) at Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Share-based Compensation. These amounts reflect the stock price at the time of the grant. In accordance with SEC rules, the amounts reported in the Stock Awards column for 2021 include the grant date fair value of the RSUs and PRSUs granted during 2021. The grant date fair value for this purpose is required to be shown even where the PRSUs were not ultimately earned. The following table provides information regarding the 2021 PRSUs based on the expected performance outcomes (and is the grant date fair value of the award, as reflected in the Summary Compensation Table) and maximum performance outcomes:
​
Name and Principal Position
​​
Grant Date
Fair Value for
2021 PRSUs
(i.e., Based
on Expected
Performance)
($)
​​
Value at
Grant Date
Assuming
Maximum
Performance
($)
​
​
John F. Crowley
​​
$3,126,461
​​
$6,252,922
​
​
Daphne Quimi
​​
898,838
​​
1,797,678
​
​
Bradley L. Campbell
​​
1,563,231
​​
3,126,461
​
​
Ellen S. Rosenberg
​​
898,838
​​
1,797,678
​
​
David M. Clark
​​
742,515
​​
1,485,032
​
​
Hung Do
​​
937,938
​​
1,875,877
​
 (3)
As described more fully below, Mr. Crowley participates in our Non-Qualified Cash Deferral Plan and for 2021, he deferred $593,013 of salary and $411,840 of bonus of the amounts reflected in the table.
 (4)
Includes $14,500 of 401(k) employer match, $800,000 of Monthly Medical Payments pursuant to Mr. Crowley’s current employment agreement (see “Additional Chief Executive Officer Benefits” above), $750 for health care savings account, $6,012 in life insurance premiums and $9,000 for executive health benefits received.
 (5)
Includes $14,500 of 401(k) employer match, $375 for health care savings account, $1,248 in life insurance premiums, $4,500 for executive health benefits received and $14,876 for financial consulting services.
39
Name and Principal Position
 Grant Date
Fair
Value for
2018 PRSUs
(i.e., Based
on Expected
Performance)
($)		 Value at
Grant Date
Assuming
Maximum
Performance
($)		 Actual
Realizable
Value at
Grant
Date
($)		 

John F. Crowley

 $2,191,229 $4,382,459  — 

William D. Baird III

  612,606  1,225,211  — 

Bradley L. Campbell

  801,095  1,602,190  — 

Jay Barth, M.D. 

  565,493  1,130,987  — 

Ellen S. Rosenberg

  565,493  1,130,987  — 
(3)
Mr. Crowley, Mr. Baird and Mr. Campbell incurred a loss on their investment selection in their deferred compensation plan account of $646,279, $25,425 and $42,375, respectively; per SEC rules, such a loss is not to be reflected in the Summary Compensation Table; please see the "Nonqualified Deferred Compensation" table below.

(4)
Includes $14,250 of 401(k) employer match, $800,000 of Monthly Medical Payments pursuant to Mr. Crowley's current employment agreement (see "Additional Chief Executive Officer Benefits" above), $750 for health care savings account and $5,567 in life insurance premiums.

(5)
Includes $17,085 of 401(k) employer match, $750 for health care savings account and $810 in life insurance premiums.

(6)
Includes $15,150 of 401(k) employer match, $750 for health care savings account and $810 in life insurance premiums.

(7)
Includes $17,230 of 401(k) employer match, $750 for health care savings account and $810 in life insurance premiums.

(8)
Includes $16,710 of 401(k) employer match, $750 for health care savings account and $810 in life insurance premiums.

(9)
As described more fully below, Mr. Crowley participates in our Non-Qualified Cash Deferral Plan and for 2018, the deferral amounts were: $510,112 of salary and $356,568 of bonus.

TABLE OF CONTENTS

 (6)
Includes $14,500 of 401(k) employer match, $750 for health care savings account, $1,248 in life insurance premiums, $4,500 for executive health benefits received, $14,876 for financial consulting services and $51,613 in U.K. taxes paid on his behalf in accordance with Mr. Campbell’s secondment agreement.
 (7)
Includes $14,500 of 401(k) employer match, $750 for health care savings account, $1,248 in life insurance premiums and $4,500 for executive health benefits received.
 (8)
Includes $14,500 of 401(k) employer match, $750 for health care savings account, $1,099 in life insurance premiums, $4,500 for executive health benefits received and $14,876 for financial consulting services.
 (9)
Dr. Do’s salary was pro-rated and is comprised of $328,050 for his service as Chief Science Officer and $53,613 for his service as Chief Scientific Advisor.
 (10)
Includes $14,500 of 401(k) employer match, $750 for health care savings account, $837 in life insurance premiums and $14,876 for financial consulting services.
Grants of Plan-Based Awards

The following table presents information concerning grants of equity awards to each of the named executive officers during 2018.

2021.
​
​​
Estimated Future Payouts
Under Equity Incentive
PRSU Awards(1)
​​
All
Other
Stock
Awards:
Number
of
Shares
of RSUs
Units(2)
(#)
​​
All Other
Option
Awards:
Number of
Securities
Underlying
Options(3)
(#)
​​
Exercise
or
Base
Price of
Option
Awards
($/Sh)
​​
Grant
Date Fair
Value of
Stock and
Option
Awards(4)
($)
​
​
Name
​​
Grant Date
​​
Threshold #
​​
Target #
​​
Maximum #
​​
​​
​​
​​
​
​
John F. Crowley
 Chairman and Chief
 Executive Officer
​​
1/4/2021
​​
​​
​​
​​
​​
185,585
​​
$21.78
​​
$2,290,936
​
​
1/4/2021
​​
​​
​​
​​
115,240
​​
​​
​​
2,509,927
​
​
1/4/2021
​​
28,810
​​
57,620
​​
115,240
​​
​​
​​
​​
1,871,498
​
​
1/4/2021
​​
11,524
​​
23,048
​​
46,096
​​
​​
​​
​​
501,985
​
​
1/4/2021
​​
11,524
​​
23,048
​​
46,096
​​
​​
​​
​​
501,985
​
​
1/4/2021
​​
5,762
​​
11,524
​​
23,048
​​
​​
​​
​​
250,993
​
​
Daphne Quimi
 Chief Financial
 Officer
​​
1/4/2021
​​
​​
​​
​​
​​
53,355
​​
21.78
​​
658,636
​
​
1/4/2021
​​
​​
​​
​​
33,131
​​
​​
​​
721,593
​
​
1/4/2021
​​
8,283
​​
16,565
​​
33,130
​​
​​
​​
​​
538,031
​
​
1/4/2021
​​
3,313
​​
6,626
​​
13,252
​​
​​
​​
​​
144,314
​
​
1/4/2021
​​
3,313
​​
6,626
​​
13,252
​​
​​
​​
​​
144,314
​
​
1/4/2021
​​
1,657
​​
3,314
​​
6,628
​​
​​
​​
​​
72,179
​
​
Bradley L. Campbell
 President and Chief
 Operating Officer
​​
1/4/2021
​​
​​
​​
​​
​​
92,792
​​
21.78
​​
1,145,462
​
​
1/4/2021
​​
​​
​​
​​
57,620
​​
​​
​​
1,254,964
​
​
1/4/2021
​​
14,405
​​
28,810
​​
57,620
​​
​​
​​
​​
935,749
​
​
1/4/2021
​​
5,762
​​
11,524
​​
23,048
​​
​​
​​
​​
250,993
​
​
1/4/2021
​​
5,762
​​
11,524
​​
23,048
​​
​​
​​
​​
250,993
​
​
1/4/2021
​​
2,881
​​
5,762
​​
11,524
​​
​​
​​
​​
125,496
​
​
Ellen Rosenberg
 Chief Legal Officer
 and Corporate
 Secretary
​​
1/4/2021
​​
​​
​​
​​
​​
53,355
​​
21.78
​​
658,636
​
​
1/4/2021
​​
​​
​​
​​
33,131
​​
​​
​​
721,593
​
​
1/4/2021
​​
8,283
​​
16,565
​​
33,130
​​
​​
​​
​​
538,031
​
​
1/4/2021
​​
3,313
​​
6,626
​​
13,252
​​
​​
​​
​​
144,314
​
​
1/4/2021
​​
3,313
​​
6,626
​​
13,252
​​
​​
​​
​​
144,314
​
​
1/4/2021
​​
1,657
​​
3,314
​​
6,628
​​
​​
​​
​​
72,179
​
​
David M. Clark
 Chief People Officer
​​
1/4/2021
​​
​​
​​
​​
​​
44,076
​​
21.78
​​
544,092
​
​
1/4/2021
​​
​​
​​
​​
27,369
​​
​​
​​
596,097
​
​
1/4/2021
​​
6,842
​​
13,684
​​
27,368
​​
​​
​​
​​
444,456
​
​
1/4/2021
​​
2,737
​​
5,473
​​
10,946
​​
​​
​​
​​
119,202
​
​
1/4/2021
​​
2,737
​​
5,473
​​
10,946
​​
​​
​​
​​
119,202
​
​
1/4/2021
​​
1,370
​​
2,739
​​
5,478
​​
​​
​​
​​
59,655
​
​
Hung Do
 Former Chief
 Science Officer
​​
1/4/2021
​​
​​
​​
​​
​​
55,675
​​
21.78
​​
687,275
​
​
1/4/2021
​​
​​
​​
​​
34,572
​​
​​
​​
752,978
​
​
1/4/2021
​​
8,643
​​
17,286
​​
34,572
​​
​​
​​
​​
561,449
​
​
1/4/2021
​​
3,457
​​
6,914
​​
13,828
​​
​​
​​
​​
150,587
​
​
1/4/2021
​​
3,457
​​
6,914
​​
13,828
​​
​​
​​
​​
150,587
​
​
1/4/2021
​​
1,729
​​
3,458
​​
6,916
​​
​​
​​
​​
73,315
​
 (1)
Amounts represent PRSUs granted to named executive officers during the 2021 fiscal year. The criteria used to determine the number of PRSUs earned by each named executive officer are described above under “Performance-Based Restricted Stock Units”. The service-vesting schedule associated with the annual PRSUs granted to all named executive officers on January 4, 2021 is three-year cliff vesting.
 
  
  
  
  
 All Other
Stock
Awards:
Number of
Shares of
RSUs
Units(2)
(#)		 All Other
Option
Awards:
Number of
Securities
Underlying
Options(3)
(#)		  
  
 
 
 Estimated Future Payouts
Under Equity Incentive
PRSU Awards(1)		 Exercise
or
Base
Price of
Option
Awards
($/Sh)		 Grant
Date Fair
Value of
Stock and
Option
Awards(4)
($)		 
Name
 Grant
Date		 Threshold
#		 Target
#		 Maximum
#		 

John F. Crowley

  1/3/2018              154,076  15.67  1,654,347 

Chairman and Chief

  1/3/2018           106,603        1,670,469 

Executive Officer

  1/3/2018  13,326  26,651  53,302           417,621 

  1/3/2018  13,325  26,650  53,300           417,606 

  1/3/2018  26,651  53,302  106,604           1,356,003 

William D. Baird, III

  1/3/2018              43,075  15.67  462,505 

Chief Financial

  1/3/2018           29,803        467,013 

Officer(5)

  1/3/2018  3,726  7,451  14,902           116,757 

  1/3/2018  3,725  7,450  14,900           116,742 

  1/3/2018  7,451  14,902  29,804           379,107 

Bradley L. Campbell

  1/3/2018              56,329  15.67  604,816 

President and Chief

  1/3/2018           38,973        610,707 

Operating Officer

  1/3/2018  4,872  9,744  19,488           152,688 

  1/3/2018  4,871  9,742  19,484           152,657 

  1/3/2018  9,744  19,487  38,974           495,749 

Jay Barth, M.D. 

  1/3/2018              39,762  15.67  426,933 

Chief Medical Officer

  1/3/2018           27,511        431,097 

  1/3/2018  3,439  6,878  13,756           107,778 

  1/3/2018  3,439  6,877  13,754           107,763 

  1/3/2018  6,878  13,756  27,512           349,953 

Ellen Rosenberg

  1/3/2018              39,762  15.67  426,933 

Chief Legal Officer

  1/3/2018           27,511        431,097 

and Corporate Secretary

  1/3/2018  3,439  6,878  13,756           107,778 

  1/3/2018  3,439  6,877  13,754           107,763 

  1/3/2018  6,878  13,756  27,512           349,953 
40
(1)
Amounts represent PRSUs granted to NEOs during the 2018 fiscal year. The criteria used to determine the number of PRSUs earned by each NEO are described above under "Performance-Based Restricted Stock Units" The service-vesting schedule associated with the annual PRSUs granted to all NEOs on January 3, 2018 is three-year cliff vesting.

(2)
Vesting of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the total number of shares vest on the first anniversary of the vesting commencement date, with 25% on each successive vesting commencement date anniversary.

(3)
Each option has a term of ten years and vests in accordance with the following schedule: 25% of the total number of shares vest on the first anniversary of the grant date and 1/48th of the total number of shares vest on the first day of the following 36 months.

(4)
Amounts represent the grant date fair value calculated in accordance with FASB ASC 718, as stated in footnote #2 to the Summary Compensation Table.

(5)
Amounts shown reflect grants made in 2018 however, pursuant to the terms of his separation agreement, Mr. Baird will receive 14,902 RSUs, 22,435 Options and a certain amount of PRSUs, with the number of PRSUs to be determined by the applicable criteria above under "Performance-Based Restricted Stock Units"; all other equity granted in 2018 was forfeited upon his resignation.

TABLE OF CONTENTS

 (2)
Vesting of the RSU is subject to the participant’s continuous service with the Company through the applicable vesting date with the following schedule: 25% of the total number of shares vest on the first anniversary of the vesting commencement date, with 25% on each successive vesting commencement date anniversary.
 (3)
Each option has a term of ten years and vests in accordance with the following schedule: 25% of the total number of shares vest on the first anniversary of the grant date and 1/36th of the total number of shares vest on the first day of each of the following 36 months.
 (4)
Amounts represent the grant date fair value calculated in accordance with FASB ASC 718, as stated in footnote #2 to the Summary Compensation Table.
Outstanding Equity Awards at Fiscal Year-End

The following table presents the outstanding equity awards held by each of the named executive officers as of December 31, 2018.2021.
​
​​
Option Awards
​​
Stock Awards
​
​
Name and Principal Position
​​
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
​​
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1)
​​
Option
Exercise
Price
($)
​​
Option
Expiration
Date
​​
Number
of
Units of
Stock
That
Have
Not
Vested (#)(2)
​​
Market
Value of
Units of
Stock
That
Have
Not
Vested
($)(4)
​​
Number
of
Unearned
Units of
Stock
That
Have Not
Vested (#)(3)
​​
Market
Value of
Unearned
Units of
Stock
That
Have Not
Vested
($)(4)
​
​
John F. Crowley
  Chairman and Chief
  Executive Officer(5)
​​
230,000(5)
​​
—
​​
11.19
​​
1/2/2025
​​
26,653(10)
​​
$307,842
​​
​​
​
​
230,000(5)
​​
—
​​
15.96
​​
6/1/2025
​​
116,739(11)
​​
1,348,335
​​
​​
​
​
250,000(5)
​​
—
​​
11.74
​​
1/4/2026
​​
192,505(12)
​​
2,223,433
​​
​​
​
​
83,333
​​
—
​​
6.10
​​
6/15/2026
​​
115,240(13)
​​
1,331,022
​​
​​
​
​
83,333
​​
—
​​
7.93
​​
6/15/2026
​​
​​
​​
64,169(15)
​​
741,152
​
​
63,485(6)
​​
—
​​
5.13
​​
1/3/2027
​​
​​
​​
64,167(15)
​​
741,129
​
​
150,834(7)
​​
3,242(10)
​​
15.67
​​
1/3/2028
​​
​​
​​
128,337(15)
​​
1,482,292
​
​
305,871(8)
​​
97,015(11)
​​
10.04
​​
1/2/2029
​​
​​
​​
23,048(16)
​​
266,204
​
​
193,296(9)
​​
210,113(12)
​​
9.55
​​
1/2/2030
​​
​​
​​
23,048(16)
​​
266,204
​
​
—
​​
185,585(13)
​​
21.78
​​
1/4/2031
​​
​​
​​
11,524(16)
​​
133,102
​
​
​​
​​
​​
​​
​​
​​
57,620(16)
​​
665,511
​
​
Daphne Quimi
 Chief Financial Officer
​​
45,000
​​
—
​​
8.61
​​
1/2/2025
​​
3,153(10)
​​
36,147
​​
​​
​
​
45,000
​​
—
​​
12.28
​​
6/1/2025
​​
28,737(11)
​​
331,912
​​
​​
​
​
50,000
​​
—
​​
9.03
​​
1/4/2026
​​
53,901(12)
​​
622,557
​​
​​
​
​
35,000
​​
—
​​
6.10
​​
6/15/2026
​​
33,131(13)
​​
382,663
​​
​​
​
​
42,372
​​
—
​​
5.13
​​
1/3/2027
​​
​​
​​
17,967(15)
​​
207,519
​
​
17,821
​​
403(10)
​​
15.67
​​
1/3/2028
​​
​​
​​
17,967(15)
​​
207,519
​
​
64,266
​​
23,888(11)
​​
10.04
​​
1/2/2029
​​
​​
​​
35,934(15)
​​
415,038
​
​
54,121
​​
58,833(12)
​​
9.55
​​
1/2/2030
​​
​​
​​
6,626(16)
​​
76,530
​
​
—
​​
53,355(13)
​​
21.78
​​
1/4/2031
​​
​​
​​
6,626(16)
​​
76,530
​
​
​​
​​
​​
​​
​​
​​
3,314(16)
​​
38,277
​
​
​​
​​
​​
​​
​​
​​
16,565(16)
​​
191,326
​
​
Bradley L. Campbell
 President and Chief
 Operating Officer
​​
65,655
​​
—
​​
3.53
​​
1/28/2023
​​
9,744(10)
​​
112,543
​​
​​
​
​
65,625
​​
—
​​
2.45
​​
1/3/2024
​​
49,390(11)
​​
570,455
​​
​​
​
​
74,777
​​
—
​​
2.94
​​
6/26/2024
​​
89,835(12)
​​
1,037,594
​​
​​
​
​
90,000
​​
—
​​
8.61
​​
1/2/2025
​​
57,620(13)
​​
665,511
​​
​​
​
​
100,000
​​
—
​​
12.28
​​
6/1/2025
​​
​​
​​
29,945(15)
​​
345,865
​
​
100,000
​​
—
​​
9.03
​​
1/4/2026
​​
​​
​​
29,945(15)
​​
345,865
​
​
75,000
​​
—
​​
6.10
​​
6/15/2026
​​
​​
​​
59,890(15)
​​
691,730
​
​
103,578
​​
—
​​
5.13
​​
1/3/2027
​​
​​
​​
11,524(16)
​​
133,102
​
​
55,137
​​
1,192(10)
​​
15.67
​​
1/3/2028
​​
​​
​​
11,524(16)
​​
133,102
​
​
110,466
​​
41,049(11)
​​
10.04
​​
1/2/2029
​​
​​
​​
5,762(16)
​​
66,551
​
​
90,206
​​
98,051(12)
​​
9.55
​​
1/2/2030
​​
​​
​​
28,810(16)
​​
332,756
​
​
—
​​
92,792(13)
​​
21.78
​​
1/4/2031
​​
​​
​​
​​
​
41

TABLE OF CONTENTS

​
​​
Option Awards
​​
Stock Awards
​
​
Name and Principal Position
​​
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
​​
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1)
​​
Option
Exercise
Price
($)
​​
Option
Expiration
Date
​​
Number
of
Units of
Stock
That
Have
Not
Vested (#)(2)
​​
Market
Value of
Units of
Stock
That
Have
Not
Vested
($)(4)
​​
Number
of
Unearned
Units of
Stock
That
Have Not
Vested (#)(3)
​​
Market
Value of
Unearned
Units of
Stock
That
Have Not
Vested
($)(4)
​
​
Ellen S. Rosenberg
 Chief Legal Officer and
 Corporate Secretary
​​
95,000
​​
—
​​
5.16
​��
2/8/2026
​​
6,880(10)
​​
79,464
​​
​​
​
​
25,000
​​
—
​​
6.10
​​
6/15/2026
​​
30,533(11)
​​
352,656
​​
​​
​
​
70,621
​​
—
​​
5.13
​​
1/3/2027
​​
51,335(12)
​​
592,919
​​
​​
​
​
38,920
​​
842(10)
​​
15.67
​​
1/3/2028
​​
33,131(13)
​​
382,663
​​
​​
​
​
68,288
​​
25,375(11)
​​
10.04
​​
1/2/2029
​​
​​
​​
17,112(15)
​​
197,644
​
​
51,544
​​
56,031(12)
​​
9.55
​​
1/2/2030
​​
​​
​​
17,111(15)
​​
197,632
​
​
—
​​
53,355(13)
​​
21.78
​​
1/4/2031
​​
​​
​​
34,223(15)
​​
395,276
​
​
​​
​​
​​
​​
​​
​​
6,626(16)
​​
76,530
​
​
​​
​​
​​
​​
​​
​​
6,626(16)
​​
76,530
​
​
​​
​​
​​
​​
​​
​​
3,314(16)
​​
38,277
​
​
​​
​​
​​
​​
​​
​​
16,565(16)
​​
191,326
​
​
David M. Clark
 Chief People Officer
​​
67,152
​​
17,690(14)
​​
12.84
​​
10/9/2028
​​
14,003(14)
​​
161,735
​​
​​
​
​
56,221
​​
20,913(11)
​​
10.04
​​
1/2/2029
​​
25,145(11)
​​
290,425
​​
​​
​
​
43,803
​​
47,636(12)
​​
9.55
​​
1/2/2030
​​
43,635(12)
​​
503,984
​​
​​
​
​
—
​​
44,076(13)
​​
21.78
​​
1/4/2031
​​
27,369(13)
​​
316,112
​​
​​
​
​
​​
​​
​​
​​
​​
​​
14,545(15)
​​
167,995
​
​
​​
​​
​​
​​
​​
​​
14,544(15)
​​
167,983
​
​
​​
​​
​​
​​
​​
​​
29,090(15)
​​
335,990
​
​
​​
​​
​​
​​
​​
​​
5,473(16)
​​
63,213
​
​
​​
​​
​​
​​
​​
​​
5,473(16)
​​
63,213
​
​
​​
​​
​​
​​
​​
​​
2,739(16)
​​
31,635
​
​
​​
​​
​​
​​
​​
​​
13,684(16)
​​
158,050
​
​
​​
​​
​​
​​
​​
​​
​​
​
​
Hung Do Former
 Chief Science Officer
​​
6,270
​​
—
​​
6.10
​​
6/15/2026
​​
7,453(10)
​​
86,082
​​
​​
​
​
19,133
​​
—
​​
5.13
​​
1/3/2027
​​
30,533(11)
​​
352,656
​​
​​
​
​
42,163
​​
912(10)
​​
15.67
​​
1/3/2028
​​
51,335(12)
​​
592,919
​​
​​
​
​
68,288
​​
25,375(11)
​​
10.04
​​
1/2/2029
​​
34,572(13)
​​
399,307
​​
​​
​
​
51,544
​​
56,031(12)
​​
9.55
​​
1/2/2030
​​
​​
​​
17,112(15)
​​
197,644
​
​
—
​​
55,675(13)
​​
21.78
​​
1/4/2031
​​
​​
​​
17,111(15)
​​
197,632
​
​
​​
​​
​​
​​
​​
​​
34,223(15)
​​
395,276
​
​
​​
​​
​​
​​
​​
​​
6,914(16)
​​
79,857
​
​
​​
​​
​​
​​
​​
​​
6,914(16)
​​
79,857
​
​
​​
​​
​​
​​
​​
​​
3,458(16)
​​
39,940
​
​
​​
​​
​​
​​
​​
​​
17,286(16)
​​
199,653
​
 
  
  
  
  
 Stock Awards 
 
 Option Awards Number
of
Units of
Stock
That
Have
Not
Vested
(#)(2)		 Market
Value of
Units of
Stock
That
Have
Not
Vested
($)(4)		  
  
 
 
  
 Market
Value of
Unearned
Units of
Stock That
Have Not
Vested
($)(4)		 
Name and Principal
Position
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable		 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1)		 Option
Exercise
Price
($)		 Option
Expiration
Date		 Number of
Unearned
Units of
Stock That
Have Not
Vested
(#)(3)		 

John F. Crowley

  103,500  — $10.36  2/3/2019  30,833 $295,380       

Chairman and Chief

  103,975  —  5.96  1/19/2021  203,252  1,947,154       

Executive Officer

  131,024  —  6.45  2/15/2022  106,603  1,021,257       

  136,378  —  4.38  6/4/2022        82,318(13)$788,597 

  1,538  —  3.53  1/28/2023        101,626  973,577 

  20,972  —  3.19  1/3/2024        106,603  1,021,257 

  230,000  —  3.82  6/26/2024             

  225,185  4,815(5) 11.19  1/2/2025             

  201,230  28,770(6) 15.96  6/1/2025             

  182,284  67,716(7) 11.74  1/4/2026             

  52,081  31,252(9) 6.10  6/15/2026             

  52,081  31,252(9) 7.93  6/15/2026             

  135,356  147,129(10) 5.13  1/3/2027             

  —  154,076(11) 15.67  1/3/2028             

William D. Baird III

  175,000  —  4.66  04/16/2022  11,250  107,775       

Chief Financial

  50,000  —  4.38  06/04/22  45,732  438,113       

Officer(12)

  38,259  —  3.53  1/28/2023  29,803  285,513       

  6,224  —  2.52  6/18/2023        24,695(13) 236,573 

  24,000  —  2.45  1/3/2024        30,487  292,065 

  90,000  —  2.94  6/26/2024        29,803  285,513 

  88,125  1,875(5) 8.61  1/2/2025             

  78,750  11,250(6) 12.28  6/1/2025             

  65,625  24,375(7) 9.03  1/4/2026             

  37,500  22,500(9) 6.10  6/15/2026             

  40,601  44,144(10) 5.13  1/3/2027             

  —  43,075(11) 15.67  1/3/2028             

Bradley L. Campbell

  36,000  —  10.36  2/3/2019  18,750  179,625       

President and Chief

  30,000  —  5.96  1/19/2021  55,894  535,465       

Operating Officer

  60,000  —  6.06  6/16/2021  38,973  373,361       

  70,000  —  6.45  2/15/2022        30,183(13) 289,146 

  80,000  —  4.38  6/4/2022        37,262  356,970 

  78,000  —  3.53  1/28/2023        38,973  373,361 

  85,000  —  2.52  6/18/2023             

  90,000  —  2.45  1/3/2024             

  90,000  —  2.94  6/26/2024             

  88,125  1,875(5) 8.61  1/2/2025             

  87,490  12,510(6) 12.28  6/1/2025             

  72,909  27,091(7) 9.03  1/4/2026             

  46,866  23,134(9) 6.10  6/15/2026             

  49,621  53,957(10) 5.13  1/3/2027             

  —  56,329(11) 15.67  1/3/2028             

Jay Barth, M.D

  95,000  —  2.29  3/3/2024  7,500  71,850       

Chief Medical Officer

  50,000  —  2.94  6/26/2024  38,110  365,094       

  78,310  1,690(5) 8.61  1/2/2025  27,511  263,555       

  78,750  11,250(6) 12.28  6/1/2025        20,579(13) 197,145 

  65,625  24,375(7) 9.03  1/4/2026        25,406  243,389 

  37,500  22,500(9) 6.10  6/15/2026        27,511  263,555 

  33,836  36,785(10) 5.13  1/3/2027             

  —  39,762(11) 15.67  1/3/2028             
 (1)
25% of the total number of shares subject to the option vest on the first anniversary of the date of grant; the remainder vest 1/36th per month thereafter, subject generally to the participant’s continuous service with the Company through the applicable vesting date.
 (2)
Vesting of the RSU is subject generally to the participant’s continuous service with the Company through the applicable vesting date with the following schedule: 25% of the total number of shares vest on the first anniversary of the grant date, with 25% on each successive grant date anniversary for the next three years.
 (3)
Vesting of PRSUs are generally subject to the attainment of performance goals applicable to such awards and the participant’s continuous service with the Company. In accordance with SEC rules, the amount shown in the table above assumes performance at target level. As described above in the section “Stock Option, Restricted Stock Unit Awards, Performance Restricted Stock Unit Awards,” the Compensation and Leadership Development Committee determined that the pipeline goal applicable to the 2019 PRSU grants had not been met; accordingly all 2019 PRSUs subject to this goal were forfeited as of December 31, 2021 and are not reported in the table above.
 (4)
The market value is based on the closing stock price of $11.55 on December 31, 2021.
 (5)
On June 16, 2021, Mr. Crowley transferred 100% of these options to a trust for the benefit of his children.
 (6)
On June 16, 2021, Mr. Crowley transferred 6,889 of these options to a trust for the benefit of his children.
 (7)
On June 16, 2021, Mr. Crowley transferred 131,580 of these options to a trust for the benefit of his children.
 (8)
On June 16, 2021, Mr. Crowley transferred 216,351 of these options to a trust for the benefit of his children.
 (9)
On June 16, 2021, Mr. Crowley transferred 142,872 of these options to a trust for the benefit of his children.
 (10)
The date of grant was January 3, 2018.

 
  
  
  
  
 Stock Awards 
 
 Option Awards Number
of
Units of
Stock
That
Have
Not
Vested
(#)(2)		 Market
Value of
Units of
Stock
That
Have
Not
Vested
($)(4)		  
  
 
 
  
 Market
Value of
Unearned
Units of
Stock That
Have Not
Vested
($)(4)		 
Name and Principal
Position
 Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable		 Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable(1)		 Option
Exercise
Price
($)		 Option
Expiration
Date		 Number of
Unearned
Units of
Stock That
Have Not
Vested
(#)(3)		 

Ellen S. Rosenberg

  88,538  36,462(8) 5.16  2/8/2026  3,124  29,928       

Chief Legal Officer and

  15,610  9,390(9) 6.10  6/15/2026  38,110  365,094       

Corporate Secretary

  33,836  36,785(10) 5.13  1/3/2027  27,511  263,555       

  —  39,762(11) 15.67  1/3/2028        20,579(13) 197,145 

                    25,406  243,389 

                    27,511  263,555 
42
(1)
25% of the total number of shares subject to the option vest on the first anniversary of the date of grant; the remainder vest 1/36th per month thereafter.

(2)
Vesting of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the total number of shares vest on the first anniversary of the grant date, with 25% on each successive grant date anniversary for the next three years.

(3)
Vesting of PRSUs are generally subject to the attainment of performance goals applicable to such awards and the participant's continuous service with the Company. In accordance with SEC rules, the amount shown in the table above assumes performance at target level for all of the 2018 PRSUs and for the 2017 PRSUs subject to the TSR goal, while the 2017 PRSUs subject to the Pompe goal are reported at 81%, which was the level at which such award was earned in 2018.

(4)
The market value is based on the closing stock price of $9.58 on December 31, 2018.

(5)
The date of the grant was January 2, 2015.

(6)
The date of the grant was June 1, 2015.

(7)
The date of grant was January 4, 2016.

(8)
The date of grant was February 8, 2016.

(9)
The date of grant was June 15, 2016.

(10)
The date of grant was January 3, 2017.

(11)
The date of grant was January 3, 2018.

(12)
Pursuant to the terms of Mr. Baird's separation agreement, upon his resignation from the Company, the vesting of 75,069 Options was accelerated and all vested options (including such accelerated options) will remain exercisable until February 9, 2020; additionally 26,443 RSUs were accelerated and became free from forfeiture restrictions upon his resignation and 60,974 PRSUs remained outstanding subject to the satisfaction of the applicable performance vesting targets, and all other Options, RSUs and PRSUs were forfeited.

(13)
On April 11, 2019, as described above in the section "Stock Option, Restricted Stock Unit Awards, Performance Restricted Stock Unit Awards," the Compensation Committee determined that the Pompe Goal applicable to the 2017 PRSU grants had been met on December 19, 2018 at an interpolated rate of 81%; accordingly, such PRSUs are reported in the table above at 81% of target. Such units generally remain subject to continued service with the company through December 31, 2019, in order for a named executive officer to receive delivery of the shares underlying the units, however William D. Baird III received 24,695 share in accordance with his separation agreement in April 2019.

TABLE OF CONTENTS

 (11)
The date of grant was January 2, 2019.
 (12)
The date of grant was January 2, 2020.
 (13)
The date of grant was January 4, 2021.
 (14)
The date of grant was October 9, 2018.
 (15)
Subject generally to the participant’s continued service and the attainment of the applicable performance goals, these PRSUs vest on December 31, 2022.
 (16)
Subject generally to the participant’s continued service and the attainment of the applicable performance goals, these PRSUs vest on December 31, 2023.
Option Exercises and Stock Vested at Year End

Our executive officers must use pre-established trading plans to sell shares of Amicus Therapeutics, Inc. stock. Trading plans may only be entered into during an open trading window and when the executive officer is not in possession of material non-public information about the Company, andCompany. Further, we also require a waiting period following the establishment of a trading plan before any trades may be executed. Our policy is designed to provide safeguards that will allow our executives an opportunity to realize the value intended by the Company in granting equity-based awards.

The following table shows information regarding option exercises and stock vested for each named executive officer during the year ended December 31, 2018.

2021.
​
Name and Principal Position
​​
Number
of
Shares
Acquired
on
Exercise
​​
Value
Realized
upon
Exercise(1)
​​
Number
of
Shares
Acquired
on
Vesting(2)
​​
Value
Realized
upon
Vesting(3)
​
​
John F. Crowley
  Chairman and Chief Executive Officer
​​
277,912
​​
$1,866,899
​​
447,558(4)
​​
$7,601,618
​
​
Daphne Quimi
 Chief Financial Officer
​​
16,628
​​
125,375
​​
108,747
​​
1,851,245
​
​
Bradley L. Campbell
 President and Chief Operating Officer
​​
191,768
​​
1,351,242
​​
208,863
​​
3,672,388
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate Secretary
​​
—
​​
—
​​
115,221(5)
​​
1,946,144
​
​
David M. Clark
 Chief People Officer
​​
—
​​
—
​​
90,236
​​
1,354,573
​
​
Hung Do
 Former Chief Science Officer
​​
—
​​
—
​​
134,632
​​
2,392,177
​
 (1)
The value realized is the difference between the fair market value of a share of our Common Stock at the time of exercise and the option exercise price, multiplied by the number of shares acquired on each exercise.
 (2)
On January 14, 2022, as described above in the section “Stock Option, Restricted Stock Unit Awards, Performance Restricted Stock Unit Awards,” the Board determined that the TSR Goal applicable to the 2019 PRSU grants had been achieved on December 31, 2021 at 128.2% of the target amount; accordingly, such PRSUs are reflected in the table at 128.2% of target for each named executive officer.
 (3)
The value realized on vesting on stock awards is based on the closing price on the date of vesting.
 (4)
The number of shares acquired on vesting includes 64,168 shares scheduled to vest on January 2, 2021 and 26,650 shares scheduled to vest on January 3, 2021 but were otherwise deferred to February 15, 2024 and January 3, 2022, respectively and are reflected in the “Non-Qualified Deferred Compensation” table below.
 (5)
The number of shares acquired on vesting includes 17,111 shares scheduled to vest on January 2, 2021 but were otherwise deferred to January 2, 2026 and are reflected in the “Non-Qualified Deferred Compensation” table below.
Name and Principal Position
 Number of
Shares
Acquired on
Exercise		 Value
Realized
upon
Exercise(1)		 Number of
Shares
Acquired on
Vesting		 Value
Realized
upon
Vesting(2)		 

John F. Crowley

  —  —  417 $6,822 

Chairman and Chief Executive Officer

             

William D. Baird III

  40,000 $537,036  15,243 $238,858 

Chief Financial Officer

             

Bradley L. Campbell

  32,500 $185,546  18,631 $291,948 

President and Chief Operating Officer

             

Jay Barth, M.D. 

  40,000 $537,036  16,453 $260,406 

Chief Medical Officer

             

Ellen S. Rosenberg

  —  —  14,266 $224,627 

Chief Legal Officer and Corporate Secretary              

             
43
(1)
The value realized is the difference between the fair market value of a share of our common stock at the time of exercise and the option exercise price, multiplied by the number of shares acquired on each exercise.

(2)
The value realized on vesting on stock awards is based on the closing price on the date of vesting.

TABLE OF CONTENTS

Non-Qualified Deferred Compensation

As described more fully above, our Non-Qualified Cash Deferral Plan (andand Stock Deferral Plan (collectively, the "Deferral Plans"“Deferral Plans”) coverscover our executive officers and non-employee directors. Earnings are determined solely by a participant'sparticipant’s hypothetical investment of any amount deferred in any pre-selected investment permitted under the Cash Deferral Plan or in the value of our stock, with respect to the Stock Deferral Plan. All amounts in the Deferral Plans are fully vested at all times.

​
Name and Principal Position
​​
Executive
Contributions
in Last
Fiscal Year
​​
Aggregate
Earnings
in Last
Fiscal Year
​​
Aggregate
Distributions
in Last
Fiscal Year
���​
Aggregate
Balance at
Last
Fiscal Year(1)
​
​
John F. Crowley
 Chairman and Chief Executive
 Officer
​​
$2,982,869(2)
​​
$(1,767,937)(3)
​​
($1,263,848)
​​
$7,062,317
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate  Secretary
​​
372,678(4)
​​
(254,406)(5)
​​
—
​​
277,061
​
 (1)
This value includes compensation earned and deferred in prior years, which was disclosed in prior year Proxy Statements.
 (2)
$593,013 of this amount is included in the salary column and $411,840 of this amount is included in the bonus column, respectively, in the summary compensation table. $1,978,016 of this amount is the vesting date value of 90,818 shares underlying RSUs that otherwise would have been delivered to the executive in 2021 if not deferred. Per the executive’s election, the shares underlying the deferral will generally be delivered to the executive on January 3, 2022 (with respect to 26,650 shares) and February 15, 2024 (with respect to 64,168 shares).
 (3)
Includes $489,092 investments earnings determined by the hypothetical investments elected by Mr. Crowley in the last fiscal year under the Cash Deferral Plan and $758,657 in losses, represented as the difference between the vesting date value of deferred RSUs and their value as of December 31, 2021 or their value as of the delivery date with respect to 30,000 shares that were delivered to Mr. Crowley on January 1, 2021.
 (4)
This amount is the vesting date value of 17,111 shares underlying RSUs that otherwise would have been delivered to the executive in 2021 if not deferred. Per the executive’s election, the shares underlying the deferral will generally be delivered to the executive on January 2, 2026.
 (5)
The loss represents the decline in value during 2021 of shares subject to RSUs deferred under the Stock Deferral Plan (measured from the end of 2020, with respect to previously deferred stock awards, or measured from the vesting date, with respect to stock awards deferred in 2021).
Name and Principal Position
 Executive
Contributions in
Last Fiscal Year		 Aggregate
Earnings in
Last
Fiscal Year		 Aggregate
Distributions in
Last
Fiscal Year		 Aggregate
Balance at
Last
Fiscal Year		 

John F. Crowley

 $1,826,520(1)$(646,279)(2) — $3,221,271(3)

Chairman and Chief Executive Officer

             

William D. Baird III

  61,350(4) (25,425)(5) —  35,925(6)

Chief Financial Officer

             

Bradley L. Campbell

  102,250(4) (42,375)(5) —  59,875(7)

President and Chief Operating Officer

             
(1)
$510,112 of this amount is included in the salary column and $356,568 of this amount is included in the bonus column, respectively, in the summary compensation table. $959,840 of this amount is the vesting date value of RSUs that otherwise would have been delivered to the executive if not deferred.

    Per the executive's election, the shares underlying the deferral will generally be delivered on each of February 1, 2020 (50,813 shares) and January 1, 2021 (10,000 shares).

(2)
Represents investments loss determined by the hypothetical investments elected by Mr. Crowley in the last fiscal year as permitted under the Deferral Plan.

(3)
This column includes $2,362,701 compensation earned and deferred in prior years, which was disclosed in prior year Proxy statements.

(4)
Represents the value of the deferred RSUs as of the vesting date that otherwise would have been delivered to the executive if not deferred. Per the executive's election, the underlying shares will generally be delivered on June 15, 2020 or upon earlier separation of the executive's service.

(5)
The loss represented is the difference between the vesting date value of the deferred RSUs and their value as of December 31, 2018.

(6)
This column includes $22,875 compensation earned and deferred in prior years, which was disclosed in prior year Proxy statements.

(7)
This column includes $38,125 compensation earned and deferred in prior years, which was disclosed in prior year Proxy statements.

Severance Benefits and Change of Control Arrangements

        We

As of December 31, 2021, we have agreed to provide severance benefits and change of control arrangements to our current executives as described below.

John F. Crowley.Crowley. We employ Mr. Crowley as our Chief Executive Officer pursuant to an employment agreement. The agreement will continue for successive one-year terms until either Mr. Crowley or the company provide written notice of termination to the other in accordance with the terms of the agreement. Upon the termination of his employment by the company other than for cause, or if the company decides not to extend Mr. Crowley'sCrowley’s agreement at the end of any term, or if Mr. Crowley resigns for good reason, Mr. Crowley has the right to receive (i) a severance payment in an amount equal to his then current base salary payable over 18 months in accordance with the company'scompany’s regular payroll practices, (ii) an additional payment equal to 150% of the target bonus for the year in which the termination occurs, (iii) continued Monthly Medical Payments for a period of 18 months, and (iv) continuation of health care coverage under COBRA with premiums to be paid by the Company for up to 29 months. Further, the vesting of all options and RSUs then held by Mr. Crowley shall accelerate by one year.year and any unvested PRSUs held by Mr. Crowley shall also accelerate, such that the portion of those PRSUs otherwise scheduled to vest during the 12 month period immediately following such separation from service will become vested. Mr. Crowley is not entitled to severance payments if the company terminates him for cause or if he resigns without good reason.

Further, if upon the termination of Mr. Crowley'sCrowley’s employment by the company other than for cause, or if the company decides not to extend his employment agreement at the end of any term, or if Mr. Crowley resigns for good reason, in each case within twelve months following a change of control in the Company, then Mr. Crowley has the right to receive (i) a severance payment in an amount equal to two times his then current base salary payable over 24 months in accordance with our regular payroll practices, (ii) an additional payment equal to 200% of the target bonus for the year in which the termination occurs, (iii) continued Monthly Medical Payments for a period of 24 months, and (iv) continuation of health care coverage under COBRA with premiums to be paid by the Company for up to 29 months. Further, the vesting of all remaining unvested options and restricted stock grants then held by Mr. Crowley would accelerate in full.
44

TABLE OF CONTENTS

Finally, if Mr. Crowley'sCrowley’s employment ceases due to his death or disability, he (or his estate, as applicable) will be entitled to (i) continuation of the Monthly Medical Payments for 12 months, and (ii) continuation of health care coverage under COBRA with premiums to be subsidized by the Company for up to 12 months. We believe that the severance package for our chief executive officer is appropriate considering his role, responsibilities and his excellent historical service to the Company.


On September 29, 2021, in connection with the Caritas-ARYA transaction, the Company announced that Mr. Crowley would become CEO of Caritas and enter into a new employment agreement with the Company as a strategic advisor. The effectiveness of this strategic advisor agreement was contingent upon the closing of the Caritas-ARYA transaction; as the transaction was terminated, the strategic advisor agreement was terminated ab initio.

    Other Named Executive Officers

Messrs. BairdCampbell, Clark and Campbell, Dr. BarthDo and Ms. Rosenberg.Mses. Quimi and Rosenberg. We employ Mr. Baird as our Chief Financial Officer, Mr. Campbell as our President and Chief Operating Officer, Dr. BarthMr. Clark as our Chief MedicalPeople Officer, Dr. Do as our Chief Scientific Advisor, Ms. Quimi as our Chief Financial Officer and Ms. Rosenberg as our Chief Legal Officer and Corporate Secretary, pursuant to their respective employment agreements. If any of these executive officers is terminated without cause (other than within 12 months following a change in control), then the executive officer has the right to receive:receive the following:

    •
continuation of such executive'sexecutive’s base salary for 12 months;

•
an amount equal to the target bonus for such executive officer pro-rated for the number of months actually worked in the year of termination;

•
accelerated vesting of optionequity awards then held by them will automatically accelerate byotherwise scheduled to vest within twelve months; and

•
continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 12 months.

In addition, if any of these executive officers is terminated other than for cause within 12 months following a change of control or, if within 12 months following those changes,a change of control, the executive officer resigns for good reason, then the executive officer has the right to receive:

    •
continuation of such executive'sexecutive’s base salary for 18 months;

•
months in an amount equal to such executive’s then current base salary;
an amount equal to such executive officer'sofficer’s target annual bonus;

•
any outstanding unvested stock options and restricted stock grantsequity awards held by the executive officer will fully vest;vest (with PRSUs vesting at target or such greater level as determined by the Board); and

•
continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 18 months.

Finally, if any of the executive'sexecutive officer’s employment ceases due to death or disability, such executive will be entitled to continuation of health care coverage under COBRA with premiums to be subsidized by the Company for up to 12 months.

As a condition to the payment of the foregoing severance benefits, a departing executive officer is required to execute a general release of claims against the Company and its affiliates. Each named executive officer is bound by non-disclosure, inventions transfer, non-solicitation and non-competition covenants that prohibit the executive officer from competing with the Company during the term of his or her employment and for twelve months after termination of employment.

Retirement Benefits under the Company'sCompany’s Equity Plan

Under the Amicus Amended and Restated 2007 Equity Incentive Plan, all participants in the plan, including each named executive officer, would generally be eligible for the retirement benefits set forth below, upon such participant'sparticipant’s termination of employment, if such participant meets the following criteria at the time of such termination:

    •
The participant must have at least 5 years of continuous service

•
The participant must be at least 55 years of age

•
The sum of the participant'sparticipant’s age and years of service with the Company must equal or exceed 67 years (collectively, the "Retirement Criteria"“Retirement Criteria”)
45

TABLE OF CONTENTS

Notwithstanding the above, if the participant'sparticipant’s employment is terminated by the Company for cause, then the retirement benefits would be forfeited. None of ourMs. Quimi is the only named executive officersofficer who met the Retirement Criteria in 2018.

2021.

    •
    Options: Any unvested Options shall continue to vest until the second anniversary of the participant'sparticipant’s separation, and all vested Options (including those eligible to vest pursuant to the preceding clause) shall remain exercisable until the earlier of (i) the 4th anniversary of the date of such separation, and (ii) the original expiration date of the term of the Option; any options not exercised in such period shall be forfeited with no further compensation due to the participant.

    •
RSUs: Any unvested RSUs that would vest up to the second anniversary of the participant'sparticipant’s separation, shall have accelerated vesting, and the shares will be delivered to the participant upon separation; any unvested RSUs beyond the two yeartwo-year date shall be forfeited with no further compensation.

•
compensation due to the participant.
PRSUs: A prorated portion of the participant'sparticipant’s PRSUs (based on the participant'sparticipant’s period of service with the Company during the performance period) would remain eligible to vest and become delivered based upon satisfaction of the goals applicable to such PRSUs (collectively, the "Equity“Equity Retirement Benefits"Benefits”).

Death and Disability
The same Equity Retirement Benefits described above afforded upon a participant'sparticipant’s retirement after satisfying the Retirement Criteria would be offered to any participant upon a termination of employment due to such participant'sparticipant’s death or disability.

Potential Payments upon Termination without Cause or Resignation for Good Reason

For each named executive officer, the following table sets forth quantitative estimates of the benefits that would have accrued if such executive'sexecutive’s employment had been terminated without cause or, in the case of Mr. Crowley, he resigned for good reason, on December 31, 20182021 other than in connection with a change of control. Amounts below reflect potential payments pursuant to the severance agreements for such named executive officers.

​
Name and Principal Position
​​
Salary
Continuation
($)
​​
Bonus
($)(1)
​​
Benefit
Continuation
($)(2)
​​
Value of
RSU &
PRSU
Vesting
($)(3)(4)
​​
Value of
Stock
Option
Vesting
($)(4)
​​
Total
($)
​
​
John F. Crowley
 Chairman and
 Chief Executive
 Officer
​​
$1,112,397(5)
​​
$723,058
​​
$1,273,695(6)
​​
$5,405,601
​​
$3,263,245
​​
$11,777,996
​
​
Daphne Quimi
 Chief Financial
 Officer
​​
470,080(7)
​​
211,536
​​
10,474
​​
1,062,772
​​
880,457
​​
2,635,319
​
​
Bradley L. Campbell
 President and Chief
  Operating Officer
​​
552,018(7)
​​
276,009
​​
31,198
​​
1,804,530
​​
1,508,303
​​
4,172,058
​
​
Ellen S. Rosenberg
 Chief Legal Officer
 and Corporate
 Secretary
​​
470,485(7)
​​
211,718
​​
24,733
​​
1,343,365
​​
885,943
​​
2,936,244
​
​
David M. Clark
 Chief People Officer
​​
440,274(7)
​​
198,123
​​
24,732
​​
1,052,462
​​
934,707
​​
2,650,298
​
​
Hung Do
 Former Chief
 Science Officer
​​
217,802(7)
​​
98,011
​​
31,198
​​
1,072,961
​​
899,549
​​
2,319,521
​
Name and Principal Position
 Salary
Continuation
($)		 Bonus
($)(1)		 Benefit
Continuation
($)(2)		 Value of
RSU & PRSU
Vesting
($)(3)(4)		 Value of
Stock
Option
Vesting
($)(4)		 Total
($)		 

John F. Crowley

  956,461(5) 573,876  1,259,604(6)$2,449,750  381,433  5,621,125 

Chairman and Chief

                   

Executive Officer

                   

William D. Baird, III

  418,658(7) 195,095  25,205  902,006  186,085  1,727,049 

Chief Financial Officer

                   

Bradley L. Campbell

  468,109(8) 327,209  25,411  921,052  195,979  1,937,761 

President and Chief

                   

Operating Officer

                   

Jay Barth, M.D. 

  457,885(8) 192,037  25,205  626,834  144,766  1,446,727 

Chief Medical Officer

                   

Ellen S. Rosenberg

  426,420(7) 208,647  21,508  605,873  238,383  1,500,831 

Chief Legal Officer and

                   

Corporate Secretary

                   
(1)
Bonus component paid in lump sum.

(2)
Other than with respect to Mr. Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 12 months.

(3)
 (1)
Bonus component paid in lump sum.
 (2)
Other than with respect to Mr. Crowley, benefits to be continued consist of premiums paid by the Company for 12 months.
 (3)
The PRSUs reported in the table are based on an assumed satisfaction of the applicable performance goals based on the tracking of such goals as of December 31, 2021. The actual number of PRSUs delivered to a named executive officer would depend on the satisfaction of each performance goal at the end of the applicable performance period.
46

TABLE OF CONTENTS

 (4)
Value of the equity that would accelerate upon such event is calculated using the closing stock price of $11.55 on December 31, 2021. In the case of stock options, the amount shown reflects the option “spread” (i.e., the difference between the option exercise price and the fair market value of our common stock) as of December 31, 2021 of stock options that would become non-forfeitable in this case.
 (5)
Base salary paid in installments over an 18-month period following such termination of employment.
 (6)
Benefits to be continued consist of estimated healthcare costs and health insurance premiums for Mr. Crowley’s family, which primarily consists of the Monthly Medical Payments paid over 18 months and up to 29 months of COBRA coverage.
 (7)
Base salary paid in installments over a 12-month period following such termination of employment.
Potential Payments upon a Change of Control
The following table sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers in the table are based on an assumed satisfactionevent of the applicable performance goals based on the tracking of such goals as of December 31, 2018. The actual number of PRSUs

    delivered to a named executive officer would depend on the satisfaction of each performance goal at the end of the applicable performance period.

(4)
Value of the equity that would accelerate upon such event is calculated using the closing stock price of $9.58change in control on December 31, 2018.

(5)
Base salary paid2021 under their applicable agreements, without regard as to whether such named executive officer’s employment was terminated in installments over an 18 month period followingconnection with such termination of employment.

(6)
Benefits to be continued consist of estimated healthcare costs and health insurance premiums for Mr. Crowley's family, which primarily consists of the Monthly Medical Payments paid over 18 months and up to 29 months of COBRA coverage.

(7)
Base salary paidchange in installments over a 6 month period following such termination of employment.

(8)
Base salary paid in installments over a 12 month period following such termination of employment.
control.

​
Name and Principal Position
​​
Value of RSU
Vesting ($)(1)
​​
Value of
PRSU
Vesting
($)(1)(2)
​​
Total
($)(1)
​
​
John F. Crowley
 Chairman and Chief Executive Officer
​​
$5,210,632
​​
$5,653,574
​​
$10,864,206
​
​
Daphne Quimi
 Chief Financial Officer
​​
1,373,549
​​
1,534,476
​​
2,908,025
​
​
Bradley L. Campbell
 President and Chief Operating Officer
​​
2,386,103
​​
2,607,345
​​
4,993,448
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate Secretary
​​
1,407,702
​​
1,526,477
​​
2,934,179
​
​
David M. Clark
 Chief People Officer
​​
1,272,256
​​
1,276,386
​​
2,548,642
​
​
Hung Do
 Former Chief Science Officer
​​
1,430,964
​​
1,543,121
​​
2,974,085
​

 (1)
The market value is based on the closing stock price of $11.55 on December 31, 2021.
 (2)
In accordance with the applicable PRSU agreements, assumes performance at target level or at the level determined as if the goal was satisfied as of the date of such change in control.
Potential Payments upon Termination Due to Change of Control

The following table sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers if his or her employment had been terminated due to a termination without cause or a resignation with good reason on December 31, 2018,2021, assuming that such termination occurs within twelve months following a change of control or, in the case of Mr. Crowley, within three months prior to or twelve months following the date on which the change of control occurs.

control.
​
Name and Principal Position
​​
Salary
Continuation
($)
​​
Bonus
($)(1)
​​
Benefit
Continuation
($)(2)
​​
Value of
RSU &
PRSU
Vesting
($)(3)
​​
Value of
Stock
Option
Vesting
($)(3)
​​
Total
($)
​
​
John F. Crowley
 Chairman and Chief
 Executive Officer
​​
$1,483,196(4)
​​
$964,077
​​
$1,673,697(5)
​​
$10,864,206
​​
$566,719
​​
$15,551,895
​
​
Daphne Quimi
 Chief Financial
 Officer
​​
705,120(6)
​​
211,536
​​
15,711
​​
2,908,025
​​
153,737
​​
3,994,129
​
​
Bradley L. Campbell
 President and Chief
 Operating Officer
​​
783,027(6)
​​
276,009
​​
46,797
​​
4,993,448
​​
258,086
​​
6,357,367
​
​
Ellen S. Rosenberg
 Chief Legal Officer
 and Corporate
 Secretary
​​
705,728(6)
​​
211,718
​​
37,100
​​
2,934,180
​​
150,378
​​
4,039,104
​
​
David M. Clark
 Chief People Officer
​​
660,411(6)
​​
198,123
​​
37,098
​​
2,548,642
​​
126,851
​​
3,571,125
​
Name and Principal Position
 Salary
Continuation
($)		 Bonus
($)(1)		 Benefit
Continuation
($)(2)		 Value of
RSU & PRSU
Vesting
($)(3)		 Value of
Stock
Option
Vesting
($)(3)		 Total
($)		 

John F. Crowley

 $1,275,281(4)$765,168 $1,659,606(5)$5,649,613 $815,047 $10,164,716 

Chairman and Chief

                   

Executive Officer

                   

William D. Baird, III

  627,987(6) 195,095  37,808  1,665,119  289,966  2,815,974 

Chief Financial Officer

                   

Bradley L. Campbell

  702,164(6) 327,209  38,117  2,115,877  354,734  3,538,101 

President and Chief

                   

Operating Officer

                   

Jay Barth M.D. 

  686,827(6) 192,037  37,808  1,450,834  257,039  2,624,544 

Chief Medical Officer

                   

Ellen S. Rosenberg

  639,630(6) 208,647  32,262  1,408,911  357,532  2,646,984 

Chief Legal Officer and

                   

Corporate Secretary

                   
47
(1)
Bonus component paid in lump sum.

(2)
Other than with respect to Mr. Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 18 months.

(3)
Value of the equity that would accelerate upon such event is calculated using the closing stock price of $9.58 on December 31, 2018.

(4)
Base salary paid in installments over a 24 month period following such termination of employment.

(5)
Benefits to be continued consist of estimated healthcare costs and health insurance premiums for Mr. Crowley's family, which primarily consists of the Monthly Medical Payments paid over 24 months and up to 29 months of COBRA coverage.

(6)
Base salary paid in installments over an 18 month period following such termination of employment.

TABLE OF CONTENTS

​
Name and Principal Position
​​
Salary
Continuation
($)
​​
Bonus
($)(1)
​​
Benefit
Continuation
($)(2)
​​
Value of
RSU &
PRSU
Vesting
($)(3)
​​
Value of
Stock
Option
Vesting
($)(3)
​​
Total
($)
​
​
Hung Do
 Former Chief
 Science Officer
​​
326,703(6)
​​
98,011
​​
46,797
​​
2,974,085
​​
150,378
​​
3,595,974
​
 (1)
Bonus component paid in lump sum.
 (2)
Other than with respect to Mr. Crowley, benefits to be continued consist of premiums paid by the Company for 18 months.
 (3)
Value of the equity that would accelerate upon such event is calculated using the closing stock price of $11.55 on December 31, 2021. In the case of stock options, the amount shown reflects the option “spread” (i.e., the difference between the option exercise price and the fair market value of our common stock) as of December 31, 2021 of stock options that would become non-forfeitable in this case.
 (4)
Base salary paid in installments over a 24-month period following such termination of employment.
 (5)
Benefits to be continued consist of estimated healthcare costs and health insurance premiums for Mr. Crowley’s family, which primarily consists of the Monthly Medical Payments paid over 24 months and up to 29 months of COBRA coverage.
 (6)
Base salary paid in installments over an 18-month period following such termination of employment.
Potential Payments upon Termination Due to Death or Disability

The following sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers if his or her employment had been terminated due to death or disability on December 31, 2018.

2021.
​
Name and Principal Position
​​
Benefit
Continuation
($)(1)
​​
Value of
RSU &
PRSU
Vesting
($)(2)
​​
Value of
Stock
Option
Vesting
($)(2)
​​
Total
($)
​
​
John F. Crowley
 Chairman and Chief Executive  Officer
​​
$830,496
​​
$7,794,268
​​
$549,910
​​
$9,174,674
​
​
Daphne Quimi
 Chief Financial Officer
​​
10,474
​​
2,037,453
​​
149,030
​​
2,196,957
​
​
Bradley L. Campbell
 President and Chief Operating
 Officer
​​
31,198
​​
3,512,013
​​
250,242
​​
3,793,453
​
​
Ellen S. Rosenberg
 Chief Legal Officer and
 Corporate Secretary
​​
24,733
​​
2,085,002
​​
145,896
​​
2,255,631
​
​
David M. Clark
 Chief People Officer
​​
24,732
​​
1,836,904
​​
123,040
​​
1,984,676
​
​
Hung Do
 Former Chief Science Officer
​​
31,198
​​
2,106,617
​​
145,896
​​
2,283,711
​
 (1)
Benefits to be continued consist of benefit continuation and HSA premiums paid by the Company for 12 months following such termination. For Mr. Crowley, this also includes the Monthly Medical Payments.
 (2)
Value of the equity that would accelerate upon such event is calculated using the closing stock price of $11.55 on December 31, 2021. In the case of stock options, the amount shown reflects the option “spread” (i.e., the difference between the option exercise price and the fair market value of our common stock) as of December 31, 2021 of stock options that would become non-forfeitable in this case.
Name and Principal Position
 Benefit
Continuation
($)(1)		 Value of RSU &
PRSU Vesting
($)(2)		 Value of Stock
Option Vesting
($)(2)		 Total
($)		 

John F. Crowley

 $824,665 $3,461,849 $3,998,414 $8,284,928 

Chairman and Chief Executive Officer

             

William D. Baird, III

  25,205  684,607  719,161  1,428,974 

Chief Financial Officer

             

Bradley L. Campbell

  25,411  1,314,975  1,443,792  2,784,179 

President and Chief Operating Officer

             

Jay Barth, M.D. 

  25,205  894,260  1,188,907  2,108,372 

Chief Medical Officer

             

Ellen S. Rosenberg

  21,508  852,338  1,055,141  1,928,987 

Chief Legal Officer and Corporate Secretary

             
48
(1)
Benefits

TABLE OF CONTENTS

Potential Payments Due to be continued consist of COBRA and HSA premiums paid by the Company for 12 monthsRetirement
The following such termination. For Mr. Crowley, this also includes the Monthly Medical Payments.

(2)
Valuesets forth quantitative estimates of the equitybenefits that would accelerate upon such event is calculated using the closing stock price of $9.58have accrued to Ms. Quimi on December 31, 2018.
2021 if she had elected to retire. Ms. Quimi was the only named executive officer to qualify for the retirement benefit in 2021.

​
Name and Principal Position
​​
Value of
RSU &
PRSU
Vesting ($)(1)
​​
Value of
Stock
Option
Vesting
($)(1)
​​
Total
($)
​
​
Daphne Quimi
 Chief Financial Officer
​​
$2,037,453
​​
$149,030
​​
$2,186,483
​

 (1)
Value of the equity that would accelerate upon such event is calculated using the closing stock price of $11.55 on December 31, 2021. In the case of stock options, the amount shown reflects the option “spread” (i.e., the difference between the option exercise price and the fair market value of our common stock) as of December 31, 2021 of stock options that would become non-forfeitable in this case.
CEO Pay Ratio

Under Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, we are required to provide the following disclosure regarding the ratio of the annual total compensation of our Chief Executive Officer to the annual total compensation of our median employee (the "Pay Ratio"“Pay Ratio”).

        While SEC rules permit using the same median employee for up to three consecutive years,

In 2021 we determined that the dramatic increase in our workforce in 2018 required the re-identification of our median employee for purposes of the Pay Ratio calculation. We identified our median employee by determining the 20182021 total annualized target cash compensation for all of our global employees (excluding our Chief Executive Officer), whether employed on a full-time,fulltime, part-time or seasonal basis, who were employed by us on October 1, 20182021 as our consistently applied compensation measure. Total annualized target cash compensation for these purposes consists of annualized base salary and annual target bonus. Once we identified our median employee, we calculated such employee'semployee’s annual total compensation for 20182021 in the same manner that we determined the total compensation of our Chief Executive Officer for purposes of the Summary Compensation Table disclosed above.

For the year ended December 31, 2018,2021, (i) the annual total compensation of our Chief Executive Officer was $7,419,963;$9,990,032; (ii) the annual total compensation of our median employee was $152,717;$197,842; and (iii) based on this information, we reasonably estimate our Pay Ratio to be 49:50:1. Because the SEC rules for identifying the median employee and calculating the Pay Ratio allow companies to use different methodologies, to apply certain exemptions, and to make reasonable estimates and assumptions, the Pay Ratio calculation presented above is a reasonable estimate and may not be comparable to the pay ratio reported by other companies.


Director Compensation

Pursuant to our Director Compensation Policy, each non-employee member of our Board received the following cash compensation for Board services during 2018,2021, as applicable:

    •
$40,00047,500 per year for service as a Board member;

•
$30,000 per year for service as Lead Independent Director;

•
$30,000 per year for service as chairperson of the Audit and Compliance Committee (inclusive of committee membership fees described below);

•
$20,000 per year for service as chairperson of the Compensation and Leadership Development Committee (inclusive of committee membership fees described below);

•
$12,500 per year for service as chairperson of the Nominating and Corporate Governance Committee or the Science and Technology Committee (inclusive of committee membership fees described below);
$12,500 per year for service as chairperson of the Science and

•
Technology Committee for service in 2021 prior to April 6, 2021 and $16,000 per year for service as chairperson of the Science and Technology Committee, effective as of April 6, 2021; and
$10,000 per year for service as a member of the Audit and Compliance Committee and $7,500 per year for service as a member of the Compensation and Leadership Development Committee, the Nominating and Corporate Governance Committee or the Science and Technology Committee.

In 2018,2021, after a review of market data, the Board approved an increase in the value of the annual director equity grant from $225,000 to $325,000 and an increase in the value of the newly appointed independent director equity grant from $400,000 to $487,500. Accordingly, in 2021 each director received an annual grant of non-qualified options and RSUs worth $150,000,
49

TABLE OF CONTENTS

$325,000, with 2/3 of the value assigned to the non-qualified stock options, and 1/3 of the value assigned to RSUs. The grant date is the date of our Annual Meeting of Stockholders and each grant will vest in full aton the following Annual Meetingfirst anniversary of Stockholders.the grant date. The exercise price of each option granted to a non-employee director will be equal to 100% of the fair market value of a share on the date of grant. Options will have a maximum term of 10 years measured from the grant date, subject to earlier termination in the event of the director'sdirector’s cessation of Board service. All of our directors are also eligible to participate in our 2007 Equity Incentive Plan.

        In September 2018, the Board approved an increase for newly

Newly appointed independent Board members whereby qualifying appointees will receive non-qualified options and RSUs with the value of $240,000,valued at $487,500, consisting of 50% RSUs and 50% Options, in connection with their election to the Board.Options. The exercise price of each option granted will be equal to 100% of the fair market value of a share on the date of the grant. Unlike the annual grant to our directors, but consistent with our grants to our named executive officers, these initial grant awards vest over a fourfour-year period. The RSUs granted to each newly appointed director vest 25% per year periodon the anniversary of the grant date whereas the options will vest 25% on the first anniversary of the date of grant with 25% vesting one year after the vesting commencement date and the remainder vesting ratably each month thereafter in equal installments over a three year period subject tothree-year period. Vesting of these initial grant awards is conditioned on the director’s continued service as a director.through each vesting date. Upon her appointment to the Board Ms. Bleilin 2021, Dr. Roberts received a new director equity grant at $240,000$487,500 value, with 50% RSUs and 50% Options. We expect to make additional initial grants of stock options and RSUs to any newly appointed independent Board members in the future.


Summary of Non-Employee Director Compensation Table

The following table provides information regarding the compensation that each of our non-employee directors earned during the year ended December 31, 2018.

2021.
​
Name
​​
Fees
Earned ($)(1)
​​
Stock
Awards
($)(2)
​​
Option
Awards ($)(2)
​​
Total
($)
​
​
Lynn D. Bleil
​​
70,000
​​
108,333
​​
216,667
​​
395,000
​
​
Robert Essner
​​
57,500
​​
108,333
​​
216,667
​​
382,500
​
​
Michael Kelly
​​
65,000
​​
108,333
​​
216,667
​​
390,000
​
​
Margaret G. McGlynn
​​
75,000
​​
108,333
​​
216,667
​​
400,000
​
​
Michael G. Raab
​​
103,276
​​
108,333
​​
216,667
​​
428,276
​
​
Eiry W. Roberts, M.D.(3)
​​
34,856
​​
243,750
​​
243,750
​​
522,356
​
​
Glenn P. Sblendorio
​​
77,500
​​
108,333
​​
216,667
​​
402,500
​
​
Craig A. Wheeler
​​
69,990
​​
108,333
​​
216,667
​​
394,990
​
​
Burke W. Whitman
​​
65,000
​​
108,333
​​
216,667
​​
390,000
​
 (1)
Represents fees earned by non-employee director pursuant to Director Compensation Policy.
 (2)
Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, Compensation—Stock Compensation. Assumptions made in this valuation are discussed in Form 10-K, at Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations—Share-based Compensation. Subject generally to continued service, annual director grants vest at the following year’s Annual Meeting while the initial director grants vest over four years.
 (3)
Dr. Roberts was elected to the Board on June 10, 2021. The fees shown in the table above represent her pro-rated fees while the equity awards reflect the grant date values of her new hire grants.
Name
 Fees
Earned
($)(1)		 RSU
Awards
($)(2)		 Option
Awards
($)(2)		 All Other
Compensation
($)		 Total
($)		 

Lynn D. Bleil

 $17,366 $120,000 $120,122  — $257,488 

Robert Essner

  50,000  50,005  99,703  —  199,708 

Ted W. Love, M.D. 

  60,000  50,005  99,703  —  209,708 

Margaret G. McGlynn

  67,500  50,005  99,703  —  217,208 

Michael G. Raab

  67,830  50,005  99,703 $39,730(4) 257,268 

Glenn P. Sblendorio

  70,000(3) 50,005  99,703  —  219,708 

Craig A. Wheeler

  55,000  50,005  99,703  —  204,708 

Donald J. Hayden, Jr.(5)

  60,659  50,005  99,703  —  210,367 
(1)
Represents fees earned by non-employee director pursuant to Director Compensation Policy.

(2)
Represents the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, Compensation—Stock Compensation. Assumptions made in this valuation are discussed in Form 10-K, at Item 7—Management's Discussion and Analysis of Financial Condition and Results of Operations—Equity Compensation. Subject generally to continued service, annual director grant options vest one year from date of grant while the initial director grant options vest over four years.

(3)
As described more fully below, Mr. Sblendorio participates in our Non-Qualified Cash Deferral Plan and for 2018, the fees deferred were $41,625.

(4)
In 2018, the Company erroneously paid amounts to Mr. Raab that he had timely elected to defer. On account of this, Mr. Raab had additional taxes and penalties on such amounts. The amount reflected above is an additional tax gross-up payment made by the Company to Mr. Raab to make him whole for such incremental taxes and penalties.

(5)
Mr. Hayden retired from the Board on October 4, 2018.

As of December 31, 2018,2021, our non-employee directors had the following number of stock options outstanding:

​
Name
​​
Aggregate
Options
Outstanding
​​
Vested/Unvested
​
​
Name
Aggregate
Options
Outstanding		Vested/Unvested

Lynn D. Bleil

​​14,605
88,763
​​0/14,605
49,906/38,857
​

​

Robert Essner

​​125,148
199,306
​​116,236/8,912
163,195/36,111
​

Donald J. Hayden, Jr.(1)

​
Michael A. Kelly
​145,148​
50,333
​136,236/8,912​
3,555/46,778
​

Ted W. Love, M.D. 

​		125,148116,236/8,912

Margaret G. McGlynn

​​150,148
184,306
​​141,236/8,912
148,195/36,111
​

​

Michael G. Raab

​​125,782
184,306
​​116,870/8,912
148,195/36,111
​

​

Eiry W. Roberts, M.D.
​​
40,625
​​
0/40,625
​
​
Glenn P. Sblendorio

​​110,148
184,306
​​101,236/8,912
148,195/36,111
​

​

Craig A. Wheeler

​​55,148
129,306
​​34,986/8,912
93,195/36,111
​
​
Burke W. Whitman
​​
80,649
​​
34,785/45,864
​
(1)
The Company recently enacted a retirement benefit available to all directors and employees whereby eligible participants will receive 12 months of accelerated vesting of their RSUs and up to two years continued vesting of their stock options upon such participant's qualified retirement. Mr. Hayden received this benefit upon his retirement.

Non-employee directors are also eligible to defer board fees pursuant to the terms of the Cash Deferral Plan, described more fully above.

50

TABLE OF CONTENTS

As of December 31, 2018,2021, our non-employee directors had the following number of restricted stock units outstanding:

​
Name
​​
Name
Aggregate
Restricted
Stock Units
Outstanding
​

​

Lynn D. Bleil

​​9,600
24,020(1)
​

​

Robert Essner

​​3,081
10,115
​

Donald J. Hayden, Jr. 

​
Michael A. Kelly
​—​
16,743
​

Ted W. Love, M.D. 

​		3,081

Margaret G. McGlynn

​​3,081
25,301(2)
​

​

Eiry W. Roberts, M.D.
​​
22,759
​
​
Michael G. Raab

​​3,081
10,115
​

​

Glenn P. Sblendorio

​​3,081
10,115
​

​

Craig A. Wheeler

​​3,081
10,115
​
​
Burke W. Whitman
​​
16,370
​

 (1)
The number of restricted stock units outstanding includes 6,250 RSUs that vested on June 4, 2020 and 5,855 that vested on June 4, 2021 but were otherwise each deferred to June 4, 2025.
 (2)
The number of restricted stock units outstanding includes 3,081 RSUs that vested on June 27, 2019, 6,250 RSUs that vested on June 4, 2020, and 5,855 RSUs that vested on June 4, 2021 but were otherwise deferred to June 7, 2023, June 4, 2024, and June 4, 2025, respectively.
Non-Qualified Deferred Compensation for Non-Employee Directors

Our Deferral Plans cover our executive officers and members of our Board. The Company does not match participants'participants’ voluntary contributions to the deferral plan.

​
Name and Principal Position
​​
Director
Contributions
in Last
Fiscal
Year
​​
Aggregate
Earnings
in Last
Fiscal
Year
​​
Aggregate
Distributions
in Last
Fiscal
Year
​​
Aggregate
Balance at
Last
Fiscal
Year
​
​
Glenn P. Sblendorio
​​
—
​​
($110,480)(2)
​​
($146,589)
​​
$114,517(4)
​
​
Lynn D. Bleil
​​
55,505(1)
​​
(27,789)(3)
​​
—
​​
321,102(4)
​
​
Margaret G. McGlynn
​​
55,505(1)
​​
(95,560)
​​
—
​​
175,398(4)
​
 (1)
Represents the vesting date value of 6,250 shares underlying deferred RSUs that otherwise would have been delivered had the director not deferred.
 (2)
Includes $13,341 investments earnings determined by the hypothetical investments elected by Mr. Sblendorio in the last fiscal year under the Cash Deferral Plan and $123,821 in losses under the RSU Deferral Plan, represented as the difference between the value of deferred RSUs as of December 31, 2020 and their value as of their delivery; 6,250 shares and 3,081 shares that were previously deferred were delivered to Mr. Sblendorio on June 4, 2021 and June 27, 2021, respectively.
 (3)
Includes $32,216 investments earnings determined by the hypothetical investments elected by Ms. Bleil in the last fiscal year under the Cash Deferral Plan and $60,005 in losses under the RSU Deferral Plan, represented as the difference between the vesting date value of 5,855 deferred RSUs and December 31, 2020 value of 6,250 RSUs, and their value as of December 31, 2021.
 (4)
This amount includes compensation earned and deferred in prior years, which was disclosed in the Summary of Non-Employee Director Compensation Table in prior year Proxy Statements.
Name and Principal Position
 Director
Contributions
in Last Fiscal
Year(1)		 Aggregate
Earnings
in Last
Fiscal Year		 Aggregate
Distributions
in Last
Fiscal Year		 Aggregate
Balance at
Last Fiscal
Year(2)		 

Glenn P. Sblendorio

 $51,750 $(3,112)$38,259 $91,274 
51
(1)
Amount deferred is reflected in the "Fees Earned" column above in the Summary Director Compensation Table.

(2)
This column includes director fees earned and deferred in prior years.


COMPENSATION COMMITTEE REPORT

        The Compensation Committee is comprised entirely of independent directors. The Compensation Committee of our Board has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K, which appears in this Proxy Statement, with our management. Based on this review and discussion, the Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and our 2018 Annual Report on Form 10-K.

Members of the Amicus Therapeutics, Inc.

Compensation Committee:

Margaret G. McGlynn, Chair
Lynn D. Bleil
Craig A. Wheeler

Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act that might incorporate this proxy statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be "soliciting material" or "filed" with the SEC and shall not be deemed to be incorporated by reference into any such filing.


TABLE OF CONTENTS

DELINQUENT SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

REPORTS

Section 16(a) of the Securities Exchange Act requires our directors and certain executive officers (“Section 16 Officers”) to file with the SEC specified forms detailing both ownership of and persons who own more than 10%changes to each individuals’ holdings of a registeredany class of our equity securities of the Company. As a practical matter, the Company assists its directors and Section 16 Officers with their compliance by monitoring these transactions and completing and filing these forms on their behalf. Following a review of the forms filed in the 2021 fiscal year and internal written correspondence regarding the same, we believe that all such reports were filed in a timely manner except for one Form 4 for Mr. Crowley, representing a sale of shares pursuant to file reportsa 10b5-1 plan, one Form 4 for Mr. Campbell, representing the exercise and sale of holdingsoptions pursuant to a 10b5-1 plan, one Form 4 for Ms. Prout representing a grant of RSUs, and transactions in ourtwo for Mr. Whitman, each representing purchases of Company Common Stock with the SEC. To our knowledge, based solely on our review of copies of the reports received by uspursuant to a 10b5-1 Plan. Each Form 4 was late due to administrative error and written representations by these individuals that no other reports were required, all such Section 16(a) filing requirements were met.

subsequently filed.

52

TABLE OF CONTENTS


SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information with respect to the beneficial ownership of our Common Stock as of April 8, 201914, 2022 for (a) the executive officers named in the Summary Compensation Table contained in this Proxy Statement, (b) each of our directors and director nominees, (c) all of our current directors and executive officers as a group and (d) each stockholder known by us to own beneficially more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.

We deem shares of Common Stock that may be acquired by an individual or group within 60 days of April 8, 201914, 2022 pursuant to the exercise of options or warrants to be outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of Common Stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 230,384,257280,152,758 shares of Common Stock outstanding on April 8, 2019.

14, 2022.

Unless otherwise indicated below, the address of each of the individuals named below is: c/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, NJ 08512.3675 Market Street, Philadelphia, Pennsylvania 19104.
​
Name and Address of Beneficial Owner
​​
Number of
Shares
Beneficially
Owned
​​
Percentage
Of Shares
Beneficially
Owned
​
​
5% Stockholders
​​
​​
​
​
Entities affiliated with Redmile Group, LLC(1)
 One Letterman Drive, Bldg. D, Suite D3-300
 San Francisco, CA 94129
​​
28,405,042
​​
9.99%
​
​
Entities affiliated with Perceptive Advisors LLC(2)
 51 Astor Place, 10th Floor
 New York, NY 10003
​​
27,356,043
​​
​9.8%
​
​
Entities affiliated with Wellington Group Holdings LLP (3)
 280 Congress Street
 Boston, MA 02210
​​
26,648,674
​​
​9.5%
​
​
Entities affiliated with The Vanguard Group(4)
 100 Vanguard Blvd.
 Malvern, PA 19355
​​
25,645,184
​​
​9.2%
​
​
Entities affiliated with BlackRock, Inc.(5)
 55 East 52nd Street
 New York, NY 10055
​​
19,810,348
​​
​7.1%
​
​
Entities affiliated with Avoro Capital Advisors LLC (6)
 110 Greene Street, Suite 800
 New York, NY 10012
​​
18,500,000
​​
​6.6%
​
​
Entities affiliated with JPMorgan Chase & Co(7)
 383 Madison Avenue
 New York, NY 10179
​​
15,338,677
​​
​5.5%
​
53

TABLE OF CONTENTS

​
Named Executive Officers and Directors
​​
Number of
Shares
Beneficially
Owned
​​
Percentage
Of Shares
Beneficially
Owned
​
​
John F. Crowley(8)
​​
​1,959,508
​​
*
​
​
Daphne Quimi(9)
​​
​613,977
​​
*
​
​
Bradley L. Campbell(10)
​​
​1,303,060
​​
*
​
​
Ellen S. Rosenberg(11)
​​
​522,933
​​
*
​
​
David M. Clark(12)
​​
​306,045
​​
*
​
​
Hung Do(13)
​​
​595,120
​​
*
​
​
Glenn P. Sblendorio(14)
​​
​228,354
​​
*
​
​
Michael G. Raab(15)
​​
​206,055
​​
*
​
​
Margaret G. McGlynn(16)
​​
​185,120
​​
*
​
​
Robert Essner(17)
​​
​230,421
​​
*
​
​
Craig A. Wheeler(18)
​​
​160,421
​​
*
​
​
Lynn D. Bleil(19)
​​
​125,446
​​
*
​
​
Burke W. Whitman(20)
​​
​134,698
​​
*
​
​
Michael A. Kelly (21)
​​
​53,766
​​
*
​
​
Eiry W. Roberts, M.D. (22)
​​
15,845
​​
*
​
​
All directors and executive officers as a group (15 persons)
​​
​6,640,769
​​
​2.4%
​
Name and Address of Beneficial Owner
 Number of
Shares
Beneficially
Owned		 Percentage
Of Shares
Beneficially
Owned		 

5% Stockholders

       

Entities affiliated with Perceptive Advisors LLC(1)

  20,724,424  9.0%

499 Park Avenue, 25th Floor

       

New York, NY 10022

       

Entities affiliated with FMR LLC(2)

  18,872,609  8.2%

245 Summer Street

       

Boston, MA 02210

       

Entities affiliated with Vanguard Group(3)

  17,171,997  7.5%

100 Vanguard Blvd.

       

Malvern, PA 19355

       

Entities affiliated with Black Rock Inc.(4)

  16,521,820  7.2%

55 East 52nd Street

       

New York, NY 10055

       
 *
Represents beneficial ownership of less than one percent of our outstanding Common Stock.
 (1)
This information is provided solely in reliance upon information included in a Schedule 13G/A filed with the SEC on February 14, 2022 by Redmile Group, LLC (“Redmile”). As of December 31, 2021, Redmile reported shared voting and dispositive power of 28,405,042 shares of common stock. Redmile’s reported beneficial ownership is comprised of 22,716,086 shares of common stock and 8,439,705 shares of common stock issuable upon the exercise of certain warrants; such warrants contain a “beneficial ownership blocker” whereby their exercise is prohibited if the holder’s beneficial ownership would exceed 9.99% of the total common stock of the Company outstanding.
 (2)
This information is provided solely in reliance upon information included in a Schedule 13G filed with the SEC on March 2, 2022 by Perceptive Advisors LLC (“Perceptive”). As of February 23, 2022, Perceptive reported shared voting and dispositive power of 27,356,043 shares of Common Stock.
 (3)
This information is provided solely in reliance upon information included in a Schedule 13G filed with the SEC on February 14, 2022 by Wellington Group Holdings LLP (“Wellington”). As of December 31, 2021, Wellington reported shared voting power of 22,901,509 shares of common stock and shared dispositive power of 26,648,674 shares of Common Stock.
 (4)
This information is provided solely in reliance upon information included in a Schedule 13G filed with the SEC on February 9, 2022 by The Vanguard Group (“Vanguard”). As of December 31, 2021, Vanguard reported shared voting power of 485,315 shares of common stock, sole dispositive power of 24,946,714 shares of common stock and shared dispositive power of 698,470 shares of common stock.
 (5)
This information is provided solely in reliance upon information included in a Schedule 13G filed with the SEC on February 2, 2022 by BlackRock, Inc. (“BlackRock”). As of December 31, 2021, BlackRock reported sole voting power of 19,460,232 shares of common stock and sole dispositive power of 19,810,348 shares of common stock.
 (6)
This information is provided solely in reliance upon information included in a Schedule 13G filed with the SEC on February 11, 2022 by Avoro Capital Advisors LLC (“Avoro”). As of December 31, 2021, Avoro reported sole voting power of 18,500,000 shares of common stock and sole dispositive power of 18,500,000 shares of common stock.
 (7)
This information is provided solely in reliance upon information included in a Schedule 13G filed with the SEC on January 19, 2022 by JPMorgan Chase & Co. (“JPM”). As of December 31, 2021, JPM reported sole voting power of 13,212,468 shares of common stock, sole dispositive power of 15,316,482 shares of common stock and shared dispositive power of 2,137 shares of common stock.
 (8)
Consists of 501,852 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 1,207,692 shares issuable upon the exercise of stock options within 60 days of April 14, 2022 in a trust f/b/o Mr. Crowley’s children, 185,069 shares held directly by Mr. Crowley and 64,895 shares held by a trust f/b/o Mr. Crowley. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (9)
Consists of 398,010 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022 and 215,967 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (10)
Consists of 990,557 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022 and 312,503 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (11)
Consists of 394,260 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 113,673 shares held directly by Ms. Rosenberg and 15,000 shares held by her spouse. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
54


TABLE OF CONTENTS

 (12)
Consists of 214,447 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022 and 91,598 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (13)
Consists of 233,175 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022 and 361,945 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (14)
Consists of 169,306 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 10,115 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 48,933 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (15)
Consists of 169,306 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 10,115 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 26,634 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (16)
Consists of 169,306 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022 and 15,814 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (17)
Consists of 199,306 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 10,115 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 21,000 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (18)
Consists of 129,306 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 10,115 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 21,000 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (19)
Consists of 87,841 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 1,000 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 36,605 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (20)
Consists of 74,136 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 11,503 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 49,059 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (21)
Consists of 41,442 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022, 10,115 restricted stock units scheduled to vest within 60 days of April 14, 2022 and 2,209 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 13, 2022 and both unvested and deferred restricted stock units as of June 14, 2022.
 (22)
Dr. Roberts joined the Board on June 10, 2021 and received a new director grant of 22,759 restricted stock units and 40,625 stock options; 25% of this grant will vest on June 10, 2022, subject to Dr. Roberts continued service with the Company through the vesting date. The number displayed above consists of 10,156 shares issuable upon the exercise of stock options exercisable within 60 days of April 14, 2022 and 5,689 restricted stock units scheduled to vest within 60 days of April 14, 2022 and excludes both unvested and deferred restricted stock units as of June 14, 2022.
Name of Beneficial Owner
 Number of
Shares
Beneficially
Owned		 Percentage
Of Shares
Beneficially
Owned		 

Named Executive Officers and Directors

       

John F. Crowley(5)

  1,746,454  * 

William D. Baird III(6)

  763,445  * 

Bradley L. Campbell(7)

  1,052,495  * 

Jay Barth, M.D.(8)

  395,985  * 

Ellen S. Rosenberg(9)

  211,077  * 

Glenn P. Sblendorio(10)

  118,983  * 

Michael G. Raab(11)

  122,684  * 

Margaret G. McGlynn(12)

  157,050  * 

Ted W. Love, M.D.(13)

  264,050  * 

Robert Essner(14)

  122,050  * 

Craig A. Wheeler(15)

  44,550  * 

Lynn D. Bleil

  —  * 

All directors and executive officers as a group (16 persons)(16)

  5,899,496  2.5%
55
*
Represents beneficial ownership of less than one percent of our outstanding Common Stock.

(1)
This information is provided solely in reliance upon information included in a Schedule 13G/A filed with the SEC on February 14, 2019 by Perceptive Advisors LLC ("Perceptive"). As of December 31, 2018, Perceptive reported shared voting and dispositive power of 20,724,424 shares of common stock.

(2)
This information is provided solely in reliance upon information included in a Schedule 13G/A filed with the SEC on February 13, 2019 by FMR LLC ("FMR"). As of December 31, 2018, FMR reported sole voting power of 918,465 shares of common stock and sole dispositive power of 18,872,609 shares of common stock.

(3)
This information is provided solely in reliance upon information included in a Schedule 13G/A filed with the SEC on February 11, 2019 by Vanguard Group ("Vanguard"). As of December 31, 2018, Vanguard reported sole voting power of 393,784 shares of common stock, shared voting power of 24,662 shares of common stock, sole dispositive power of 16,773,389 shares of common stock and shared dispositive power of 398,608 shares of common stock.

(4)
This information is provided solely in reliance upon information included in a Schedule 13G/A filed with the SEC on February 4, 2019 by Blackrock Inc. ("Blackrock"). As of December 31, 2018, Blackrock reported sole voting power of 16,044,033 shares of common stock and sole dispositive power of 16,521,820 shares of common stock.


(5)
Consists of 1,587,643 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019, 93,916 shares held directly by Mr. Crowley and 64,895 shares held by a trust f/b/o Mr. Crowley. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and both unvested and deferred restricted stock units as of June 7, 2019.

(6)
Consists of 687,182 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 76,263 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and both unvested and deferred restricted stock units as of June 7, 2019.

(7)
Consists of 997,155 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 55,340 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and both unvested and deferred restricted stock units as of June 7, 2019.

TABLE OF CONTENTS

(8)
Consists of 373,617 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019, 22,348 shares held directly by Dr. Barth and 20 shares held by his daughter. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and both unvested and deferred restricted stock units as of June 7, 2019.

(9)
Consists of 179,634 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 16,443 shares held directly by Ms. Rosenberg and 15,000 shares held by her spouse. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(10)
Consists of 101,236 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 17,747 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(11)
Consists of 116,870 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 5,814 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(12)
Consists of 141,236 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 15,814 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(13)
Consists of 116,236 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 147,814 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(14)
Consists of 116,236 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 5,814 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(15)
Consists of 38,736 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 5,814 shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and unvested restricted stock units as of June 7, 2019.

(16)
Consists of 4,999,039 shares issuable upon the exercise of stock options exercisable within 60 days of April 8, 2019 and 900,457 total shares held of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after June 7, 2019 and both unvested and deferred restricted stock units as of June 7, 2019.


POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS

Our Board maintains a formal written policy for the review of any transaction, arrangement or relationship in which Amicus is a participant and one of our executive officers, directors, director nominees, 5% stockholders (or their immediate family members), each of whom we refer to as a "related“related party,"” has a direct or indirect interest. If a related party proposes to enter into such a transaction, arrangement or relationship, which we refer to as a "related“related party transaction,"” the related party must report the proposed transaction to our Chief Financial Officer or Senior Vice President, Finance.Officer. The proposed related party transaction must be reviewed and, if deemed appropriate, approved by the Board'sBoard’s Audit and Compliance Committee prior to entry into such transaction, or ratified as soon as reasonably practicable after discovery that approval is required.

The Audit and Compliance Committee may approve or ratify the transaction only if the Audit and Compliance Committee determines that, under all of the circumstances, the transaction is not inconsistent with the Company'sCompany’s best interests and does not violate its Code of Business Conduct and Ethics. Any related party transactions that are ongoing in nature will be reviewed annually. The Audit and Compliance Committee will review and consider such information regarding the related party transaction as it deems appropriate. In the last fiscal year, the Company did not enter into any transactions disclosable pursuant to Item 404(a) of Regulation S-K.

56

TABLE OF CONTENTS


PROPOSAL NO. 2—APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN

Overview

In this proposal, we are requesting stockholders approve the amendment and restatement of the Amicus Amended and Restated 2007 Equity Incentive Plan (as amended, the "2007 Plan"“2007 Plan”) to increase the number of shares of common stockCommon Stock available for issuance under the 2007 Plan by 7,000,0006,000,000 shares. The board of directorsBoard approved the amendment and restatement of the 2007 Plan on April 18, 201914, 2022 subject to and effective upon stockholder approval. The 2007 Plan, as amended and restated if this proposal is approved, is described in more detail below. If this proposal is not approved by our stockholders, the amendment and restatement of the 2007 Plan will not become effective, but the 2007 Plan will remain in effect in accordance with its present terms.

Recommendation:

The Board of Directors recommends the vote "FOR"“FOR” the approval of the Amended and Restated 2007 Equity Incentive Plan.

We are asking our stockholders to approve the 2007 Plan. The Compensation and Leadership Development Committee approved the 2007 Plan, subject to approval of the Board and the stockholders, and the Board approved the 2007 Plan, subject to approval of the stockholders.

The 2007 Plan is substantially similar to the existing version of the Amended and Restated 2007 Equity Incentive Plan (the "Existing Plan"“Existing Plan”). last approved by stockholders at the 2021 annual meeting. The only change on which our stockholders will be voting on is an increase of 7,000,0006,000,000 shares of Common Stock available for issuance as equity incentive awards, including for the issuance of full-value equity awards.

        In addition to the above described change, which the stockholders will be voting on, the Board has made an amendment to the Existing Plan, since the last time the plan was presented for stockholder action. On December 21, 2018, the Board revised the Existing Plan to provide all eligible participants with the Equity Retirement Benefits upon a termination of such participant's employment after satisfaction of the Retirement Criteria (or upon the termination of a participant's employment due to death or disability) (the "Retirement Amendment"). As this change did not require stockholder approval, if our stockholders do not approve the 2007 Plan, the Existing Plan, including the Retirement Amendment, will remain in effect.

Background and Reason for the Proposal

Equity compensation has historically been a key element of our compensation program. The ability to grant stock options and restricted stock units has enabled us to attract and retain highly talented employees. Additionally, equity awards have also allowed us to link incentive rewards to Company performance, to encourage employee ownership in our stock and to align the interests of employees with those of our stockholders. Equity based compensation is a common form of compensation in our industry. Without the ability to grant stock options and restricted stock units, we would be at a disadvantage against our competitors for recruiting and retaining key talent. We expect that we will be required to grow our employee population over the coming years to meet the requirements of a global commercial enterprise. If we did not expand the pool of shares available, we would also be unable to offer competitive total compensation packages necessary to attract, retain and motivate individuals critical to our future success.

The purpose of the 2007 Plan is to encourage ownership of our Common Stock by employees and directors of the Company and to provide additional incentive for them to promote the success of the Company'sCompany’s business through the grant of awards of shares of the Company'sCompany’s Common Stock. As of April 8, 2019,March 24, 2022, there were 3,579,9039,889,511 shares remaining for issuance under the Existing Plan. We are therefore seeking approval of the 2007 Plan in order to make an additional 7,000,0006,000,000 shares of our Common Stock available for issuance as Awards under the 2007 Plan.


The Board believes that the 2007 Plan will serve a critical role in attracting and retaining officers and employees and in motivating these individuals to strive to meet our goals and that, without the additional shares which may be offered under the 2007 Plan, we would be at a competitive disadvantage to our peers. The Board further believes that the increased number of shares that would be available for issuance under the 2007 Plan would provide the Compensation and Leadership Development Committee with the flexibility to make the types and amounts of awards it believes are necessary to attract and retain qualified individuals. As our employee base continues to grow, the Board believes that it is in the best interests of the Company and its stockholders to make reasonable increases to the number of shares available for issuance under the 2007 Plan, based on year-over-year forecasts, to ensure that the Company can keep pace with such growth and continue attracting the best possible talent as the Company completes its transition into a fully integrated, global commercial company.

57

TABLE OF CONTENTS

    Considerations Relating to the Additional Shares Under the 2007 Plan

In recommending the 2007 Plan to the Board for approval, the Compensation and Leadership Development Committee reviewed analyses prepared by Pay Governance, the committee'scommittee’s independent compensation consultant. Considerations taken into account by the compensation committeeCompensation and Leadership Development Committee included the following:

•

Competitiveness

The market for high caliber, experienced talent in our industry and in our geographic location is extremely competitive. We compete not only with other similar sized and larger biotechnology companies, but we also compete for talent directly with much larger pharmaceutical companies that have significantly greater resources and generous compensation practices. Our ability to grant equity awards is critical to our ability to be competitive and to attract, retain and motivate the talent we need to best position our Company for success.

•

Limited duration of current shares available

If we do not increase the shares available for issuance under the Existing Plan, we expect the number of available shares under the Existing Plan to be substantially depleted by the midpoint of 2020January 2023 and that we would then be unable to continue to grant broad-based equity awards. If our stockholders approve the amendment and restatement, we estimate that the shares reserved for issuance under the 2007 Plan, as amended and restated, would be sufficient for up to 18-2412-18 months of awards based on projected increase in overall number of employees, projected employee turnover and historical grant practices.

•

Employee growth/turnover

The number of full-time employees increased from 325483 at December 31, 20172020 to 508496 at December 31, 2018. We are projecting a 38% increase in 20192021. For 2022 and a 15% increase in 2020. In addition,2023, we are projecting hiring patterns and employee turnover that is consistentin-line with the turnover rate ofour peer group and the biotechnology industry generally. In 2018,2021, we had a total of 718 new hires and promotions involving positions at the vice president level or higher. We expect to increase our hiring at all levels, including senior management, in 2019 and 2020. Accordingly, we anticipate an increase in new hire equity grants in 20192022 and 2020,2023, which are traditionally 75% to 225% greater in value than annual grants, with those in excess of such range requiring Compensation Committee review.grants. As the overall number of employees continues to increase,generally increases, we are planning for a resulting increase in annual equity grants as well.

•

Broad-based equity programs

We believe broad-based equity programs are important to our ability to attract, retain and motivate employees throughout the Company and align employee interests with those of our stockholders. Historically, less than 30% of the total equity awards granted under the Existing Plan have gone to our named executive officers.


    Eligible Participants/Administration

The 2007 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Code, to employees, and non-qualifiedrestricted stock options andunits, restricted stock, other stock awards and Performance Awards to our employees, directors and directors. consultants, as well as the employees, directors and consultants of our affiliates (although incentive stock options may only be granted to our employees and the employees of our subsidiary corporations).
As of April 8, 2019,March 24, 2022, approximately 534479 employees and sevennine directors (not including Mr. Crowley and Mr. Campbell, who are included in the number of employees) were eligible to participate in the 2007 Plan.
The 2007 Plan will be administered by the Compensation and Leadership Development Committee of our Board, provided that the Board may itself exercise any of the powers and responsibilities assigned to the Compensation and Leadership Development Committee under the 2007 Plan.

Subject to the provisions of the 2007 Plan, the Compensation and Leadership Development Committee has been granted the discretion to determine when awards are made, which employeesservice providers receive awards, the form of an award, the number of shares subject to each award, and all other relevant terms of the award, including vesting and acceleration of vesting, if any. The Compensation and Leadership Development Committee also has been granted broad discretion to construe and interpret the 2007 Plan and adopt rules and regulations thereunder. The Compensation and Leadership Development Committee also may delegate to an executive officer or officers the authority to grant awards under the 2007 Plan to non-officer employees and to consultants, subject to such guidelines as the Compensation and Leadership Development Committee establishes.

58

TABLE OF CONTENTS

    Number of Shares Authorized Under the 2007 Plan

        The

Under the Existing Plan, the number of authorized shares of our Common Stock that would be available for issuance after the original effective date underof the 2007 Plan is 27,058,70343,558,703 shares, subject to adjustment to avoid dilution or enlargement of intended benefits in the event of certain significant corporate events. If the amendment and restatement of the 2007 Plan is approved by the stockholders, this will increase by 6,000,000 shares to 49,558,703 shares. No more than 17,058,70339,558,703 of the shares of Common Stock are available for issuance under the 2007 Plan after the original effective date underof the 2007 Plan (upon approval of the requested 6,000,000 share increase) as awards of restricted stock, restricted stock units, performance restricted stock units, stock grants and any other similar awards whose intrinsic value is not solely dependent on appreciation in the price of our Common Stock after the date of grant. Each of the above numbers is exclusive of any grants made under the 2007 Plan prior to the effective date of the approval of the amendment by the Board. If any shares of Common Stock covered by an award granted under the 2007 Plan, or to which such an award relates, are forfeited, or if an award has expired, terminated or has been canceled for any reason whatsoever (other than by reason of exercise or vesting), then the shares covered by such award shall again be, or shall become, shares with respect to which awards may be granted under the 2007 Plan. Shares of Common Stock underlying awards under the 2007 Plan that have been used to satisfy withholding obligations or pay an exercise price will not again be available for a future award.

Subject to such adjustments as provided below, no employee will, in a single calendar year, be granted awards under the 2007 Plan with respect to more than 5,000,000 shares of Common Stock.

Summary of the 2007 Plan

This section summarizes certain key features of the 2007 Plan, almost all of which remain unchanged. The only change besidesremains unchanged from prior stockholder approval, except for the requested increase in the number of authorized shares of common stock, subject to stockholder approval, was the inclusion of a retirement benefit as summarized above.shares. The summary is qualified in its entirety by reference to the complete text of the 2007 Plan. Stockholders are urged to read the actual text of the stated 2007 Plan in its entirety which is set forth inExhibit A to this proxy statement.

Term of the 2007 Plan

No award may be granted under the 2007 Plan after April 2026, which is the 10th anniversary of the date on which the term of the 2007 Plan was approved by the Board.last extended. Awards granted prior to the expiration of the 2007 Plan shall not expire solely by reason of the termination of the plan.

        The closing price of a share of our Common Stock on April 8, 2019 was $14.30.


    Terms and Conditions of Options

Options granted under the 2007 Plan shall be, as determined by the Compensation and Leadership Development Committee, non-qualified or incentive stock options for federal income tax purposes, and shall be subject to the foregoing and the following terms and conditions and to such other terms and conditions, not inconsistent therewith, as determined by the Compensation and Leadership Development Committee:

Option Exercise Price.Price. The price at which shares of Common Stock may be acquired under each non-qualified stock option and incentive stock option shall not be less than 100% of the fair market value of a share on the date such option is granted; provided, however, that the exercise price of any incentive stock option granted to any participant who, at the time of grant, owns more than 10% of the total combined voting power of all classes of the Company'sCompany’s stock (a "Ten“Ten Percent Holder"Holder”) shall be at least 110% of the fair market value of the stock on the date of such grant.

Exercisability        Exercisability.. Options granted under the 2007 Plan shall be exercisable at such time and upon such terms and conditions as may be determined by the Compensation and Leadership Development Committee; provided, however, that in no event shall an option be exercisable more than ten years after its grant date or five years after the date it is granted to a Ten Percent Holder. An option may be exercised by a participant providing written notice specifying the number of shares of Common Stock with respect to which the option is then being exercised. The purchase price for the shares as to which an option is exercised shall be paid to the Company pursuant to one or more of the following methods:
(i)
cash or check payable to the Company;
(ii)
shares of Common Stock having a fair market value equal to the aggregate option exercise price for the shares being purchased, and only with the Compensation and Leadership Development Committee’s approval; or
(iii)
if there is a public market for the shares at such time, through and under the terms and conditions of any formal cashless exercise program authorized by the Company entailing the sale of Common Stock subject to any option in a brokered transaction (other than to the Company).
59

TABLE OF CONTENTS

    (i)
    cash or check payable to the Company;

    (ii)
    shares of Common Stock having a fair market value equal to the aggregate option exercise price for the shares being purchased, and only with the Compensation Committee's approval; or

    (iii)
    if there is a public market for the shares at such time, through and under the terms and conditions of any formal cashless exercise program authorized by the Company entailing the sale of Common Stock subject to any option in a brokered transaction (other than to the Company).

No participant shall be deemed for any purpose to be a stockholder of the Company with respect to any shares of Common Stock issuable pursuant to an option until the participant has given written notice of exercise of the option, and has paid in full for such shares.

    shares and has made arrangements to satisfy any tax withholding due in connection with such exercise.

Terms and Conditions of Restricted Stock

Shares of restricted stock may be issued under the 2007 Plan for such consideration, in cash, other property or services, or any combination thereof, as determined by the Compensation and Leadership Development Committee. During the period of time in which the shares of restricted stock are subject to a risk of forfeiture (the "Restriction Period"“Restriction Period”), such shares shall be subject to limitations on transferability and a risk of forfeiture arising on the basis of such conditions related to the performance of services, Company performance or otherwise as the Compensation and Leadership Development Committee may determine and set forth in an award agreement. Any such risk of forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Compensation and Leadership Development Committee on such basis as it deems appropriate. Except as otherwise provided in the 2007 Plan or an applicable award agreement, at all times prior to the lapse of the Restriction Period, the participant shall have all of the rights of a stockholder of the Company, including the right to vote the shares of restricted stock.

Terms and Conditions of Restricted Stock Units

Each restricted stock unit (“RSU”) shall entitle the recipient to a share of Common Stock at the close of a Restriction Period as established by the Compensation and Leadership Development Committee and subject to a risk of forfeiture arising on the basis of such conditions related to the performance of services, Company performance or otherwise as the Compensation and Leadership Development Committee may determine and set forth in an award agreement. Any such risk of


forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Compensation and Leadership Development Committee on such basis as it deems appropriate. A participant holding restricted stock unitsRSUs shall not be deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common Stock subject to such restricted stock unitsRSUs except to the extent that the Restriction Period with respect to such restricted stock unitsRSUs shall have closed and a certificate shall have been issued for such shares of Common Stock.

Terms and Conditions of Stock Grants

Stock grants are unrestricted shares of our Common Stock. Stock grants may be issued under the 2007 Plan for such consideration, in cash or other property or services, or any combination thereof, as determined by the Compensation and Leadership Development Committee. Stock grants may be awarded in such circumstances as the Compensation and Leadership Development Committee deems appropriate, including in recognition of significant contributions to the success of the Company or in lieu of compensation otherwise already due.

Terms and Conditions of Performance Awards

The Compensation and Leadership Development Committee may grant Performance Awards ("PRSUs") under the 2007 Plan, which may be denominated as a number of shares of Common Stock or a specified number of other awards (or a combination of both). Generally, PRSUsPerformance Awards require satisfaction of pre-established Performance Goals (as defined in the following sentence). The potential performance metrics include: cash flow; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based compensation, earnings before interest, taxes, depreciation and amortization, and net earnings); earnings per share; growth in earnings or earnings per share; stock price; return on equity or average stockholder equity; total stockholder return or growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in revenue or return on sales; income or net income; operating income, net operating income or net operating income after tax; operating profit or net operating profit; operating margin; return on operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget comparisons; growth in stockholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring goals; development and implementation of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance the Company'sCompany’s revenue or profitability or enhance its customer base; and/or merger and acquisitions (each, a "Performance Goal"“Performance Goal” and collectively the "Performance Goals"“Performance Goals”). Such Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the individual grantee or any subsidiary, division, department or function within the Company and may be measured on an absolute or relative basis.
60

TABLE OF CONTENTS

The Compensation and Leadership Development Committee may provide, at the time a Performance Goal is established, that adjustments will be made to the applicable Performance Goal to take into account, in the manner specified by the Compensation and Leadership Development Committee, the impact of one or more of the following:

    •
gain or loss from all or certain claims and/or litigation and insurance recoveries,

•
the impairment of tangible or intangible assets,

•
stock-based compensation expense,

    •
    extraordinary, unusual or infrequently occurring events reported in the Company'sCompany’s public filings,

    •
restructuring activities reported in the Company'sCompany’s public filings,

•
investments, dispositions or acquisitions,

•
loss from the disposal of certain assets,

•
gain or loss from the early extinguishment, redemption, or repurchase of debt,

•
cash or non-cash charges related to site closings,

•
changes in accounting principles, or any other item, event or circumstance that would not cause an award to fail to constitute "qualified“qualified performance-based compensation"compensation” under Section 162(m) of the Code, to the extent such exemption is available.

Transferability

Unless otherwise determined by the Compensation and Leadership Development Committee, an award (other than a stock award)grant) shall not be transferable or assignable by a participant otherwise than by will or by the laws of descent and distribution. However, the applicable award agreement or the Compensation and Leadership Development Committee may provide that a nonstatutorynon-qualified statutory stock option, shares of restricted stock or restricted stock unitsRSUs may be transferred by the participant to a family member, so long as such transfer is without payment of any consideration.

Death, Disability or Retirement

The participants in the 2007 Plan are generally be eligible for the retirement benefits set forth below, if such participant meets the following criteria at the time of such participant'sparticipant’s termination of service:

    •
The participant must have at least 5 years of continuous service;

•
The participant must be at least 55 years of age; and

•
The sum of the participant'sparticipant’s age and years of service with the Company must equal or exceed 67 years.

        Notwithstanding the above, if the participant's service is terminated by the Company for cause, then the following

The retirement benefits would be forfeited.

    •
    (collectively, the “Equity Retirement Benefits”) are:
Options: any unvested Options shall continue to vest until the second anniversary of the participant'sparticipant’s separation, and all vested Options (including those eligible to vest pursuant to the preceding clause) shall remain exercisable until the earlier of the (i) the 4th anniversary of the date of such separation, andor (ii) the original expiration date of the term of the Option; any options not exercised in such period shall be forfeited with no further compensation due to the participant.

•
RSUs:
RSUs and Restricted Stock: any unvested RSUs or restricted stock that would vest up to the second anniversary of the participant'sparticipant’s separation, shall have accelerated vesting, and the shares will be delivered to the participant upon separation; any unvested RSUs or restricted stock scheduled to vest beyond the two yeartwo-year date shall be forfeited with no further compensation.


•
PRSUs: a prorated portion of the participant'sparticipant’s PRSUs (based on the participant'sparticipant’s period of service with the Company during the performance period) would remain eligible to vest and become delivered based upon satisfactionactual performance through the end of the goals applicable to such PRSUs (collectively, the "Equity Retirement Benefits").

performance period.

The same Equity Retirement Benefits described above afforded upon a participant's retirement after satisfying the Retirement Criteria wouldwill also be offeredprovided to any participant upon a termination of service due to such participant'sparticipant’s death or disability.
61

TABLE OF CONTENTS


    Change in Control

Subject to the applicable provisions of the award agreement, in the event of a change of control of the Company after the effective date of the 2007 Plan, the Compensation and Leadership Development Committee generally shall have the discretion to provide for any or all of the following:

    •
the acceleration, in whole or in part, of any or all outstanding options that are not exercisable in full at the time of the change of control;

•
the lapse or termination of the risk of forfeiture with respect to outstanding awards of restricted stock and restricted stock units;

•
RSUs;
the assumption of outstanding options or restricted stock units,RSUs, or the substitution of outstanding options or restricted stock unitsRSUs with equivalent options or restricted stock units,RSUs, as the case may be, by the acquiring or succeeding corporation or entity; or

•
the termination of all options and restricted stock unitsRSUs (other than those assumed or substituted for), which termination may or may not be in exchange for some payment or other consideration, as determined in the sole discretion of the Compensation and Leadership Development Committee.

Adjustments

In the event of any change in the outstanding shares by reason of merger, consolidation, sale of all or substantially all of the property of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or other distribution with respect to such outstanding shares, an appropriate and proportionate adjustment will be made in (i) the maximum number and kinds of shares that may be issued under the 2007 Plan, (ii) the numbers and kinds of shares or other securities subject to the then outstanding awards; (iii) the exercise price for each share or other unit of any other securities subject to then outstanding options; and (iv) the repurchase price of each share of restricted stock then subject to a risk of forfeiture in the form of a Company repurchase right.

    In those cases, performance goals applicable to outstanding awards will also be adjusted as necessary or appropriate.

Termination ofor Amendments to the 2007 Plan

The Board may at any time terminate or make such amendments or modifications of the 2007 Plan as it shall deem advisable; provided, however, that no such amendment or modification shall be made without the consent of a participant if such change would:

    •
reduce the number of shares subject to an award, increase the purchase price applicable to shares subject to such award or materially adversely affect the provisions applicable to such award that relate to the vesting or exercisability of such award or the shares subject thereto;

•
result in an incentive stock option no longer being treated as such within the meaning of Section 422 of the Code; or

•
not apply to all other awards outstanding on the date of such amendment or modification.

In addition, stockholder approval may be required for “material amendments” to the 2007 Plan under Nasdaq Listing Rules. Examples of amendments that may be deemed “material” for this purpose include amendments that increase the number of shares of Common Stock available for issuance under the 2007 Plan (other than adjustments to reflect mergers, recapitilizations, stock splits or similar events or transactions), that expand the types of awards available or the persons eligible to receive awards under the 2007 Plan, or that extend the term of the 2007 Plan.
No Repricing of Stock Options Without Stockholder Approval
Without the approval of stockholders, the Compensation and Leadership Development Committee may not, directly or indirectly, reduce the exercise price of options outstanding under the 2007 Plan (other than for adjustments to reflect mergers, recapitilizations, stock splits or other similar events or transactions).
Federal Income Tax Consequences Relating to Awards Under the 2007 Plan

The current United States federal income tax treatment of awards under the 2007 Plan is generally described below. This description of tax consequences is not a complete description. There may be different income tax consequences under certain circumstances, and there may be gift and estate tax consequences. Local, state and other taxing authorities may also tax awards under the plan. Tax laws are subject to change.
62

TABLE OF CONTENTS


    Incentive Stock Options

There generally are no federal income tax consequences to a participant or to the Company upon the grant of an incentive stock option. A participant will not recognize income for purposes of the regular federal income tax upon the exercise of an incentive stock option. However, for purposes of the alternative minimum tax, in the year in which a participant exercises an incentive stock option, the amount by which the fair market value of the shares acquired upon exercise exceeds the exercise price will be included in a participant'sparticipant’s alternative minimum taxable income.

A participant will recognize income when he or she sells stock acquired upon exercise of an incentive stock option. If a participant disposes of the shares acquired upon exercise of an incentive stock option after two years from the date the option was granted and one year from the date the shares were transferred upon the exercise of the option, a participant will recognize long-term capital gain or loss in the amount of the difference between the amount realized on the sale and the exercise price. The Company will not be entitled to any corresponding tax deduction.

If a participant disposes of shares acquired upon the exercise of an incentive stock option before satisfying both holding period requirements (a "disqualifying disposition"“disqualifying disposition”), a participant'sparticipant’s gain recognized on the disposition will be taxed as ordinary income to the extent of the difference between the fair market value of the shares on the date of exercise (or the amount realized on the disposition, if less) and the exercise price. The Company will generally be entitled to a deduction in that amount. The gain, if any, in excess of the amount recognized as ordinary income will be long-term or short-term capital gain, depending upon the length of time the participant held the shares before the disposition.

Nonqualified Stock Options

There are generally no federal income tax consequences to a participant or to the Company upon the grant of a nonqualified stock option. Upon the exercise of a nonqualified stock option, a participant will recognize ordinary income in an amount equal to the excess of the fair market value of the shares at the time of exercise over the aggregate exercise price paid. The Company generally will be entitled to a corresponding federal income tax deduction. The participant will have a tax basis in the shares equal to the exercise price plus the amount of income recognized at the time of exercise.

When a participant sells shares of stock acquired through the exercise of a nonqualified stock option, the participant will have a capital gain or loss in an amount equal to the difference between the amount realized on the sale and the tax basis in the shares. The capital gain tax rate will depend on a number of factors, including the length of time the participant held the shares prior to selling them.

Restricted Stock

A participant will generally not recognize federal taxable income when he or she receives a grant of restricted stock, and the Company will not be entitled to a deduction, until the stock is transferable by the participant or is otherwise no longer subject to a substantial risk of forfeiture. When the stock is either transferable or is no longer subject to a substantial risk of forfeiture, a participant will recognize ordinary income in an amount equal to the fair market value of the shares at that time (less any amounts paid for the shares), and generally, the Company will be entitled to a deduction in the same amount. Any gain or loss recognized by the participant upon a later disposition of the shares will be capital gain or loss. A participant'sparticipant’s holding period for purposes of determining whether that capital gain or loss is long-term or short-term will be counted from the date the stock became transferable or ceased to be subject to a substantial risk of forfeiture.

A participant may elect to recognize ordinary income in the year when the share award is granted in an amount equal to the fair market value of the shares subject to the award (less any amounts paid for such shares) at the time of grant, determined without regard to any restrictions. This election is referred to as a


Section 83(b) election. In that event, the Company will be entitled to a corresponding deduction in the same year. Any gain or loss recognized by the participant upon a later disposition of the shares will be capital gain or loss. A participant'sparticipant’s holding period for purposes of determining whether that capital gain or loss is long-term or short-term will be counted from the date of the original transfer to the participant. The participant may not claim a credit for any tax previously paid on stock that is later forfeited.

Restricted Stock Units

If a participant is granted a restricted stock unit,RSU, he or she will not be required to recognize any taxable income at the time of grant. Upon distribution of shares or cash in respect of a restricted stock unit,RSU, the fair market value of those shares or the amount of that cash will be taxable to the participant as ordinary income and the Company will receive a deduction equal to the income recognized by the participant. The subsequent disposition of shares acquired pursuant to a restricted stock unitRSU will result in capital gain or loss (based on the difference between the price received on disposition and the market value of the shares at the time of their distribution). The capital gain tax rate will depend on a number of factors, including the length of time the participant held the shares prior to selling them.
63

TABLE OF CONTENTS

    Performance Awards

If a Performance Award is settled by the issuance of unrestricted shares of our Common Stock, the participant receiving the shares will recognize ordinary income equal to the value of the shares at the time of issuance and the Company will be entitled to a congruent deduction. Those shares will then have a tax basis equal to their fair market value on the date of issuance, and the holding period of those shares will commence on that date for purposes of determining whether a subsequent disposition of the shares will result in long-term or short-term capital gain or loss.

If a Performance Award is settled by the issuance of another type of award under the 2007 Plan, the tax consequences of that other award will be the same as described above with respect to the relevant type of award.

Section 162(m) of the Internal Revenue Code

Section 162(m) of the Code limits the federal income tax deductions a publicly held company can claim for compensation in excess of $1,000,000 paid to certain executive officers (generally, the officers who are "named“named executive officers"officers” in the summary compensation table in the issuer'sissuer’s proxy statement). With respect to grants made prior to November 2, 2017, "qualified“qualified performance-based compensation"compensation” was not counted against the $1,000,000 deductibility limit. Under the 2007 Plan, options granted prior to this date with an exercise price at least equal to 100% of the fair market value of the underlying shares at the date of grant may satisfy the requirements for treatment as "qualified“qualified performance-based compensation." In addition, Performance Awards, granted prior to this date, that are conditioned upon achievement of certain Performance Goals may satisfy the requirements for treatment as "qualified performance-based compensation."” Following the enactment of the Tax Cuts and Jobs Act, beginning with the 2018 calendar year, the $1,000,000 annual deduction limitation under Section 162(m) applies to all compensation paidgranted to these executive officers with no exception for qualified performance-based compensation. Accordingly, our ability to actually receive a corresponding deduction for the equity awards described above may be limited by this new tax law.

limited.

If the 2007 Plan is approved by stockholders, awards under the 2007 Plan will be determined by the Compensation and Leadership Development Committee in its discretion, and it is, therefore, not possible to predict the number, name or positions of persons who will benefit from the 2007 Plan, if it is approved by stockholders, or the terms of any such benefits. However, the following table sets forth information with respect to awards granted under the Existing Plan during the 20182021 fiscal year.

​
Name and Principal Position
​​
Number
of
Options
​​
Number
of
Stock Units(1)
​
​
John F. Crowley
 Chairman and Chief Executive Officer
​​
185,585
​​
230,480
​
​
Daphne Quimi
 Chief Financial Officer
​​
53,355
​​
66,262
​
​
Bradley L. Campbell
 President and Chief Operating Officer
​​
92,792
​​
115,240
​
​
Ellen S. Rosenberg
 Chief Legal Officer and Corporate Secretary
​​
53,355
​​
66,262
​
​
David M. Clark
 Chief People Officer
​​
44,076
​​
54,738
​
​
Hung Do
 Chief Scientific Advisor
​​
55,675
​​
69,144
​
​
All current executive officers as a group(2)
​​
429,163
​​
532,982
​
​
All current directors who are not executive officers as a group
​​
329,513
​​
103,679
​
​
All employees, including all current officers who are not executive officers, as a group
​​
2,503,618
​​
2,554,496
​
 (1)
Includes RSUs and PRSUs at target level.
 (2)
Excludes Dr. Do who is no longer an executive officer.
Name and Principal Position
 Number of
Options		 Number of
Stock
Units(1)		 

John F. Crowley

  154,076  213,206 

Chairman and Chief Executive Officer

       

William D. Baird, III

  43,075  59,606 

Chief Financial Officer

       

Bradley L. Campbell

  56,329  77,946 

President and Chief Operating Officer

       

Jay Barth, M.D. 

  39,762  55,022 

Chief Medical Officer

       

Ellen S. Rosenberg

  39,762  55,022 

Chief Legal Officer and Corporate Secretary

       

All current executive officers as a group

  487,422  607,361 

All current directors who are not executive officers as a group

  14,605  28,086 

All employees, including all current officers who are not executive officers as a group

  1,783,041  1,176,541 
64
(1)
Includes RSUs and PRSUs at target level for TSR and pipeline goal

TABLE OF CONTENTS

In accordance with SEC rules, the following table lists all options granted to the individuals and groups indicated below since the adoption of the 2007 Plan. The option awards listed below for the covered executives and directors include the option awards listed in the executive and director compensation tables beginning on page 3839 and 49,50, respectively, of this proxy statement and are not additional awards. As of April 8, 2019,March 24, 2022, the closing price of a share of our Common Stock on was $14.30$9.53 per share.

​
Persons or
Groups of Persons
​​
Options
​

​

John F. Crowley

3,299,353


 Chairman Chief Executive Officer

​​
4,442,651
​

William D. Baird, III

​		1,015,820

Daphne Quimi
Chief Financial Officer

​​
826,353
​

​

Bradley L. Campbell

1,399,922


 President and Chief Operating Officer

​​
1,964,526
​

Jay Barth, M.D. 

​		738,027

Chief Medical Officer

Ellen S. Rosenberg

354,046


 Chief Legal Officer and Corporate Secretary

​​
649,020
​

​

David M. Clark
 Chief People Officer
​​
407,757
​
​
Hung Do
 Chief Scientific Advisor
​​
765,274
​
​
All current executive officers as a group

​​8,054,784
8,288307
​

​

All current directors who are not executive officers as a group

​​44,605
544,322
​

​

Each nominee for election as a director

​​—
4,687,039
​

​

Each associate of any such director, executive officer or nominees

​​
—
​

​

Each other person who received or is to receive 5% of such options, warrants or rights

​​
—
​

​

All employees, including all current officers who are not executive officers as a group

​​23,740,555
33,016,387
​

    Vote Required

The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to approve the 2007 Plan.

Abstentions will have the effect of a vote against this proposal.

Securities Authorized for Issuance under our Equity Compensation Plans

(as of December 31, 2021)
​
Plan category
​​
Number of
securities
to be issued
upon exercise of
outstanding
options,
warrants
and rights (a)
​​
Weighted-average
exercise price of
outstanding
options
​​
Number of
securities
remaining
available for
future issuance
under equity
compensation
plans
(excluding
securities
reflected in
column (a))
​
​
Equity compensation plans approved by security holders
​​
​22,072,613(1)
​​
$11.08(2)
​​
18,322,154
​
​
Equity compensation plans not approved by security holders
​​
—
​​
—
​​
—
​
​
Total
​​
​22,072,613
​​
$11.08
​​
18,322,154
​
 (1)
Includes awards granted under the Company’s Existing Plan and the 2007 Director Option Plan (the “2007 Director Plan”). The 2007 Director Plan expired in June 2020 and no further awards may be granted under it.
 (2)
The weighted average exercise price for these options is determined without regard to RSUs and PRSUs included in column (a).
Plan category
 Number of securities
to be issued upon
exercise of outstanding
options (a)		 Weighted-average
exercise price of
outstanding options		 Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))(2)		 

Equity compensation plans approved by security holders(1)

  15,810,441 $8.63  9,257,741 

Equity compensation plans not approved by security holders

  —  —  — 

Total

  15,810,441 $8.63  9,257,741 
(1)
Includes awards granted under the Company's Existing Plan and the 2007 Director Option Plan (the "2007 Director Plan"). The number of shares available for issuance under the 2007 Director Plan is increased annually on January 1 of each year by 100,000 shares provided that the Board may waive the annual increase in shares available for issuance.

(2)
Of the total presented there are no shares available for issuance as restricted stock, restricted stock units or stock grants.

    Clawback Policy

As described above, the Board has adopted a Clawback Policy which allows the Board to recoup bonus and equity awards made to executives in the event of misconduct leading to a restatement and other misconduct.

No such events occurred in 2021.

65

TABLE OF CONTENTS


PROPOSAL NO. 3—INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit and Compliance Committee has appointed Ernst & Young LLP, independent registered public accounting firm, to audit our financial statements for the fiscal year ending December 31, 2019.2022. The Board proposes that the stockholders ratify this appointment. Ernst & Young LLP audited our financial statements for the fiscal year ended December 31, 2019.2021. We expect that representatives of Ernst & Young LLP will be present at the meeting,Annual Meeting, will be able to make a statement if they so desire, and will be available to respond to appropriate questions.

Recommendation

The Board recommends the vote "FOR"“FOR” to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm, and proxies solicited by the Board will be voted in favor of such ratification unless a stockholder indicates otherwise on the proxy.

Fees for Audit Services

The following table presents fees for professional audit services rendered by Ernst & Young LLP for the audit of our annual financial statements for the years ended December 31, 20182021 and 2017,2020, and fees


billed for other services rendered by Ernst & Young LLP during those periods. All of such fees were approved by the Audit and Compliance Committee.

​
​​
December 31,
​
​
​​
2021
​​
2020
​
​
Audit Fees
​​
$1,956,154
​​
$1,787,281
​
​
Audit-Related Fees
​​
500,000
​​
—
​
​
Tax Fees
​​
20,000
​​
18,000
​
​
All Other Fees
​​
24,075
​​
31,544
​
​
Total
​​
$2,500,229
​​
$1,836,825
​
 
 December 31, 
 
 2018 2017 

Audit Fees

 $1,852,238 $1,956,979 

Audit-Related Fees

  —  — 

Tax Fees

 $165,234 $24,658 

All Other Fees

 $119,911 $78,435 
​​​ ​ ​​ ​ ​

Total

 $2,137,383 $2,060,072 
​​​ ​ ​​ ​ ​
​​​​​​​​
​​​ ​ ​​ ​ ​

Fees for audit services included fees associated with the annual financial statement audit, an audit of our internal controls over financial reporting and reviews of the quarterly reports on Form 10-Q for both 20182021 and 2017.2020. In 20182021 and 2017,2020, the audit fees included costs of statutory audits of a number of our foreign subsidiaries. In 2017, theThe audit fees also includedinclude costs associated with our filing of two registration statements in 2021 and, in 2020, costs associated with the review of our Prospectus Supplement for an equity financing. The audit-related fees in 2021 relate to professional services rendered that are reasonably related to the performance of the audit of our financial statements. Specifically, these costs include fees for audit procedures related to Caritas carve-out financial statements and related SEC filings. There were no audit-related fees in 2020. Fees for tax services in 20182021 and 20172020 included fees associated with certain permitted compliance and advisory services. AllFor both 2021 and 2020, all other fees in 2018 and 2017 included the subscription fees paid for access to the Ernst & Young LLP on line Accounting & Auditing Research Tool and fees related to a permittedpricing compliance assessment project. There were no audit-related fees in 2018 and 2017.

reporting for the UK.

Policy on Audit and Compliance Committee Pre-Approval of Audit and Permissible Non-audit Services of Independent Registered Public Accounting Firm

Consistent with SEC policies regarding auditor independence, the Audit and Compliance Committee has responsibility for appointing, setting compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit and Compliance Committee has established a policy to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm.

Prior to engagement of the independent registered public accounting firm for the next year'syear’s audit, management will submit an aggregate estimate of services expected to be rendered during that year for each of four categories of services to the Audit and Compliance Committee for approval.
1.
Audit Services include audit work performed in the preparation of financial statements, as well as work that only the independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards.
2.
Audit-Related Services are for assurance and related services that are traditionally performed by the independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.
3.
Tax Services include all services performed by the independent registered public accounting firm’s tax personnel except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.
4.
Other Fees are those associated with services not captured in the other categories.
66

TABLE OF CONTENTS

    1.
    Audit services include audit work performed in the preparation of financial statements, as well as work that only the independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards.

    2.
    Audit-Related services are for assurance and related services that are traditionally performed by the independent registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.

    3.
    Tax services include all services performed by the independent registered public accounting firm's tax personnel except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.

    4.
    Other Fees are those associated with services not captured in the other categories.

Prior to engagement, the Audit and Compliance Committee pre-approves these services by category of service. The fees are budgeted, and the Audit and Compliance Committee requires the independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise when it may become


necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit and Compliance Committee requires specific pre-approval before engaging the independent registered public accounting firm.

The Audit and Compliance Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational purposes only, any pre-approval decisions to the Audit and Compliance Committee at its next scheduled meeting.

In the event the stockholders do not ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm, the Audit and Compliance Committee will reconsider its appointment.

The affirmative vote of a majority of the shares voted affirmatively or negatively on the matter at the Annual Meeting is required to ratify the appointment of the independent registered public accounting firm.

67

TABLE OF CONTENTS


REPORT OF AUDIT AND COMPLIANCE COMMITTEE

The Audit and Compliance Committee of the Board, which currently consists entirely of directors who meet the independence and experience requirements of the rules and regulations of NASDAQ and the Exchange Act, has furnished the following report.

The Audit and Compliance Committee assists the Board in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and the quality of internal and external audit processes. This Committee reviews and reassesses our charter annually and recommends any changes to the Board for approval. The Audit and Compliance Committee is responsible for overseeing our financial reporting process on behalf of the Board, and for the appointment, compensation, retention, and oversight of the work of Ernst & Young LLP. In fulfilling its responsibilities for the financial statements for fiscal year 2018,2021, the Audit and Compliance Committee took the following actions:

    •
Reviewed and discussed the audited financial statements for the fiscal year ended 20182021 with management and Ernst & Young LLP, our independent registered public accounting firm;

•
Discussed with Ernst & Young LLP the matters required to be discussed by the applicable requirements of the PCAOB Auditing Standard No.16, Communications with Audit and Compliance Committees;the SEC; and

•
Received written disclosures and the letter from Ernst & Young LLP required by the applicable requirements of the PCAOB regarding itsErnst & Young LLP’s communications with the Audit and Compliance Committee concerning independence as required by Rule 3526 of the PCAOB (Communications with Audit and Compliance Committees Concerning Independence).independence. The Audit and Compliance Committee further discussed Ernst & Young'sYoung’s independence with Ernst & Young LLP. The Audit and Compliance Committee also considered the status of pending litigation, taxation matters and other areas of oversight relating to the financial reporting and audit process that the Committee determined appropriate.

Based on the Audit and Compliance Committee'sCommittee’s review of the audited financial statements, discussions with management and Ernst & Young LLP and written disclosures and the letter from Ernst & Young LLP regarding its communications with the Audit and Compliance Committee concerning independence as required by applicable requirements of the Public Company Accounting Oversight Board, the Audit and Compliance Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as amended,2021 for filing with the SEC.

The Board subsequently approved inclusion of the audited financial statements in the 10-K.

Members of the Amicus Therapeutics, Inc.
Audit and Compliance Committee

Glenn P. Sblendorio, Chair
Robert Essner
Michael A. Kelly
Michael G. Raab


Burke W. Whitman
Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act or the Exchange Act that might incorporate this proxy statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be "soliciting material"“soliciting material” or "filed"“filed” with the SEC and shall not be deemed to be incorporated by reference into any such filing.
68

TABLE OF CONTENTS



PROPOSAL NO. 4—ADVISORY VOTE ON EXECUTIVE COMPENSATION

We are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the SEC'sSEC’s rules. This proposal, which is commonly referred to as "say-on-pay,"“say-on-pay,” is required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, which added Section 14A to the Exchange Act. Section 14A of the Exchange Act also requires that stockholders have the opportunity to cast an advisory vote with respect to whether future executive compensation advisory votes will be held every one, two or three years. In accordance with the results of this advisory vote at the 2017 Annual Meeting, the Company'sCompany’s Board determined that the Company will hold an advisory vote on the compensation of the Company'sCompany’s named executive officers every year.

Our executive compensation program for our executive officers is designed to attract, motivate, and retain individuals of superior ability and managerial talent who can successfully perform and succeed in our environment. Our named executive officers are rewarded for the achievement of our near-term and longer-term financial and strategic goals and for driving corporate performance. This program contains elements of cash and equity-based compensation designed to align the interests of our executives with those of our stockholders as well as have the appropriate incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual compensation earned through our pay-for-performance compensation program to the achievement of corporate goals. We also make equity grants designed to align our named executive officers'officers’ compensation to the long-term performance of Amicus in addition to creating an ownership culture that helps unify the interests of our executives and stockholders. The Company generally targets aggregate total direct compensation for the named executive officers as a group to approximately the 50th percentile of our peer group at target performance levels in setting our executive compensation programs. Our Board and the Compensation and Leadership Development Committee regularly review the compensation programs for our named executive officers and undertake a comprehensive annual review to ensure that our compensation policies and programs align with current market practices and the interests of our stockholders.

The "Compensation“Compensation Discussion and Analysis"Analysis” section of this proxy statement describes in detail our executive compensation program and the decisions made by the Compensation and Leadership Development Committee with respect to the fiscal year ended December 31, 2018.

2021.

In 2018,2021, despite the challenges of a global pandemic, the Company made significant progress towards completingall of its goal of becoming a fully integrated globalcorporate goals and exceeded its commercial, companyPompe, financial, and met or exceeded almost all corporate objectives.people & culture goals. The Company obtainedcontinued the strong commercialization of Galafold®, concluding the year with regulatory approvals in key geographies for Galafold, including the US and Japan. The approvals in the US and Japan were accompanied with what we believe are strong labels and all mutations/variants included.over 40 countries since launch. In addition, the Company established both US and Japanese commercial organizations and recognized $91.2approximately $300 million of global product revenue for Galafold, exceeding revenue guidance.Galafold®. The Company also significantly furthered its Pompe program by working with US and EU regulators to designannouncing topline results for the PROPEL trial, the largest controlled lysosomal storage disease study ever, receiving a Phase 3 study which includes both ERT switch and ERT naïve patients, givingpositive scientific opinion from the study more power and potentially allowing for a broader label. This was coupled withMHRA through EAMS in the successful manufacturing of ATB200 atU.K., completing the 1000L commercial scale and dosingsubmission of the first patient inrolling BLA and NDA to the Phase 3 study with material fromFDA, and submitting the 1000L batch.marketing authorization application for AT-GAA, which was subsequently validated by the EMA. The Company also strengthenedprogressed its product pipeline by acquiring 14 gene therapy programs with two ofand explored various ways to derive maximum value from the programs, (CLN6 and CLN3) already in the clinic. We believe that tremendous progress was made in the fourth quarterdespite adverse market conditions, but ultimately fell short of 2018 in creating an infrastructure to support these programs, which included entering into a collaboration agreement with the University of Pennsylvania and beginning execution on staffing, facilities, leadership and governance plans. Finally,meeting this pipeline corporate goal. Financially, the Company substantially fortified its financial position, ending the year with approximately $500$482.5 million in cash and cash equivalents dueand completed a private equity placement. This private placement provided an additional approximately $200 million of cash, which extended the Company’s cash runway under its current operating budget and allows the Company to raising $314 millionstay on the path to profitability in 2023. Finally, the Company continued building upon the succession plans for its most critical roles, announced the transition of the chief executive officer to the executive chair of the Board and the appointment of a new chief executive officer, and continued to strengthen its culture of diversity, equity and inclusion through an increased focus and significant progress on diverse and inclusive recruiting and hiring. All of the aforementioned achievements aligned with the corporate objectives, and the Compensation and Leadership Development Committee determined, and the Board approved, that the Company outperformed the corporate goals in the aggregate, resulting in a follow-on equity offering, completing a $150 million debt financing and finishing the year with below budgeted expenses. These actions have provided the Company with a cash runway that is expected to fund ongoing operations until at least mid-2021.

102% corporate multiplier for 2021.

Our Board is therefore asking stockholders to approve, on an advisory basis, the following resolution:

    "

“RESOLVED, that the compensation paid to the named executive officers of Amicus Therapeutics, as disclosed pursuant to the compensation disclosure rules of the SEC, including the compensation discussion and analysis, the compensation tables and any related material disclosed in this proxy statement, is hereby approved."

”

As an advisory vote, this proposal is not binding. The outcome of this advisory vote will not overrule any decision by us or our Board (or any committee thereof), create or imply any change to our fiduciary duties or those of our Board (or any committee thereof), or create or imply any additional fiduciary duties for us or our Board (or any committee thereof). However, our Compensation and Leadership Development Committee and Board value the opinions expressed by our stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for named executive officers.

69

TABLE OF CONTENTS

FORWARD-LOOKING STATEMENTS

This Proxy Statement contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All“forward-looking statements” that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, included in this Proxy Statement, the accompanying prospectusthat discuss our current expectation and the documents incorporated by reference herein and therein regardingprojections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management are forward-looking statements. Themanagement. These statements may be preceded by, followed by or include the words "anticipate," "believe," "estimate," "expect," "potential," "intend," "may," "plan," "predict," "project," "will," "should," "would"“aim,” “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negatives or plurals thereof, and other words and terms of similar expressions are intended to identify forward-looking statements,meaning, although not all forward-looking statements contain these identifying words. The inclusion of
We have based these forward-looking statements should not be regarded as a representation by uson our current expectations and projections about future events. Although we believe that any of our plans will be achieved. Any or all ofassumptions made in connection with the forward-looking statements in this Proxy Statement may turn outare reasonable, we cannot assure you that the assumptions and expectations will prove to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. In addition,correct. You should understand that, all forward-looking statements are subject to other important factors and risks detailed in our Form 10-K. You are cautionedIn light of these risks and uncertainties, we may not toactually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on theseour forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements whichwe make. These forward-looking statements speak only as of the date hereof. All forward-looking statements are qualified in their entirety byof this cautionary statement, and, except as required by law, weproxy statement. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or update this news release to reflect eventsfuture developments make it clear that projected results expressed or circumstances after the date hereof.


implied in such statements will not be realized, except as may be required by law.

OTHER MATTERS

The Board knows of no other business which will be presented to the 20192022 Annual Meeting. If any other business is properly brought before the 20192022 Annual Meeting, proxies in the enclosed form will be voted in accordance with the judgment of the individuals named as proxies on the proxy card.


STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR

If you wish to submit a proposal to be considered for inclusion in next year'syear’s proxy materials or nominate a director, your proposal must be in proper form according to SEC Regulation 14A, Rule 14a-8 and received by the Secretary of the Company no later than December 31, 2019.27, 2022. Proposals received after that date will not be included in the proxy materials we send out in connection with the 20202023 Annual Meeting of Stockholders. If a proposal is received before that date, the proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in accordance with our Restated By-laws, stockholder notice of any such proposal, other than a stockholder proposal intended to be included in our proxy statement and submitted pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, must be received by us not earlier than December 1, 2019November 27, 2022 and not later than December 31, 2019;27, 2022; provided, however, that in the event that the date of the 20202023 Annual Meeting of Stockholders is more than 30 days before or more than 60 days after the anniversary date of the 20202022 Annual Meeting of Stockholders, notice by the stockholder to be timely must be delivered not earlier than the close of business on the 90th day prior to such 20202022 Annual Meeting of Stockholders and not later


than the close of business on the later of the 60th day prior to such 20202023 Annual Meeting of Stockholders or the 10th day following the day on which we make a public announcement of the date of the 20202023 Annual Meeting of Stockholders. All stockholder proposals should be marked for the attention of Chief Legal Officer and Corporate Secretary, c/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.

3675 Market Street, Philadelphia, Pennsylvania 19104.

Our Annual Report on Form 10-K for the fiscal year ended December 31, 20182021 (other than the exhibits thereto), filed with the SEC, which provides additional information about us, is available on the Internet atwww.amicusrx.com and is available in paper form to beneficial owners of our Common Stock without charge upon written request to Secretary, c/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.


3675 Market Street, Philadelphia, Pennsylvania 19104.

DELIVERY OF PROXY MATERIALS

Some banks, brokers, and other nominee record holders may be participating in the practice of "householding"“householding” proxy statements and annual reports. This means that only one copy of this Proxy Statement, the Notice of 20192022 Annual Meeting of Stockholders and our Annual Report to Stockholders may have been sent to multiple stockholders in your household. Householding is designed to reduce duplicate mailings and save significant printing and postage costs. If you receive a household mailing this year and would like to receive additional copies of this Proxy Statement, the Notice of 20192022 Annual Meeting of Stockholders and our Annual Report to Stockholders, please call us at (609) 662-2000(215) 921-7600 or send a written request to Chief Legal Officer and Corporate Secretary, c/o Amicus Therapeutics, Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512.3675 Market Street, Philadelphia, Pennsylvania 19104. If you want to receive separate copies of our Proxy Statement, Notice of our Annual Meeting of Stockholders and our Annual Report to Stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact us at the above address and phone number.
70

TABLE OF CONTENTS



ExhibitEXHIBIT A

AMENDED AND RESTATED
AMICUS THERAPEUTICS, INC.
2007 EQUITY INCENTIVE PLAN

1.     Purpose

1.
Purpose
This Plan is intended to encourage ownership of Common Stock by employees, consultants and directors of the Company and its Affiliates and to provide additional incentive for them to promote the success of the Company'sCompany’s business through the grant of Awards of shares of the Company'sCompany’s Common Stock. The Plan is intended to be an incentive stock option plan within the meaning of Section 422 of the Code but not all Awards granted hereunder are required to be Incentive Options.

2.     Definitions

2.
Definitions
As used in the Plan the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise:

2.1. “Accelerate"Accelerate"”, "Accelerated"“Accelerated”, and “Acceleration and"Acceleration"”, when used with respect to an Option, means that as of the time of reference such Option will become exercisable with respect to some or all of the shares of Common Stock for which it was not then otherwise exercisable by its terms, and, when used with respect to Restricted Stock, Restricted Stock Units or Performance Awards, as the case may be, means that the Risk of Forfeiture and/or Performance Goals otherwise applicable to such Award, as the case may be, shall expire or be satisfied with respect to some or all of the shares of underlying such Award.

2.2. “"Acquiring Person"Person” means, with respect to any Transaction or any acquisition described in clause (ii) of the definition of Change of Control, the surviving or acquiring person or entity in connection with such Transaction or acquisition, as the case may be, provided that if such surviving or acquiring person or entity is controlled, directly or indirectly, by any other person or entity (an "Ultimate“Ultimate Parent Entity"Entity”) that is not itself controlled by any entity or person that is not a natural person, the term "Acquiring Person"“Acquiring Person” shall mean such Ultimate Parent Entity.

2.3. “Affiliate"Affiliate"” means, with respect to any person or entity, any other person or entity controlling, controlled by or under common control with the first person or entity.

2.4. “"Applicable Voting Control Percentage"Percentage” means (i) at any time prior to the initial public offering of the Company, a percentage greater than fifty percent (50%) and (ii) at any time from and after the initial public offering of the Company, twenty percent (20%).

2.5. “Award"Award"” means any grant or sale pursuant to the Plan of Options, Restricted Stock, Restricted Stock Units, Stock Grants or Performance Awards.

2.6. “"Award Agreement"Agreement” means an agreement between the Company and the recipient of an Award, setting forth the terms and conditions of the Award.

2.7. “"Beneficial Ownership"Ownership” has the meaning ascribed to such term in Rule 13d-3, or any successor rule thereto, promulgated by the Securities and Exchange Commission pursuant to the Exchange Act.

2.8. “Board"Board"” means the Company'sCompany’s board of directors.

2.9. “"Change of Control"Control” means (i) the closing of any Sale of the Company Transaction or (ii) the direct or indirect acquisition, in a single transaction or a series of related transactions, by any person or Group (other than the Company or a Controlled Affiliate of the Company) of Beneficial Ownership of previously outstanding shares of capital stock of the Company if (A) immediately after such acquisition, such person or Group, together with their respective Affiliates, shall own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage of the total voting power of the


outstanding A-1 capital stock of the Company and (B) immediately prior to such acquisition, such person or Group, together with their respective Affiliates, did not own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage of the total voting power of the outstanding capital stock of the Company. Notwithstanding anything expressed or implied in the foregoing provisions of this definition to the contrary, any direct or indirect acquisition referred to in clause (ii) above in this definition shall not be treated

A-1

TABLE OF CONTENTS

as a Change of Control if, at any time prior to or after such direct or indirect acquisition, a majority of the members of the board of directors of the Company as constituted immediately prior to such direct or indirect acquisition consent in writing to exclude such direct or indirect acquisition from the scope of this definition. Notwithstanding the foregoing, with respect to any Award issued under the Plan, which is subject to Section 409A of the Code, no event shall set forth above shall be deemed to be a Change of Control, unless such event would also be considered a "change“change in ownership or effective control of a corporation or in the ownership of a substantial portion of the assets of a corporation"corporation” under Section 409A(a)(2)(A)(v) of the Code and the regulations thereunder.

2.10. “Code"Code"” means the Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto, and any regulations issued from time to time thereunder.

2.11. “"Controlled Affiliate"Affiliate” means, with respect to any person or entity, any other person or entity that is controlled by such person or entity.

2.12. “Committee"Committee"” means any committee of the Board delegated responsibility by the Board for the administration of the Plan, as provided in Section 5 of the Plan. For any period during which no such committee is in existence, the term "“CommitteeCommittee"” shall mean the Board and all authority and responsibility assigned the Committee under the Plan shall be exercised, if at all, by the Board.

2.13. “Common S"Commontock Stock"” means common stock, par value $0.01 per share, of the Company.

2.14. “Company"Company"” means Amicus Therapeutics, Inc., a corporation organized under the laws of the State of Delaware.

2.15. “"Exchange Act"t” means the Securities Exchange Act of 1934, as amended.

2.16. “"Grant Date"Date” means the date as of which an Option is granted, as determined under Section 7.1(a).

2.17. “Group"Group"” has the meaning ascribed to such term in Section 13(d)(3) of the Exchange Act or any successor section thereto.

2.18. “"Incentive Option"Option” means an Option which by its terms is to be treated as an "incentive“incentive stock option"option” within the meaning of Section 422 of the Code.

2.19. “"Market Value"Value” means the value of a share of Common Stock on a particular date determined by such methods or procedures as may be established by the Committee. Unless otherwise determined by the Committee, the Market Value of Common Stock as of any date is the closing price for the Common Stock as reported on the NASDAQ Global market (or on any other national securities exchange on which the Common Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the next preceding date for which a closing price was reported.

2.20. “"Nonstatutory Option"Option” means any Option that is not an Incentive Option.

2.21. “Option"Option"” means an option granted under the Plan to purchase shares of Common Stock.

2.22. “Optionee"Optionee"” means an employee, consultant or director of the Company to whom an Option shall have been initially granted under the Plan.

2.23. “Participant"Participant"” means any holder of an outstanding Award under the Plan.


2.24. "“Performance Award"” means shares of Common Stock or other Awards that, pursuant to Section 7.5 are granted, vested and/or settled upon the achievement of specified performance conditions

conditions.

2.25. "“Performance Goals"” means any goals established by the Committee in its sole discretion, the attainment of which is substantially uncertain at the time such goals are established. Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the individual Participant or any subsidiary, division, department or function within the Company or any subsidiary in which the Participant is employed. Performance Goals may be measured on an absolute or relative basis. Relative performance may be measured by a group of peer companies or by a financial market index. Performance Goals may be based upon: cash flow; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and
A-2

TABLE OF CONTENTS

charges for stock-based compensation, earnings before interest, taxes, depreciation and amortization, and net earnings); earnings per share; growth in earnings or earnings per share; stock price; return on equity or average stockholder equity; total stockholder return or growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in revenue or return on sales; income or net income; operating income, net operating income or net operating income after tax; operating profit or net operating profit; operating margin; return on operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget comparisons; growth in stockholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring goals; development and implementation of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance the Company'sCompany’s revenue or profitability or enhance its customer base; and merger and acquisitions.

2.26. “"Performance Period"Period” means the period selected by the Committee during which the performance of the Company, any subsidiary, any department or division of the Company or any subsidiary, or any individual is measured for the purpose of determining the extent to which a Performance Goal has been achieved.

2.27. “Plan"Plan"” means this 2007 Amended and Restated Equity Incentive Plan of the Company, as amended and in effect from time to time.

2.28. “"Restricted Stock"Stock” means a grant or sale pursuant to the Plan of shares of Common Stock to a Participant subject to a Risk of Forfeiture.

2.29. “"Restricted Stock Units"Units” means rights granted pursuant to the Plan to receive shares of Common Stock at the close of a Restriction Period, subject to a Risk of Forfeiture.

2.30. “"Restriction Period"Period” means the period of time, established by the Committee in connection with an Award of Restricted Stock or Restricted Stock Units, during which the shares of Restricted Stock or Restricted Stock Units are subject to a Risk of Forfeiture described in the applicable Award Agreement.

2.31. “"Risk of Forfeiture"Forfeiture” means a limitation on the right of a Participant to retain an Award of Restricted Stock or Restricted Stock Units, including subjecting such Award to a Performance Goals and/or a right in the Company to reacquire such Restricted Stock at less than its then Market Value and/or the forfeiture of Restricted Stock Units held by a Participant, arising because of the occurrence or non-occurrence of specified events or conditions.


2.32.���“        2.32.  "Sale of the Company Transaction"Transaction” means any Transaction in which the stockholders of the Company immediately prior to such Transaction, together with any and all of such stockholders'stockholders’ Affiliates, do not own or hold, immediately after consummation of such Transaction, shares of capital stock of the Acquiring Person in connection with such Transaction possessing at least a majority of the total voting power of the outstanding capital stock of such Acquiring Person.

2.33. “"Securities Act"Act” means the Securities Act of 1933, as amended.

2.34. “"Stock Grant"Grant” means the grant pursuant to the Plan of shares of Common Stock not subject to restrictions or other forfeiture conditions.

2.35. “"Ten Percent Owner"Owner” means a person who owns, or is deemed within the meaning of Section 422(b)(6) of the Code to own, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (or any parent or subsidiary corporations of the Company, as defined in Section 424(e) and (f), respectively, of the Code). Whether a person is a Ten Percent Owner shall be determined with respect to each Option based on the facts existing immediately prior to the Grant Date of such Option.
A-3

TABLE OF CONTENTS

2.36. “Transaction"Transaction"” means any merger or consolidation of the Company with or into another person or entity or the sale or transfer of all or substantially all of the assets of the Company, in each case in a single transaction or in a series of related transactions.
2.37 “Retirement

        2.37.  "Retirement"” means a Participant'sParticipant’s termination of employment or service with the Company for any reason other than a termination by the Company for Cause where (a) such Participant has attained at least 5 years of continuous service with the Company, (b) the Participant is at least 55 years of age and (c) the sum of such Participant'sParticipant’s age and years of service with the Company equals or exceeds 67 years.

3.     Term of the Plan

3.
Term of the Plan
Unless the Plan shall have been earlier terminated by the Board, Awards may be granted under this Plan at any time in the period commencing on the Effective Date of approval of the Amended and restated version of the Plan by the Board and ending immediately prior to the tenth anniversary the Effective Date. Awards granted pursuant to the Plan within such period shall not expire solely by reason of the termination of the Plan.

4.     Stock Subject to the Plan: Limits

4.
Stock Subject to the Plan: Limits
Subject to the provisions of Section 8 of the Plan, at no time shall the number of shares of Common Stock issued pursuant to or subject to outstanding Awards granted under the Plan (including, without limitation, pursuant to Incentive Options), nor the number of shares of Common Stock issued pursuant to Incentive Options, exceed 27,058,703,49,558,703, with respect to shares of Common Stock. For purposes of applying the foregoing limitation, if any Option expires, terminates, or is cancelled for any reason without having been exercised in full, or if any Award of Restricted Stock is forfeited, the shares not purchased by the Participant or forfeited by the Participant shall again be available for Awards thereafter to be granted under the Plan. In the event the exercise price of an Option or a Participant'sParticipant’s withholding obligations is paid through the delivery of shares of Common Stock, the number of shares so tendered shall not again be available for the grant of Awards under the Plan. Shares of Common Stock issued pursuant to the Plan may be either authorized but unissued shares or shares held by the Company in its treasury.

In addition, not more than 17,058,70339,558,703 of the total number of shares of Common Stock reserved for issuance under the Plan (as adjusted under Section 8) may be granted or sold as Awards of Restricted Stock, Restricted Stock Units, Stock Grants, and any other similar Awards (including, without limitation, Restricted Stock, Restricted Stock Units, Stock Grants, and any other similar Awards underlying a Performance Award) ("(“Full-Value Awards"Awards”) whose intrinsic value is not solely dependent on appreciation in the price of shares of Common Stock after the date of grant. Options and any other similar Awards shall


not be subject to, and shall not count against, the limit described in the preceding sentence. If a Full-Value Award expires, is forfeited, or otherwise lapses as described in this Section 4, the shares of Common Stock that were subject to the Award shall be restored to the total number of shares of Common Stock available for grant or sale as Full-Value Awards.

The maximum number of shares of Common Stock with respect to which Awards may be granted hereunder to any employee of the Company during any fiscal year of the Company shall be five million (5,000,000) shares of Common Stock.

5.     Administration

5.
Administration
The Plan shall be administered by the Committee;provided, however, that at any time and on any one or more occasions the Board may itself exercise any of the powers and responsibilities assigned the Committee under the Plan and when so acting shall have the benefit of all of the provisions of the Plan pertaining to the Committee'sCommittee’s exercise of its authorities hereunder;and provided further that the Committee may delegate to an executive officer or officers the authority to grant Awards hereunder to employees who are not officers, and to consultants, in accordance with such guidelines as the Committee shall set forth at any time or from time to time. Subject to the provisions of the Plan, the Committee shall have complete authority, in its discretion, to make or to select the manner of making all determinations with respect to each Award to be granted by the Company under the Plan in addition to any other determination allowed the Committee under the Plan including, without limitation: (a) the employee, consultant or director to receive the Award; (b) the form of Award; (c) whether an Option (if granted to an employee) will be an Incentive Option or a Nonstatutory
A-4

TABLE OF CONTENTS

Option; (d) the time of granting an Award; (e) the number of shares subject to an Award; (f) the exercise price of an Option or purchase price, if any, for shares of Restricted Stock or for a Stock Grant and the method of payment of such exercise price or such purchase price; (g) the term of an Option; (h) the vesting period of shares of Restricted Stock or of Restricted Stock Units and any acceleration thereof; (i) the exercise date or dates of an Option and any acceleration thereof; (j) the effect of termination of any employment, consulting or Board member relationship with the Company or any of its Affiliates on the subsequent exercisability of an Option or on the Risk of Forfeiture of Restricted Stock or Restricted Stock Units; (k) whether, and to certify that, Performance Goals to which an Award is subject are satisfied; and (l) the terms and conditions of any Award granted under the Plan (including, but not limited to, restrictions as to vesting, transferability or forfeiture, exercisability or settlement of an Award and waivers or accelerations thereof, and establishment, waivers of or modifications to Performance Goals relating to an Award, based in each case on such considerations as the Committee shall determine) and all other matters to be determined in connection with an Award. In making such determinations, the Committee may take into account the nature of the services rendered by the respective employees, consultants and directors, their present and potential contributions to the success of the Company and its Affiliates, and such other factors as the Committee in its discretion shall deem relevant. Subject to the provisions of the Plan, the Committee shall also have complete authority to interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it, to determine the terms and provisions of the respective Award Agreements (which need not be identical), and to make all other determinations necessary or advisable for the administration of the Plan. The Committee'sCommittee’s determinations made in good faith on matters referred to in this Plan shall be final, binding and conclusive on all persons having or claiming any interest under the Plan or an Award made pursuant hereto.

6.
Authorization and Eligibility

6.     Authorization and Eligibility

The Committee may grant from time to time and at any time prior to the termination of the Plan one or more Awards, either alone or in combination with any other Awards, to any employee of or consultant to one or more of the Company and its Affiliates or to any non-employee member of the Board or of any board of directors (or similar governing authority) of any Affiliate. However, only employees of the Company or of any parent or subsidiary corporations of the Company, as defined in Sections 424(e) and (f), respectively, of the Code, shall be eligible for the grant of an Incentive Option. Further, in no event shall the number of shares of Common Stock covered by Options or other Awards granted to any one person in any one calendar year (or portion of a year) ending after such date exceed fifty percent (50%) of the aggregate number of shares of Common Stock subject to the Plan.

Each grant of an Award shall be subject to all applicable terms and conditions of the Plan (including but not limited to any specific terms and conditions applicable to that type of Award set out in the following Section), and such other terms and conditions, not inconsistent with the terms of the Plan, as the Committee may prescribe. No prospective Participant shall have any rights with respect to an Award, unless and until such Participant has executed an agreement evidencing the Award, delivered a fully executed copy thereof to the Company, and otherwise complied with the applicable terms and conditions of such Award.

7.     Specific Terms of Awards

7.
Specific Terms of Awards
7.1. Options.
(a) Options.

            (a)Date of Grant. The granting of an Option shall take place at the time specified in the Award Agreement. Only if expressly so provided in the applicable Award Agreement shall the Grant Date be the date on which the Award Agreement shall have been duly executed and delivered by the Company and the Optionee.

(b)         (b)Exercise Price.The price at which shares of Common Stock may be acquired under each Option shall be not less than 100% of the Market Value of Common Stock on the Grant Date, or with respect to a grant of an Incentive Option not less than 110% of the Market Value of Common Stock on the Grant Date if the Optionee is a Ten Percent Owner.

(c)         (c)Option Period. No Incentive Option or Nonstatutory Option may be exercised on or after the tenth anniversary of the Grant Date, or on or after the fifth anniversary of the Grant Date if the Optionee is a Ten Percent Owner.
A-5

TABLE OF CONTENTS

(d) Exercisability.

        (d)    Exercisability. An Option may be immediately exercisable or become exercisable in such installments, cumulative or non-cumulative, as the Committee may determine. Any Option may be a Performance Award, subject to Section 7.5. In the case of an Option not otherwise immediately exercisable in full, the Committee may Accelerate such Option in whole or in part at any time.

(e)         (e)Effect of Termination of Employment or Board Member Relationship. Unless the Committee shall provide otherwise with respect to any Option, if the applicable Optionee'sOptionee’s association with the Company or any of its Affiliates as an employee or director ends, and immediately following the end of any such association, such Optionee is not associated with the Company or any of its Affiliates as an employee or director ("(“SeparationSeparation"”), then:

(i) if the Optionee'sOptionee’s association ends due to the Optionee'sOptionee’s death, Disability, or Retirement, any unvested Options held by such Optionee shall continue to vest until the second anniversary of such Optionee'sOptionee’s Separation, and all of such Optionee'sOptionee’s vested Options (including those that vest pursuant to the preceding clause) shall remain exercisable until the earlier of the (i) the 4th anniversary of the date of such Separation, and (ii) the original expiration date of the term of the Option; any Options not exercised in such period shall be forfeited with no further


      compensation due to the Participant, unless otherwise determined by the Committee at or after grant; and

(ii) if the Optionee'sOptionee’s association ends for any reason other than the Optionee'sOptionee’s death, Disability, or Retirement, regardless of whether the end of such association is effected by the Company, (whether voluntarily or involuntarily, including because an entity with which such Optionee has any such association ceases to be an Affiliate of the Company), any unvested Options held by such Optionee shall be immediately forfeited and all vested Options held by such Participant shall cease to be exercisable in any respect upon the earlier of (i) ninety (90) days following such Optionee'sOptionee’s Separation, and (ii) the original expiration date of the term of the Option; any Options not exercised in such period shall be forfeited with no further compensation due to the Optionee.

Military or sick leave or other bona fide leave shall not be deemed a termination of employment, provided that it does not exceed the longer of ninety (90) days or the period during which the absent Optionee'sOptionee’s reemployment rights, if any, are guaranteed by statute or by contract.

(f)         (f)Transferability.    Transferability. Except as otherwise provided in this subsection (f), Options shall not be transferable, and no Option or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution (subject always to the provisions of subsection (e) above). Except as otherwise provided in this subsection (f), all of a Participant'sParticipant’s rights in any Option may be exercised during the life of such Participant only by such Participant or such Participant'sParticipant’s legal representative. However, the applicable Award Agreement or the Committee (at or after the grant of a Nonstatutory Option) may provide that a Nonstatutory Option may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration whatsoever and that no transfer of a Nonstatutory Option shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, "family member"“family member” means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant'sParticipant’s household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of Nonstatutory Options to third parties pursuant to this subsection (f), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time. The restrictions on transferability set forth in this subsection (f) shall in no way preclude any Participant from effecting "cashless"“cashless” exercises of an Option pursuant to the terms of the Plan.
A-6

TABLE OF CONTENTS

(g)         (g)Method of Exercise. An Option may be exercised by a Participant giving written notice, in the manner provided in Section 15, specifying the number of shares of Common Stock with respect to which the Option is then being exercised. The notice shall be accompanied by payment in the form of cash or check payable to the order of the Company in an amount equal to the exercise price of the shares of Common Stock to be purchased or, subject in each instance to the Committee'sCommittee’s approval, acting in its sole discretion and subject to such conditions, if any, as the Committee may deem necessary to comply with applicable laws, rules and regulations or to avoid adverse accounting effects to the Company, by delivery to the Company of shares of Common Stock having a Market Value equal to the exercise price of the shares to be purchased. If the Common Stock is traded on an established market, payment of any exercise price may also be made through and under the terms and conditions of any formal cashless exercise program authorized by the Company entailing the sale of the Common


    Stock subject to any Option in a brokered transaction (other than to the Company). Receipt by the Company of such notice and payment in any authorized or combination of authorized means shall constitute the exercise of the Option. Within thirty (30) days thereafter but subject to the remaining provisions of the Plan, the Company shall deliver or cause to be delivered to the Participant or his agent a certificate or certificates for the number of shares then being purchased. Such shares shall be fully paid and nonassessable. Notwithstanding any of the foregoing provisions in this subsection (g) to the contrary, (A) no Option shall be considered to have been exercised unless and until all of the provisions governing such exercise specified in the Plan and in the relevant Award Agreement shall have been duly complied with; and (B) the obligation of the Company to issue any shares upon exercise of an Option is subject to the provisions of Section 9.1 hereof and to compliance by the Optionee and the Participant with all of the provisions of the Plan and the relevant Award Agreement.

(h)         (h)Limit on Incentive Option Characterization. An Incentive Option shall be considered to be an Incentive Option only to the extent that the number of shares of Common Stock for which the Option first becomes exercisable in a calendar year does not have an aggregate Market Value (as of the date of the grant of the Option) in excess of the "current limit"“current limit”. The current limit for any Optionee for any calendar year shall be $100,000minusminus the aggregate Market Value at the date of grant of the number of shares of Common Stock available for purchase for the first time in the same year under each other Incentive Option previously granted to the Optionee under the Plan, and under each other incentive stock option previously granted to the Optionee. Any shares of Common Stock which would cause the foregoing limit to be violated shall be deemed to have been granted under a separate Nonstatutory Option, otherwise identical in its terms to those of the Incentive Option.

(i)         (i)Notification of Disposition. Each person exercising any Incentive Option granted under the Plan shall be deemed to have covenanted with the Company to report to the Company any disposition of such shares prior to the expiration of the holding periods specified by Section 422(a)(1) of the Code and, if and to the extent that the realization of income in such a disposition imposes upon the Company federal, state, local or other withholding tax requirements, or any such withholding is required to secure for the Company an otherwise available tax deduction, to remit to the Company an amount in cash sufficient to satisfy those requirements.

(j)         (j)Rights Pending Exercise. No person holding an Option shall be deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common Stock issuable pursuant to such Option (including without limitation, that no Optionee shall have any entitlement to receive any dividends paid with respect to any shares of Common Stock issuable pursuant to such Option) except to the extent that such Option shall have been exercised with respect thereto and, in addition, a certificate shall have been issued therefor and delivered to such person or his agent.

7.2. Restricted Stock.

(a)         (a)Purchase Price. Shares of Restricted Stock shall be issued under the Plan for such consideration, in cash, other property or services, or any combination thereof, as is determined by the Committee.
A-7

TABLE OF CONTENTS

(b)         (b)Issuance of Certificates. Subject to subsection (c) below, each Participant receiving an Award of Restricted Stock shall be issued a stock certificate in respect of such shares of Restricted Stock. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award substantially in the following form:

The transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and an Award Agreement entered into by the registered owner and Amicus


      Therapeutics, Inc. Copies of such Plan and Agreement are on file in the offices of Amicus Therapeutics, Inc.

(c)         (c)Escrow of Shares. The Committee may require that the stock certificates evidencing shares of Restricted Stock be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock power, endorsed in blank, relating to the Common Stock covered by such Award.

(d)         (d)Restrictions and Restriction Period. During the Restriction Period applicable to shares of Restricted Stock, such shares shall be subject to limitations on transferability and a Risk of Forfeiture arising on the basis of such conditions related to the performance of services, Company or Affiliate performance or otherwise as the Committee may determine and provide for in the applicable Award Agreement. Any grant of Restricted Stock may be a Performance Award, subject to Section 7.5. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems appropriate.

(e)         (e)Rights Pending Lapse of Risk of Forfeiture or Forfeiture of Award. Except as otherwise provided in the Plan or the applicable Award Agreement, at all times prior to lapse of any Risk of Forfeiture applicable to, or forfeiture of, an Award of Restricted Stock, the Participant shall have all of the rights of a stockholder of the Company, including the right to vote the shares of Restricted Stock.

(f) Effect of Termination of Employment or Board Member Relationship.

(i)         (i)Termination due to death, Disability, or Retirement.Retirement. If the applicable original grantee incurs a Separation from the Company or any of its Affiliates during the Restriction Period due to such grantee'sgrantee’s death, Disability, or Retirement, then unvested shares of Restricted Stock held by such Participant shall accelerate with respect to the shares of unvested Restricted Stock that were initially scheduled to vest within the two-year period following the Participant'sParticipant’s Separation and the restrictions thereon shall lapse and the Award of such Restricted Stock shall become immediately nonforfeitable (and all Restricted Stock that would vest after such two (2) year period would be forfeited upon such Separation with no further compensation due to the Participant, unless otherwise determined by the Committee at or after grant).

(ii)         (ii)Other Terminations.Unless otherwise determined by the Committee at or after grant and subject to the applicable provisions of the Award Agreement, if the applicable original grantee incurs a Separation from the Company or any of its Affiliates during the Restriction Period, for any reason other than the grantee'sgrantee’s death, Disability, or Retirement during the Restriction Period, regardless of whether the end of such association is effected by the Company, any such Affiliate or such original grantee (whether voluntarily or involuntarily, including because an entity with which such original grantee has any such association ceases to be an Affiliate of the Company), then all outstanding unvested shares of Restricted Stock granted to such Participant, shall be forfeited or otherwise subject to return to or repurchase by the Company if and to the extent so provided by, and subject to and in accordance with, the terms of the applicable Award Agreement; provided, however, that military or sick leave or other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety (90) days or the period during which the absent original grantee'sgrantee’s reemployment rights, if any, are guaranteed by statute or by contract.

(g)         (g)Lapse of Restrictions. If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock, the certificates for such shares shall be delivered to the Participant promptly if not theretofore so delivered.
A-8

TABLE OF CONTENTS

(h) Transferability.

        (h)    Transferability. Except as otherwise provided in this subsection (h), shares of Restricted Stock shall not be transferable, and no share of Restricted Stock or interest therein may be sold,


    transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution (subject always to the provisions of subsection (f) above). The applicable Award Agreement or the Committee (at or after the grant of a share of Restricted Stock) may provide that such share of Restricted Stock may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration whatsoever and that no transfer of a share of Restricted Stock shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, "family member"“family member” means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant'sParticipant’s household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of shares of Restricted Stock to third parties pursuant to this subsection (h), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time.

(i)         (i)Dividends.    Dividends. At the discretion of the Committee, Participants may be entitled to receive payments equivalent to any dividends paid with respect to Common Stock underlying grants of Restricted Stock but only if such Restricted Stock actually vests. Unless the Committee shall provide otherwise, such amounts shall be paid, if at all, without interest or other earnings.

7.3. Restricted Stock Units.

(a)         (a)Character.    Character. Each Restricted Stock Unit shall entitle the recipient to a share of Common Stock at a close of such Restriction Period as the Committee may establish and subject to a Risk of Forfeiture arising on the basis of such conditions relating to the performance of services, Company or Affiliate performance or otherwise (including any applicable Performance Goal) as the Committee may determine and provide for in the applicable Award Agreement. Any grant of Restricted Stock Units may be a Performance Award, subject to Section 7.5. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems appropriate.

(b)         (b)Issuance of Certificates. Unless otherwise determined by the Committee at or after grant and subject to the applicable provisions of the Award Agreement, at the close of the Restriction Period applicable to any Restricted Stock Units (including, without limitation, the close of the applicable Restriction Period as a result of (i) any Acceleration of Restricted Stock Units in accordance with the terms of this Plan or any applicable Award Agreement, (ii) any waiver, lapse or termination of the Risk of Forfeiture applicable to Restricted Stock Units in accordance with the terms of this Plan or any applicable Award Agreement or (iii) any shortening of the Restriction Period applicable to any Restricted Stock Units in accordance with the terms of this Plan or any applicable Award Agreement), the Company shall deliver or cause to be delivered to the Participant that is the holder of such Restricted Stock Units a stock certificate in respect of the shares of Common Stock subject to such Restricted Stock Units. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such shares of Common Stock substantially in the following form:

The transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and an Award Agreement entered into by the registered owner and Amicus Therapeutics, Inc. Copies of such Plan and Agreement are on file in the offices of Amicus Therapeutics, Inc.

A-9

    TABLE OF CONTENTS

    (c) Dividends.

              (c)    Dividends. Participants shall not be entitled to receive any dividends declared with respect to Common Stock referenced in grants of Restricted Stock Units until the shares underlying such award is delivered to the Participant, if ever.

    (d) Effect of Termination of Employment or Board Member Relationship.

    (i)         (i)Termination due to death, Disability, or Retirement.If the applicable original grantee incurs a Separation from the Company or any of its Affiliates during the Restriction Period due to such grantee'sgrantee’s death, Disability, or Retirement, then all outstandingunvested shares of Restricted Stock Units held by such Participant shall accelerate with respect to the shares of unvested Restricted Stock Units that are still subject to Risk of Forfeiture, shall continuewere initially scheduled to vest untilwithin the second anniversarytwo-year period following the Participant’s Separation and the restrictions thereon shall lapse and the Award of such SeparationRestricted Stock Units shall become immediately nonforfeitable (and all Restricted Stock Units that would vest after such two (2) year period would be forfeited upon such Separation with no further compensation due to the Participant, unless otherwise determined by the Committee at or after grant); provided however that if such Restricted Stock Units are unvested Performance Restricted Stock Units, then a pro-rata portion (based on the number of completed days of the grantee'sgrantee’s affiliation with the Company in the applicable performance period divided by the total number of days in the applicable performance period) of such Performance Restricted Stock Units will remain eligible to vest after the grantee'sgrantee’s Separation, to the extent earned based on the actual performance of the Company through the end of the applicable performance period. Any Restricted Stock Units or Performance Restricted Stock Units that vest pursuant to this Section 7.3(d) will be settled on the date otherwise specified in the applicable Award Agreement.

    (ii)         (ii)Other Terminations.Unless otherwise determined by the Committee at or after grant and subject to the applicable provisions of the Award Agreement, if the applicable original grantee incurs a Separation for any reason other than the grantee'sgrantee’s death, Disability, or Retirement during the Restriction Period, then all unvested Restricted Stock Units and/or unvested Performance Restricted Stock Units that are still subject to Risk of Forfeiture shall be forfeited or otherwise subject to return to the Company in accordance with the terms of the applicable Award Agreement; provided, however, that military or sick leave or other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety (90) days or the period during which the absent original grantee'sgrantee’s reemployment rights, if any, are guaranteed by statute or by contract."”
    (e) Transferability.

            (e)    Transferability. Except as otherwise provided in this subsection (e), Restricted Stock Units shall not be transferable, and no Restricted Stock Unit or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated. The applicable Award Agreement or the Committee (at or after the grant of a Restricted Stock Unit) may provide that such Restricted Stock Unit may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration whatsoever and that no transfer of a Restricted Stock Unit shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, "family member"“family member” means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant'sParticipant’s household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of Restricted Stock Units to third parties pursuant to this subsection (e), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time.


      (f)         (f)Rights Pending Close of Applicable Restriction Period. No person holding Restricted Stock Units shall be deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common Stock subject to such Restricted Stock Units, except to the extent that the Restricted

    A-10

    TABLE OF CONTENTS

    Period with respect to such Restricted Stock Units shall have closed and, in addition, a certificate shall have been issued for such shares of Common Stock and delivered to such person or his agent. Shares of Common Stock subject to Restricted Stock Units shall be issued and outstanding only if and to the extent that a stock certificate representing such shares has been issued and delivered in accordance with the provisions of this Section 7.3.

    7.4. Stock Grants.

    (a)         (a)In General. Stock Grants shall be issued for such consideration, in cash, other property or services, or any combination thereof, as is determined by the Committee. Without limiting the generality of the foregoing, Stock Grants may be awarded in such circumstances as the Committee deems appropriate, including without limitation in recognition of significant contributions to the success of the Company or its Affiliates or in lieu of compensation otherwise already due. Stock Grants shall be made without forfeiture conditions of any kind.

    (b)         (b)Issuance of Certificates. Each Participant receiving a Stock Grant shall be issued a stock certificate in respect of such Stock Grant. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award substantially in the following form:

    The transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics, Inc. 2007 Equity Incentive Plan. A copy of such Plan is on file in the offices of Amicus Therapeutics, Inc.

    7.5. Performance Awards.

    (a)         (a)Performance Awards Generally. The Committee may grant Performance Awards in accordance with this Section. Performance Awards may be denominated as a number of shares of Common Stock, or specified number of other Awards (or a combination thereof) which may be earned upon achievement or satisfaction of Performance Goals, as specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance Award by conditioning the vesting or settlement of the Award upon the achievement or satisfaction of such Performance Goals, which the Committee may use in its discretion from time to time.

    (b)         (b)Qualified Performance-Based Compensation Under Section 162(m). Performance Awards intended to constitute "qualified“qualified performance-based compensation"compensation” under Section 162(m) of the Code may be granted by the Committee and will be subject to the terms of this Section. When a Performance Award is made, the Committee shall establish in writing (i) the objective performance goals that must be met, (ii) the period during which performance will be measured, (iii) the maximum amounts that may be paid if the performance goals are met, and (iv) any other conditions that the Committee deems appropriate and consistent with the requirements of section 162(m) of the Code for "qualified“qualified performance-based compensation."” The grant, vesting and/or settlement of a Performance Award subject to this Section will be contingent upon achievement of one or more Performance Goals. The Committee shall establish the applicable Performance Goals in writing either before the beginning of the Performance Period or during a Performance Period ending no later than the earlier of (i) 90 days after the beginning of the Performance Period or (ii) the date on which 25% of the Performance Period has been completed, or such other date as may be required or permitted under applicable regulations under section 162(m) of the Code. The performance goals shall satisfy the requirements for "qualified“qualified performance-based compensation,"” including the requirement that the achievement of the goals be substantially uncertain at the time they are established and that the


      performance goals be established in such a way that a third party with knowledge of the relevant facts could determine whether and to what extent the performance goals have been met. The Committee shall not have discretion to increase the amount of compensation that is payable, but may reduce the amount of compensation that is payable, pursuant to Awards identified by the Committee as "qualified“qualified performance-based compensation."

      ”

    (c)         (c)Adjustments to Performance Goals. The Committee may adjust Performance Goals to take into account, in any objective manner specified by the Committee, the impact of one or more of the following: (A) gain or loss from all or certain claims and/or litigation and insurance recoveries, (B) the impairment of tangible or intangible assets, (C) stock-based compensation expense, (D) extraordinary,
    A-11

    TABLE OF CONTENTS

    unusual or infrequently occurring events reported in the Company'sCompany’s public filings, (E) restructuring activities reported in the Company'sCompany’s public filings, (F) investments, dispositions or acquisitions, (G) loss from the disposal of certain assets, (H) gain or loss from the early extinguishment, redemption, or repurchase of debt, (I) cash or non-cash charges related to site closing expenses, (J) changes in accounting principles, or (K) any other item, event or circumstance that would not cause an Award to fail to constitute "qualified“qualified performance-based compensation"compensation” under Section 162(m) of the.the Code. Such an adjustment may relate to the Company or to any subsidiary, division or other operational unit of the Company or its Affiliates, as determined by the Committee at the time the Performance Goals are established. Any adjustment shall be determined in accordance with generally accepted accounting principles and standards, unless such other objective method of measurement is designated by the Committee at the time Performance Goals are established. In addition, adjustments will be made as necessary to any Performance Goals related to the Company'sCompany’s stock to reflect changes in corporate capitalization, including a recapitalization, stock split or combination, stock dividend, spin-off, merger, reorganization or other similar event or transaction affecting the Company'sCompany’s stock.

    (d)         (d)Other Terms of Performance Awards. The Committee may specify other terms pertinent to a Performance Award in the applicable Award Agreement, including terms relating to the treatment of that Award in the event of a Change in Control prior to the end of the Performance Period.

    (e)         (e)Certification of Results. The Committee shall certify the results regarding any Performance Goals for the Performance Period specified in the Award Agreement after the Performance Period ends. The Committee shall determine the amount, if any, to be paid pursuant to each Award based on the achievement of the applicable Performance Goals and the satisfaction of all other terms of the Award Agreement.

    7.6. Awards to Participants Outside the United States.

    The Committee may modify the terms of any Award under the Plan granted to a Participant who is, at the time of grant or during the term of the Award, resident or primarily employed outside of the United States in any manner deemed by the Committee to be necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in which the Participant is then resident or primarily employed, or so that the value and other benefits of the Award to the Participant, as affected by foreign tax laws and other restrictions applicable as a result of the Participant'sParticipant’s residence or employment abroad, shall be comparable to the value of such an Award to a Participant who is resident or primarily employed in the United States. An Award may be modified under this Section 7.47.6 in a manner that is inconsistent with the express terms of the Plan, so long as such modifications will not contravene any applicable law or regulation. The Committee may establish supplements to, or amendments, restatements, or alternative versions of the Plan for the purpose of granting and administrating any such modified Award. No such modification, supplement, amendment, restatement or alternative version may increase the share limit of Section 4.

    8.
    		Adjustment Provisions

    8.1. 8.     Adjustment Provisions

            8.1.Adjustment for Corporate Actions. Subject to the provisions of Section 8.2, if subsequent to the Effective Date, the outstanding shares of Common Stock (or any other securities covered by the Plan by reason of the prior application of this Section) are increased, decreased, or exchanged for a different number or kind of shares or other securities, or if additional shares or new or different shares or other securities are distributed with respect to such shares of Common Stock or other securities, through merger, consolidation, sale of all or substantially all the property of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or other distribution with respect to such shares of Common Stock, or other securities, an appropriate and proportionate adjustment will be made in (i) the maximum numbers and kinds of shares provided in Section 4, (ii) the numbers and kinds of shares or other securities subject to the then outstanding Awards, (iii) the exercise price for each share or other unit of any other securities subject to then outstanding Options (without change in the aggregate purchase price as to which such Options remain exercisable), and (iv) the Performance Goal applicable to any outstanding Performance Award.

    8.2.         8.2.Change of Control. Subject to the applicable provisions of the Award Agreement, in the event of a Change of Control, the Committee shall have the discretion, exercisable in advance of, at the time of, or (except to the extent otherwise provided below) at any time after, the Change of Control, to provide for any or all of the following (subject to and upon such terms as the Committee may deem appropriate): (A) the
    A-12

    TABLE OF CONTENTS

    Acceleration, in whole or in part, of any or all outstanding Options (including Options that are assumed or replaced pursuant to clause (D) below) that are not exercisable in full at the time the Change of Control, such Acceleration to become effective at the time of the Change of Control, or at such time following the Change of Control that the employment, consulting or Board member relationship of the applicable Optionee or Optionees with the Company and its Affiliates terminates, or at such other time or times as the Committee shall determine; (B) the lapse or termination of the Risk of Forfeiture (including, without limitation, any or all of the Company'sCompany’s repurchase rights) with respect to outstanding Awards of Restricted Stock, such lapse or termination to become effective at the time of the Change of Control, or at such time following the Change of Control that the employment, consulting or Board member relationship with the Company and its Affiliates of the Participant or Participants that hold such Awards of Restricted Stock (or the person to whom such Awards of Restricted Stock were initially granted) terminates, or at such other time or times as the Committee shall determine; (C) the lapse or termination of the Risk of Forfeiture with respect to any or all outstanding Awards of Restricted Stock Units (including Restricted Stock Units that are assumed or replaced pursuant to clause (D) below), such lapse or termination to become effective at the time of the Change of Control, or at such time following the Change of Control that the employment, consulting or Board member relationship with the Company and its Affiliates of the Participant or Participants that hold such Awards of Restricted Stock Units (or the person to whom such Awards of Restricted Stock Units were initially granted) terminates, or at such other time or times as the Committee shall determine; (D) the assumption of outstanding Options or Restricted Stock Units, or the substitution of outstanding Options or Restricted Stock Units with equivalent options or equivalent restricted stock units, as the case may be, by the acquiring or succeeding corporation or entity (or an affiliate thereof); (E) the termination of all Options (other than Options that are assumed or substituted pursuant to clause (D) above) that remain outstanding at the time of the consummation of the Change of Control, provided that, the Committee shall have made the determination to effect such termination prior to the consummation of the Change of Control and the Committee shall have given, or caused to be given, to all Participants written notice of such potential termination at least five business days prior to the consummation of the Change of Control, and provided, further, that, if the Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of such terminated Options on account of such termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined (and which could consist of, in the Committee'sCommittee’s sole and absolute discretion, payment to the applicable Optionee or Optionees of an amount of cash equal to the difference between the Market Value of the shares of Common Stock for


    which the Option is then exercisable and the aggregate exercise price for such shares under the Option or cancellation for no payment (or other consideration with respect to Options for which the exercise price exceeds the Market Value of the shares of Common Stock underlying the Option), then the Company shall be required to make, or cause to be made, such payment or provide, or cause to be provided, such consideration in accordance with the terms and conditions so determined by the Committee, otherwise the Company shall not be required to make any payment or provide any consideration in connection with, or as a result of, the termination of Options pursuant to the foregoing provisions of this clause (E); (F) the termination of all Restricted Stock Units (other than Restricted Stock Units that are assumed or substituted pursuant to clause (D) above) that remain outstanding at the time of the consummation of the Change of Control, provided that, if the Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of such terminated Restricted Stock Units on account of such termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined (and which could consist of, in the Committee'sCommittee’s sole and absolute discretion, payment to the applicable Participant or Participants of an amount of cash equal to the Market Value of the shares of Common Stock subject to the terminated Restricted Stock Units), then the Company shall be required to make such payment or provide such consideration in accordance with the terms and conditions so determined by the Committee, otherwise the Company shall not be required to make any payment or provide any consideration in connection with, or as a result of, the termination of Restricted Stock Units pursuant to the foregoing provisions of this clause (F) and/or (G) the reduction of any Performance Period applicable to a Performance Award or the satisfaction (or the failure to of such satisfaction) of any applicable Performance Goals with respect to Performance Awards. The provisions of this Section 8.2 shall not be construed as to limit or restrict in any way the Committee'sCommittee’s general authority under Sections 7.1(d) or 7.2(d) hereof to Accelerate Options in whole or in part at any time or to waive or terminate at any time any Risk of Forfeiture applicable to shares of Restricted Stock or Restricted Stock Units. Each outstanding Award that is assumed in connection with a

    A-13

    TABLE OF CONTENTS

    Change of Control, or is otherwise to continue in effect subsequent to a Change of Control, will be appropriately adjusted, immediately after the Change of Control, as to the number and class of securities and the price at which it may be exercised in accordance with Section 8.1.

    8.3.         8.3.Dissolution or Liquidation. Upon dissolution or liquidation of the Company, each outstanding Option shall terminate, but the Optionee (if at the time he or she has an employment, consulting or Board member relationship with the Company or any of its Affiliates) shall have the right, immediately prior to such dissolution or liquidation, to exercise the Option to the extent exercisable on the date of such dissolution or liquidation.

    8.4.         8.4.Related Matters. Any adjustment in Awards made pursuant to this Section 8 shall be determined and made, if at all, by the Committee and shall include any correlative modification of terms, including of Option exercise prices, rates of vesting or exercisability, Risks of Forfeiture, adjustment of Performance Goals and/or Performance Periods and applicable repurchase prices for Restricted Stock, which the Committee may deem necessary or appropriate so as to ensure that the rights of the Participants in their respective Awards are not substantially diminished nor enlarged as a result of the adjustment and corporate action other than as expressly contemplated in this Section 8. No fraction of a share shall be purchasable or deliverable upon exercise, but in the event any adjustment hereunder of the number of shares covered by an Award shall cause such number to include a fraction of a share, such number of shares shall be adjusted to the nearest smaller whole number of shares. No adjustment of an Option exercise price per share pursuant to this Section 8 shall result in an exercise price which is less than the par value of the Common Stock.

    9.
    		Settlement of Awards
    9.1. 9.     Settlement of Awards

            9.1.Violation of Law. Notwithstanding any other provision of the Plan or the relevant Award Agreement, if, at any time, in the reasonable opinion of the Company, the issuance of shares of Common


    Stock covered by an Award may constitute a violation of law, then the Company may delay such issuance and the delivery of a certificate for such shares until (i) approval shall have been obtained from such governmental agencies, other than the Securities and Exchange Commission, as may be required under any applicable law, rule, or regulation and (ii) in the case where such issuance would constitute a violation of a law administered by or a regulation of the Securities and Exchange Commission, one of the following conditions shall have been satisfied:

    (a) the shares are at the time of the issue of such shares effectively registered under the Securities Act; or

    (b) the Company shall have determined, on such basis as it deems appropriate (including an opinion of counsel in form and substance satisfactory to the Company) that the sale, transfer, assignment, pledge, encumbrance or other disposition of such shares or such beneficial interest, as the case may be, does not require registration under the Securities Act or any applicable state securities laws.

    9.2.         9.2.Corporate Restrictions on Rights in Stock. Any Common Stock to be issued pursuant to Awards granted under the Plan shall be subject to all restrictions upon the transfer thereof which may be now or hereafter imposed by the Certificate of Incorporation and the By-laws of the Company, each as amended and in effect from time to time. Whenever Common Stock is to be issued pursuant to an Award, if the Committee so directs at the time of grant (or, if such Award is an Option, at any time prior to the exercise thereof), the Company shall be under no obligation, notwithstanding any other provision of the Plan or the relevant Award Agreement to the contrary, to issue such shares until such time, if ever, as the recipient of the Award (and any person who exercises any Option, in whole or in part), shall have become a party to and bound by any agreement that the Committee shall require in its sole discretion. In addition, any Common Stock to be issued pursuant to Awards granted under the Plan shall be subject to all stop-transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities laws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

    9.3.         9.3.Investment Representations. The Company shall be under no obligation to issue any shares covered by an Award unless the shares to be issued pursuant to Awards granted under the Plan have been
    A-14

    TABLE OF CONTENTS

    effectively registered under the Securities Act or the Participant shall have made such written representations to the Company (upon which the Company believes it may reasonably rely) as the Company may deem necessary or appropriate for purposes of confirming that the issuance of such shares will be exempt from the registration requirements of that Act and any applicable state securities laws and otherwise in compliance with all applicable laws, rules and regulations, including but not limited to that the Participant is acquiring shares for his or her own account for the purpose of investment and not with a view to, or for sale in connection with, the distribution of any such shares.
    9.4. Registration.

            9.4.    Registration. If the Company shall deem it necessary or desirable to register under the Securities Act or other applicable statutes any shares of Common Stock issued or to be issued pursuant to Awards granted under the Plan, or to qualify any such shares of Common Stock for exemption from the Securities Act or other applicable statutes, then the Company shall take such action at its own expense. The Company may require from each recipient of an Award, or each holder of shares of Common Stock acquired pursuant to the Plan, such information in writing for use in any registration statement, prospectus, preliminary prospectus or offering circular as is reasonably necessary for such purpose and may require reasonable indemnity to the Company and its officers and directors from such holder against all losses, claims, damage and liabilities arising from such use of the information so furnished and caused by any untrue statement of any material fact therein or caused by the omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances under which they were made.

    9.5. Lock-Up.


            9.5.    Lock-Up. Without the prior written consent of the Company or the managing underwriter in any public offering of shares of Common Stock, no Participant shall sell, make any short sale of, loan, grant any option for the purchase of, pledge or otherwise encumber, or otherwise dispose of, any shares of Common Stock during the one hundred-eighty (180) day period commencing on the effective date of the registration statement relating to any underwritten public offering of securities of the Company. The foregoing restrictions are intended and shall be construed so as to preclude any Participant from engaging in any hedging or other transaction that is designed to or reasonably could be expected to lead to or result in, a sale or disposition of any shares of Common Stock during such period even if such shares of Common Stock are or would be disposed of by someone other than such Participant. Such prohibited hedging or other transactions would include, without limitation, any short sale (whether or not against the box) or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any shares of Common Stock or with respect to any security that includes, relates to, or derives any significant part of its value from any shares of Common Stock. Without limiting the generality of the foregoing provisions of this Section 9.5, if, in connection with any underwritten public offering of securities of the Company, the managing underwriter of such offering requires that the Company'sCompany’s directors and officers enter into a lock-up agreement containing provisions that are more restrictive than the provisions set forth in the preceding sentence, then (a) each Participant (regardless of whether or not such Participant has complied or complies with the provisions of clause (b) below) shall be bound by, and shall be deemed to have agreed to, the same lock-up terms as those to which the Company'sCompany’s directors and officers are required to adhere; and (b) at the request of the Company or such managing underwriter, each Participant shall execute and deliver a lock-up agreement in form and substance equivalent to that which is required to be executed by the Company'sCompany’s directors and officers.

    9.6.         9.6.Placement of Legends; Stop Orders; Etc. Each share of Common Stock to be issued pursuant to Awards granted under the Plan may bear a reference to the investment representations made in accordance with Section 9.3 in addition to any other applicable restrictions under the Plan, the terms of the Award and, if applicable, under any agreement between the Company and any Optionee and/or Participant, and to the fact that no registration statement has been filed with the Securities and Exchange Commission in respect to such shares of Common Stock. All certificates for shares of Common Stock or other securities delivered under the Plan shall be subject to such stock transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities law, and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions.

    9.7.         9.7.Tax Withholding. Whenever shares of Common Stock are issued or to be issued pursuant to Awards granted under the Plan, the Company shall have the right to require the recipient to remit to the Company an amount sufficient to satisfy federal, state, local or other withholding tax requirements if, when,
    A-15

    TABLE OF CONTENTS

    and to the extent required by law (whether so required to secure for the Company an otherwise available tax deduction or otherwise) prior to the delivery of any certificate or certificates for such shares. The obligations of the Company under the Plan shall be conditional on satisfaction of all such withholding obligations and the Company shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the recipient of an Award. However, in such cases Participants may elect, subject to the approval of the Committee, acting in its sole discretion, to satisfy anany applicable withholding requirements, in whole or in part, by having the Company withhold shares to satisfy their tax obligations. Participants may elect to have shares of their Common Stock withheld having a Market Value on the date the tax is to be determined that is no greater than maximum individual statutory rate, which could be imposed on the transaction, provided however, that with respect to Participants who are also subject to Section 16b-3 of the Exchange Act, such Participant may only have shares of their Common Stock withheld at a rate that does not exceed such Participant'sParticipant’s estimated federal state, local and foreign tax obligations attributable to the underlying transaction. All elections shall be irrevocable, made in


    writing, signed by the Participant, and shall be subject to any restrictions or limitation that the Committee deems appropriate.

    10.   Reservation of Stock

    10.
    		Reservation of Stock
    The Company shall at all times during the term of the Plan and any outstanding Options granted hereunder reserve or otherwise keep available such number of shares of Common Stock as will be sufficient to satisfy the requirements of the Plan (if then in effect) and such Options and shall pay all fees and expenses necessarily incurred by the Company in connection therewith.

    11.   No Special Service Rights

    11.
    		No Special Service Rights
    Nothing contained in the Plan or in any Award Agreement shall confer upon any recipient of an Award any right with respect to the continuation of his or her employment, consulting or Board member relationship or other association with the Company (or any Affiliate), or interfere in any way with the right of the Company (or any Affiliate), subject to the terms of any separate employment, consulting or Board member agreement or provision of law or corporate articles or by-laws to the contrary, at any time to terminate such employment, consulting or Board member agreement or to increase or decrease, or otherwise adjust, the other terms and conditions of the recipient'srecipient’s employment, consulting or Board member relationship or other association with the Company and its Affiliates.

    12.   Nonexclusivity of the Plan

    12.
    		Nonexclusivity of the Plan
    Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders of the Company shall be construed as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including without limitation, the granting of stock options, restricted stock and restricted stock units other than under the Plan, and such arrangements may be either applicable generally or only in specific cases.

    13.   Termination and Amendment of the Plan

    13.
    		Termination and Amendment of the Plan
    The Board may at any time terminate the Plan or make such amendments or modifications of the Plan as it shall deem advisable. In the event of the termination of the Plan, the terms of the Plan shall survive any such termination with respect to any Award that is outstanding on the date of such termination, unless the holder of such Award agrees in writing to terminate such Award or to terminate all or any of the provisions of the Plan that apply to such Award. Unless the Board otherwise expressly provides, any amendment or modification of the Plan shall affect the terms of any Award outstanding on the date of such amendment or modification as well as the terms of any Award made from and after the date of such amendment or modification;provided, however, that, except to the extent otherwise provided in the last sentence of this paragraph, (i) no amendment or modification of the Plan shall apply to any Award that is outstanding on the date of such amendment or modification if such amendment or modification would reduce the number of shares subject to such Award, increase the purchase price applicable to shares subject to such Award or materially adversely affect the provisions applicable to such Award that relate to the vesting or exercisability of such Award or of the shares subject to such Award, (ii) no amendment or modification of the Plan shall apply to any Incentive Option that is outstanding on the date of such amendment or modification if such amendment or modification would result in such Incentive Option no longer being treated as an "incentive“incentive stock option" option”
    A-16

    TABLE OF CONTENTS

    within the meaning of Section 422 of the Code and (iii) no amendment or modification of the Plan shall apply to any Award that is outstanding on the date of such amendment or modification unless such amendment or modification of the Plan shall also apply to all other Awards outstanding on the date of such amendment or modification. In the event of any amendment or modification of the Plan that is described in clause (i), (ii) or (iii) of the foregoing proviso, such amendment or modification of the Plan shall apply to any Award outstanding on the date of such amendment or modification only if the recipient of such Award consents in writing thereto.


    The Committee may amend or modify, prospectively or retroactively, the terms of any outstanding Award without amending or modifying the terms of the Plan itself,provided that as amended or modified such Award is consistent with the terms of the Plan as in effect at the time of the amendment or modification of such Award, but no such amendment or modification of such Award shall, without the written consent of the recipient of such Award, reduce the number of shares subject to such Award, increase the purchase price applicable to shares subject to such Award, adversely affect the provisions applicable to such Award that relate to the vesting or exercisability of such Award or of the shares subject to such Award, or otherwise materially adversely affect the terms of such Award (except for amendments or modifications to the terms of such Award or of the stock subject to such Award that are expressly permitted by the terms of the Plan or that result from any amendment or modification of the Plan in accordance with the provisions of the first paragraph of this Section 13), or, if such Award is an Incentive Option, result in such Incentive Option no longer being treated as an "incentive“incentive stock option"option” within the meaning of Section 422 of the Code.

    Without the approval of the Company'sCompany’s stockholders, the Committee will not, directly or indirectly, reduce the exercise price of an outstanding Option (other than in accordance with the adjustment provisions of Section 8.1).

    14.   Interpretation of the Plan

    14.
    		Interpretation of the Plan
    In the event of any conflict between the provisions of this Plan and the provisions of any applicable Award Agreement, the provisions of this Plan shall control, except if and to the extent that the conflicting provision in such Award Agreement was authorized and approved by the Committee at the time of the grant of the Award evidenced by such Award Agreement or is ratified by the Committee at any time subsequent to the grant of such Award, in which case the conflicting provision in such Award Agreement shall control. Without limiting the generality of the foregoing provisions of this Section 14, insofar as possible the provisions of the Plan and such Award Agreement shall be construed so as to give full force and effect to all such provisions. In the event of any conflict between the provisions of this Plan and the provisions of any other agreement between the Company and the Optionee and/or Participant, the provisions of such agreement shall control except as required to fulfill the intention that this Plan constitute an incentive stock option plan within the meaning of Section 422 of the Code, but insofar as possible the provisions of the Plan and any such agreement shall be construed so as to give full force and effect to all such provisions.

    15.   Notices and Other Communications

    15.
    		Notices and Other Communications
    Any notice, demand, request or other communication hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person or duly sent by first class registered, certified or overnight mail, postage prepaid, or telecopied with a confirmation copy by regular, certified or overnight mail, addressed or telecopied, as the case may be, (i) if to the recipient of an Award, at his or her residence address last filed with the Company and (ii) if to the Company, at its principal place of business, addressed to the attention of its Chief Executive Officer, or to such other address or telecopier number, as the case may be, as the addressee may have designated by notice to the addressor. All such notices, requests, demands and other communications shall be deemed to have been received: (i) in the case of personal delivery, on the date of such delivery; (ii) in the case of mailing, when received by the addressee; and (iii) in the case of facsimile transmission, when confirmed by facsimile machine report.

    16.   Governing Law

    16.
    		Governing Law
    The Plan and all Award Agreements and actions taken thereunder shall be governed, interpreted and enforced in accordance with the laws of the State of New Jersey, without regard to the conflict of laws principles thereof.
    A-17

    TABLE OF CONTENTS

    17.   Effective Date

    17.
    		Effective Date
    This Amended and Restated 2007 Equity Incentive Plan was approved by the Board on April 18, 201921, 2016 (the Effective Date"“Effective Date”) and subsequently approved by the stockholders of the Company effective June 27, 2019.

    stockholders.
    A-18

    TABLE OF CONTENTS


    VOTE BY INTERNET - www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on 06/26/2019. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. ELECTRONIC DELIVERYTABLE OF FUTURE PROXY MATERIALS If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years. AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ08512 ATTN: ELLEN S. ROSENBERG VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on 06/26/2019. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. For Withhold For All Except To withhold authority to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the AllAll The Board of Directors recommends you vote FOR all of the following nominees: nominee(s) on the line below. 0 0 0 1. Election of Directors Nominees 01 John F. Crowley 02 Margaret G. McGlynn 03 Michael G. Raab 04 Glenn P. Sblendorio The Board of Directors recommends you vote FOR proposals 2, 3 and 4. For 0 0 0 Against 0 0 0 Abstain 0 0 0 2. Approval of the Amended and Restated 2007 Equity Incentive Plan to add 7,000,000 shares to the equity pool. 3. Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019. Approval, on an advisory basis, the Company's executive compensation. 4. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date 0000420328_1 R1.0.1.18CONTENTS


    Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice & Proxy Statement, Annual Report are available at www.proxyvote.com AMICUS THERAPEUTICS, INC. Annual Meeting of Stockholders June 27, 2019 9:00 AM This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) Bradley L. Campbell and Ellen S. Rosenberg, or either of them, as proxies, each with the power to appoint (his/her) substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of common stock of AMICUS THERAPEUTICS, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of stockholder(s) to be held at 09:00 AM, EDT on 6/27/2019, at the offices of Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, NJ 08512, and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations. Continued and to be signed on reverse side 0000420328_2 R1.0.1.18



    QuickLinks

    NOTICE OF 2019 ANNUAL MEETING OF STOCKHOLDERS
    IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE 27, 2019.
    THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 2019 ANNUAL MEETING OF STOCKHOLDERS AND OUR 2018 ANNUAL REPORT TO STOCKHOLDERS ARE AVAILABLE AT: www.sec.gov , through the Investor Relations section of our web site at www.amicusrx.com or at http://www.proxyvote.com
    PROPOSAL NO. 1—ELECTION OF DIRECTORS
    AMICUS CORPORATE GOVERNANCE
    COMPENSATION DISCUSSION AND ANALYSIS—2018
    Summary Compensation Table
    COMPENSATION COMMITTEE REPORT
    SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
    POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS
    PROPOSAL NO. 2—APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN
    PROPOSAL NO. 3—INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
    REPORT OF AUDIT AND COMPLIANCE COMMITTEE
    PROPOSAL NO. 4—ADVISORY VOTE ON EXECUTIVE COMPENSATION
    FORWARD-LOOKING STATEMENTS
    OTHER MATTERS
    STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR
    DELIVERY OF PROXY MATERIALS
    AMENDED AND RESTATED AMICUS THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN